ZA200200816B - Corynebacterium glutamicum genes encoding phosphoenolpyruvate: Sugar phosphotransferase system proteins. - Google Patents
Corynebacterium glutamicum genes encoding phosphoenolpyruvate: Sugar phosphotransferase system proteins. Download PDFInfo
- Publication number
- ZA200200816B ZA200200816B ZA200200816A ZA200200816A ZA200200816B ZA 200200816 B ZA200200816 B ZA 200200816B ZA 200200816 A ZA200200816 A ZA 200200816A ZA 200200816 A ZA200200816 A ZA 200200816A ZA 200200816 B ZA200200816 B ZA 200200816B
- Authority
- ZA
- South Africa
- Prior art keywords
- nucleic acid
- pts
- acid molecule
- protein
- corynebacterium
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 396
- 102000004169 proteins and genes Human genes 0.000 title claims description 309
- 241000186226 Corynebacterium glutamicum Species 0.000 title claims description 128
- 235000000346 sugar Nutrition 0.000 title claims description 58
- 229930029653 phosphoenolpyruvate Natural products 0.000 title claims description 13
- 108091000080 Phosphotransferase Proteins 0.000 title claims description 11
- 102000020233 phosphotransferase Human genes 0.000 title claims description 11
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 title claims 5
- 235000018102 proteins Nutrition 0.000 claims description 303
- 150000007523 nucleic acids Chemical class 0.000 claims description 251
- 102000039446 nucleic acids Human genes 0.000 claims description 229
- 108020004707 nucleic acids Proteins 0.000 claims description 229
- 238000000034 method Methods 0.000 claims description 117
- 125000003729 nucleotide group Chemical group 0.000 claims description 98
- 239000002773 nucleotide Substances 0.000 claims description 95
- 241000186216 Corynebacterium Species 0.000 claims description 83
- 230000000694 effects Effects 0.000 claims description 71
- 239000013598 vector Substances 0.000 claims description 70
- 239000012847 fine chemical Substances 0.000 claims description 65
- 150000001413 amino acids Chemical group 0.000 claims description 63
- 238000004519 manufacturing process Methods 0.000 claims description 63
- 235000001014 amino acid Nutrition 0.000 claims description 58
- 229940024606 amino acid Drugs 0.000 claims description 54
- 230000014509 gene expression Effects 0.000 claims description 53
- 244000005700 microbiome Species 0.000 claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 102000004190 Enzymes Human genes 0.000 claims description 44
- 108090000790 Enzymes Proteins 0.000 claims description 44
- 239000013604 expression vector Substances 0.000 claims description 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 41
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 40
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 40
- 239000008103 glucose Substances 0.000 claims description 40
- 229920001184 polypeptide Polymers 0.000 claims description 36
- 230000001105 regulatory effect Effects 0.000 claims description 30
- 241000186146 Brevibacterium Species 0.000 claims description 25
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 19
- 229940088594 vitamin Drugs 0.000 claims description 18
- 229930003231 vitamin Natural products 0.000 claims description 18
- 235000013343 vitamin Nutrition 0.000 claims description 18
- 239000011782 vitamin Substances 0.000 claims description 18
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 16
- 239000005720 sucrose Substances 0.000 claims description 16
- 229930091371 Fructose Natural products 0.000 claims description 15
- 239000005715 Fructose Substances 0.000 claims description 15
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 13
- 241000186227 Corynebacterium diphtheriae Species 0.000 claims description 12
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 9
- 230000004048 modification Effects 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 9
- 239000002777 nucleoside Substances 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 8
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 7
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 7
- 239000002585 base Substances 0.000 claims description 7
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 150000007524 organic acids Chemical class 0.000 claims description 7
- 235000005985 organic acids Nutrition 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 6
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 6
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- 229930182830 galactose Natural products 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 125000003835 nucleoside group Chemical group 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 6
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 claims description 5
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 claims description 5
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 150000001491 aromatic compounds Chemical class 0.000 claims description 4
- 229940009098 aspartate Drugs 0.000 claims description 4
- 150000002009 diols Chemical class 0.000 claims description 4
- 229930195712 glutamate Natural products 0.000 claims description 4
- 229940049906 glutamate Drugs 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 229930001119 polyketide Natural products 0.000 claims description 3
- 125000000830 polyketide group Chemical group 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 3
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 3
- 241000186145 Corynebacterium ammoniagenes Species 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 241000187561 Rhodococcus erythropolis Species 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 235000012539 Bacterium linens Nutrition 0.000 claims 1
- 241000186310 Brevibacterium linens Species 0.000 claims 1
- 241001517047 Corynebacterium acetoacidophilum Species 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 241000234435 Lilium Species 0.000 claims 1
- 241000319304 [Brevibacterium] flavum Species 0.000 claims 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 140
- 125000003275 alpha amino acid group Chemical group 0.000 description 79
- 108020004414 DNA Proteins 0.000 description 60
- 150000001875 compounds Chemical class 0.000 description 44
- 229940088598 enzyme Drugs 0.000 description 43
- 230000000692 anti-sense effect Effects 0.000 description 37
- 230000015572 biosynthetic process Effects 0.000 description 35
- 229910052799 carbon Inorganic materials 0.000 description 34
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 33
- 108091028043 Nucleic acid sequence Proteins 0.000 description 30
- 241000894006 Bacteria Species 0.000 description 29
- 101150001834 PTS gene Proteins 0.000 description 29
- 230000031146 intracellular signal transduction Effects 0.000 description 28
- 102000037865 fusion proteins Human genes 0.000 description 25
- 108020001507 fusion proteins Proteins 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 108091026890 Coding region Proteins 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 23
- 239000000543 intermediate Substances 0.000 description 22
- 239000000126 substance Substances 0.000 description 21
- 239000000523 sample Substances 0.000 description 20
- 108020004999 messenger RNA Proteins 0.000 description 19
- -1 arachidonic acid) Chemical class 0.000 description 18
- 150000008163 sugars Chemical class 0.000 description 18
- 230000032258 transport Effects 0.000 description 18
- 125000000539 amino acid group Chemical group 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 230000001413 cellular effect Effects 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 230000008676 import Effects 0.000 description 15
- 230000000295 complement effect Effects 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 239000002243 precursor Substances 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 230000015556 catabolic process Effects 0.000 description 13
- 230000004927 fusion Effects 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 108010078791 Carrier Proteins Proteins 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 12
- 238000000855 fermentation Methods 0.000 description 12
- 230000004151 fermentation Effects 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000002703 mutagenesis Methods 0.000 description 12
- 231100000350 mutagenesis Toxicity 0.000 description 12
- 239000013615 primer Substances 0.000 description 12
- 238000003259 recombinant expression Methods 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 11
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 238000010561 standard procedure Methods 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 230000014616 translation Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 10
- 241000233866 Fungi Species 0.000 description 10
- 230000037353 metabolic pathway Effects 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- 235000015107 ale Nutrition 0.000 description 9
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 9
- 239000012707 chemical precursor Substances 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 238000002744 homologous recombination Methods 0.000 description 9
- 230000006801 homologous recombination Effects 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 8
- 108091005461 Nucleic proteins Proteins 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 108090000994 Catalytic RNA Proteins 0.000 description 7
- 102000053642 Catalytic RNA Human genes 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 7
- 235000019161 pantothenic acid Nutrition 0.000 description 7
- 239000011713 pantothenic acid Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000004952 protein activity Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000012552 review Methods 0.000 description 7
- 108091092562 ribozyme Proteins 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 6
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010021466 Mutant Proteins Proteins 0.000 description 6
- 102000008300 Mutant Proteins Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000005842 biochemical reaction Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 229940041514 candida albicans extract Drugs 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000003527 eukaryotic cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 235000001968 nicotinic acid Nutrition 0.000 description 6
- 239000011664 nicotinic acid Substances 0.000 description 6
- 229940014662 pantothenate Drugs 0.000 description 6
- 210000001236 prokaryotic cell Anatomy 0.000 description 6
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 6
- 235000019192 riboflavin Nutrition 0.000 description 6
- 229960002477 riboflavin Drugs 0.000 description 6
- 239000002151 riboflavin Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- 108091033380 Coding strand Proteins 0.000 description 5
- 238000000018 DNA microarray Methods 0.000 description 5
- 102000005720 Glutathione transferase Human genes 0.000 description 5
- 108010070675 Glutathione transferase Proteins 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 239000007984 Tris EDTA buffer Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 235000019152 folic acid Nutrition 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229960003512 nicotinic acid Drugs 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000004144 purine metabolism Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 235000008521 threonine Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 229930003270 Vitamin B Natural products 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 206010013023 diphtheria Diseases 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000037041 intracellular level Effects 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 235000021436 nutraceutical agent Nutrition 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- OTOIIPJYVQJATP-BYPYZUCNSA-N (R)-pantoic acid Chemical compound OCC(C)(C)[C@@H](O)C(O)=O OTOIIPJYVQJATP-BYPYZUCNSA-N 0.000 description 3
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical group O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 102000003939 Membrane transport proteins Human genes 0.000 description 3
- 108090000301 Membrane transport proteins Proteins 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 229950006790 adenosine phosphate Drugs 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 229960004050 aminobenzoic acid Drugs 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 230000008238 biochemical pathway Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000001851 biosynthetic effect Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000006652 catabolic pathway Effects 0.000 description 3
- 239000012539 chromatography resin Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 239000005516 coenzyme A Substances 0.000 description 3
- 229940093530 coenzyme a Drugs 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 3
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 3
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 3
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 150000002224 folic acids Chemical class 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002093 isoelectric focusing polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 235000006109 methionine Nutrition 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 239000002417 nutraceutical Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 3
- 230000004147 pyrimidine metabolism Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000019157 thiamine Nutrition 0.000 description 3
- 239000011721 thiamine Substances 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- DJJCXFVJDGTHFX-ZAKLUEHWSA-N uridine-5'-monophosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-ZAKLUEHWSA-N 0.000 description 3
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000589158 Agrobacterium Species 0.000 description 2
- 241001136792 Alle Species 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- PCDQPRRSZKQHHS-UHFFFAOYSA-N Cytidine 5'-triphosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-UHFFFAOYSA-N 0.000 description 2
- XPYBSIWDXQFNMH-UHFFFAOYSA-N D-fructose 1,6-bisphosphate Natural products OP(=O)(O)OCC(O)C(O)C(O)C(=O)COP(O)(O)=O XPYBSIWDXQFNMH-UHFFFAOYSA-N 0.000 description 2
- KTVPXOYAKDPRHY-SOOFDHNKSA-N D-ribofuranose 5-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O KTVPXOYAKDPRHY-SOOFDHNKSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 101710096438 DNA-binding protein Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000012824 chemical production Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000002742 combinatorial mutagenesis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- PCDQPRRSZKQHHS-ZAKLUEHWSA-N cytidine-5'-triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO[P@](O)(=O)O[P@@](O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-ZAKLUEHWSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- RNBGYGVWRKECFJ-UHFFFAOYSA-N fructose-1,6-phosphate Natural products OC1C(O)C(O)(COP(O)(O)=O)OC1COP(O)(O)=O RNBGYGVWRKECFJ-UHFFFAOYSA-N 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 238000003208 gene overexpression Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 239000012092 media component Substances 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 230000009061 membrane transport Effects 0.000 description 2
- 235000013379 molasses Nutrition 0.000 description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000003499 nucleic acid array Methods 0.000 description 2
- 230000037360 nucleotide metabolism Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- FPWMCUPFBRFMLH-UHFFFAOYSA-N prephenic acid Chemical compound OC1C=CC(CC(=O)C(O)=O)(C(O)=O)C=C1 FPWMCUPFBRFMLH-UHFFFAOYSA-N 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 239000002213 purine nucleotide Substances 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UDOGNMDURIJYQC-UHFFFAOYSA-N 2-amino-6-methyl-1h-pteridin-4-one Chemical compound N1C(N)=NC(=O)C2=NC(C)=CN=C21 UDOGNMDURIJYQC-UHFFFAOYSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- AQSRRZGQRFFFGS-UHFFFAOYSA-N 2-methylpyridin-3-ol Chemical compound CC1=NC=CC=C1O AQSRRZGQRFFFGS-UHFFFAOYSA-N 0.000 description 1
- UGPOBASOHYMNAK-UHFFFAOYSA-N 3'-O-methyltricetin Chemical compound OC1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 UGPOBASOHYMNAK-UHFFFAOYSA-N 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- PQGCEDQWHSBAJP-TXICZTDVSA-N 5-O-phosphono-alpha-D-ribofuranosyl diphosphate Chemical compound O[C@H]1[C@@H](O)[C@@H](O[P@](O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O PQGCEDQWHSBAJP-TXICZTDVSA-N 0.000 description 1
- WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000219498 Alnus glutinosa Species 0.000 description 1
- 241000252073 Anguilliformes Species 0.000 description 1
- 241000857945 Anita Species 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 235000009581 Balanites aegyptiaca Nutrition 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100190606 Caenorhabditis elegans egl-8 gene Proteins 0.000 description 1
- 101100282369 Caenorhabditis elegans gcc-2 gene Proteins 0.000 description 1
- 101100150283 Caenorhabditis elegans sre-6 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000631130 Chrysophyllum argenteum Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000289527 Cordyline terminalis Species 0.000 description 1
- 235000009091 Cordyline terminalis Nutrition 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- NGHMDNPXVRFFGS-IUYQGCFVSA-N D-erythrose 4-phosphate Chemical compound O=C[C@H](O)[C@H](O)COP(O)(O)=O NGHMDNPXVRFFGS-IUYQGCFVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 241000964486 Egle Species 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241001658031 Eris Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 206010051998 Febrile infection Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010001496 Galectin 2 Proteins 0.000 description 1
- 102100021735 Galectin-2 Human genes 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000057621 Glycerol kinases Human genes 0.000 description 1
- 108700016170 Glycerol kinases Proteins 0.000 description 1
- 102000002667 Glycine hydroxymethyltransferase Human genes 0.000 description 1
- 108010043428 Glycine hydroxymethyltransferase Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000288105 Grus Species 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241001235200 Haemophilus influenzae Rd KW20 Species 0.000 description 1
- 102100023696 Histone-lysine N-methyltransferase SETDB1 Human genes 0.000 description 1
- 101710168120 Histone-lysine N-methyltransferase SETDB1 Proteins 0.000 description 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 description 1
- 101710134306 Macrophage scavenger receptor types I and II Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 241000252067 Megalops atlanticus Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical class [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100365384 Mus musculus Eefsec gene Proteins 0.000 description 1
- 101100504379 Mus musculus Gfral gene Proteins 0.000 description 1
- 101100421142 Mus musculus Selenon gene Proteins 0.000 description 1
- 241000204051 Mycoplasma genitalium Species 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 101100378851 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) alg-3 gene Proteins 0.000 description 1
- 101100380548 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) apg-2 gene Proteins 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101001041669 Oryctolagus cuniculus Corticostatin 1 Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- ZNXZGRMVNNHPCA-UHFFFAOYSA-N Pantetheine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-UHFFFAOYSA-N 0.000 description 1
- 101100150299 Penicillium chrysogenum SREP gene Proteins 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 240000004350 Prunus spinosa Species 0.000 description 1
- 235000010829 Prunus spinosa Nutrition 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 1
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-M S-carboxylatomethyl-L-cysteine(1-) Chemical compound [O-]C(=O)[C@@H]([NH3+])CSCC([O-])=O GBFLZEXEOZUWRN-VKHMYHEASA-M 0.000 description 1
- 229910003798 SPO2 Inorganic materials 0.000 description 1
- 101100478210 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spo2 gene Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 241000718007 Taenionema palladium Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000223892 Tetrahymena Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 1
- 241000218220 Ulmaceae Species 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- BEGNGYUSAPAHKH-FOBYXSAKSA-N [O-]C(CNC[S+]=C(N1)N([C@@H]([C@@H]2O)O[C@H](CO)[C@H]2O)C=CC1=O)=O Chemical compound [O-]C(CNC[S+]=C(N1)N([C@@H]([C@@H]2O)O[C@H](CO)[C@H]2O)C=CC1=O)=O BEGNGYUSAPAHKH-FOBYXSAKSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000012435 analytical chromatography Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000007621 bhi medium Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000001486 biosynthesis of amino acids Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000001818 capillary gel electrophoresis Methods 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- BKHZIBWEHPHYAI-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol Chemical compound ClC(Cl)Cl.CC(C)CCO BKHZIBWEHPHYAI-UHFFFAOYSA-N 0.000 description 1
- ZYWFEOZQIUMEGL-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol;phenol Chemical compound ClC(Cl)Cl.CC(C)CCO.OC1=CC=CC=C1 ZYWFEOZQIUMEGL-UHFFFAOYSA-N 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 125000003346 cobalamin group Chemical group 0.000 description 1
- 239000010941 cobalt Chemical class 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical class [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 101150064923 dapD gene Proteins 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 101150036185 dnaQ gene Proteins 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 101150036612 gnl gene Proteins 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005431 ipriflavone Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000011777 magnesium Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical class [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000001369 metatartaric acid Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000001320 near-infrared absorption spectroscopy Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- ZNXZGRMVNNHPCA-VIFPVBQESA-N pantetheine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-VIFPVBQESA-N 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- LYCRXMTYUZDUGA-UYRKPTJQSA-N pimeloyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LYCRXMTYUZDUGA-UYRKPTJQSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 229940076376 protein agonist Drugs 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical class OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012409 standard PCR amplification Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 239000005460 tetrahydrofolate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- BWHOZHOGCMHOBV-BQYQJAHWSA-N trans-benzylideneacetone Chemical compound CC(=O)\C=C\C1=CC=CC=C1 BWHOZHOGCMHOBV-BQYQJAHWSA-N 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
CORYNEBACTERIUM GLUTAMICUM GENES ENCODING co
PHOSPHOENOLPYRUVATE: SUGAR PHOSPHOTRANSFERASE SYSTEM Co
PROTEINS
This application claims priority to U.S. Provisional Patent Application No.: 60/142,691, filed on July 1, 1999, and also to U.S. Provisional Patent Application No.: 60/150,310, filed on August 23, 1999, incorporated herein in their entirety by this reference. This application also claims priority to German Patent Application No.: 19942095.5, filed on September 3, 1999, and also to German Patent Application No.: 19942097.1, filed on September 3, 1999, incorporated herein in their entirety by this reference.
Certain products and by-products of naturally-occurring metabolic processes in cells have utility in a wide array of industries, including the food, feed, cosmetics, and pharmaceutical industries. These molecules, collectively termed ‘fine chemicals’, include organic acids, both proteinogenic and non-proteinogenic amino acids, nucleotides and nucleosides, lipids and fatty acids, diols, carbohydrates, aromatic compounds, vitamins and cofactors, and enzymes. Their production is most conveniently performed through large-scale culture of bacteria developed to produce and secrete large quantities of a particular desired molecule. One particularly useful organism for this purpose is Corynebacterium glutamicum, a gram positive, nonpathogenic bacterium. Through strain selection, a number of mutant strains have been developed which produce an array of desirable compounds. However, selection of strains improved for the production of a particular molecule is a time-consuming and difficult process.
The invention provides novel bacterial nucleic acid molecules which have a variety of uses. These uses include the identification of microorganisms which can be used to produce fine chemicals, the modulation of fine chemical production in C.
glutamicum or related bacteria, the typing or identification of C. glutamicum or related . bacteria, as reference points for mapping the C. glutamicum genome, and as markers for transformation. These novel nucleic acid molecules encode proteins, referred to herein as phosphoenolpyruvate:sugar phosphotransferase system (PTS) proteins.
C. glutamicum is a gram positive, aerobic bacterium which is commonly used in industry for the large-scale production of a variety of fine chemicals, and also for the degradation of hydrocarbons (such as in petroleum spills) and for the oxidation of terpenoids. The PTS nucleic acid molecules of the invention, therefore, can be used to identify microorganisms which can be used to produce fine chemicals, e.g., by fermentation processes. Modulation of the expression of the PTS nucleic acids of the invention, or modification of the sequence of the PTS nucleic acid molecules of the invention, can be used to modulate the production of one or more fine chemicals from a } microorganism (e.g., to improve the yield or production of one or more fine chemicals from a Corynebacterium or Brevibacterium species). ‘The PTS nucleic acids of the invention may also be used to identify an organism as being Corynebacterium glutamicum or a close relative thereof, or to identify the presence of C. glutamicum or a relative thereof in a mixed population of microorganisms. The invention provides the nucleic acid sequences of a number of C. glutamicum genes; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning a region of a C. glutamicum gene which is unique to this organism, one can ascertain whether this organism is present. Although Corynebacterium glutamicum itself is nonpathogenic, it is related to species pathogenic in humans, such as Corynebacterium diphtheriae (the causative agent of diphtheria); the detection of such organisms is of significant clinical relevance.
The PTS nucleic acid molecules of the invention may also serve as reference points for mapping of the C. glutamicum genome, or of genomes of related organisms.
Similarly, these molecules, or variants or portions thereof, may serve as markers for genetically engineered Corynebacterium or Brevibacterium species.
The PTS proteins encoded by the novel nucleic acid molecules of the invention are capable of, for example, transporting high-energy carbon-containing molecules such as glucose into C. glutamicum, or of participating in intracellular signal transduction in this microorganism. Given the availability of cloning vectors for use in
Corynebacterium glutamicum, such as those disclosed in Sinskey et al., U.S. Patent No. } 4,649,119, and techniques for genetic manipulation of C. glutamicum and the related
Brevibacterium species (e.g., lactofermentum) (Yoshihama et al, J. Bacteriol. 162: 591- 597 (1985), Katsumata et al., J. Bacteriol. 159: 306-311 (1984); and Santamaria et al., J.
Gen. Microbiol. 130: 2237-2246 (1984)), the nucleic acid molecules of the invention may be utilized in the genetic engineering of this organism to make it a better or more efficient producer of one or more fine chemicals.
The PTS molecules of the invention may be modified such that the yield, production, and/or efficiency of production of one or more fine chemicals is improved.
For example, by modifying a PTS protein involved in the uptake of glucose such that it is optimized in activity, the quantity of glucose uptake or the rate at which glucose is translocated into the cell may be increased. The breakdown of glucose and other sugars within the cell provides energy that may be used to drive energetically unfavorable biochemical reactions, such as those involved in the biosynthesis of fine chemicals.
This breakdown also provides intermediate and precursor molecules necessary for the biosynthesis of certain fine chemicals, such as amino acids, vitamins and cofactors. By increasing the amount of intracellular high-energy carbon molecules through modification of the PTS molecules of the invention, one may therefore increase both the energy available to perform metabolic pathways necessary for the production of one or more fine chemicals, and also the intracellular pools of metabolites necessary for such production.
Further, the PTS molecules of the invention may be involved in one or more intracellular signal transduction pathways which may affect the yields and/or rate of production of one or more fine chemical from C. glutamicum. For example, proteins necessary for the import of one or more sugars from the extracellular medium (e.g, HPr,
Enzyme I, or a member of an Enzyme II complex) are frequently posttranslationally modified upon the presence of a sufficient quantity of the sugar in the cell, such that they are no longer able to import that sugar. While this quantity of sugar at which the transport system is shut off may be sufficient to sustain the normal functioning of the cell, it may be limiting for the overproduction of the desired fine chemical. Thus, it may be desirable to modify the PTS proteins of the invention such that they are no longer responsive to such negative regulation, thereby permitting greater intracellular . concentrations of one or more sugars to be achieved, and, by extension, more efficient production or greater yields of one or more fine chemicals from organisms containing such mutant PTS proteins.
This invention provides novel nucleic acid molecules which encode proteins, referred to herein as phosphoenolpyruvate:sugar phosphotransferase system (PTS) proteins, which are capable of, for example, participating in the import of high-energy carbon moleculcs (e.g., glucose, fructose, or sucrose) into C. glutamicum, and/or of participating in one or more C. glutamicum intracellular signal transduction pathways.
Nucleic acid molecules encoding a PTS protein are referred to herein as PTS nucleic acid molecules. In a preferred embodiment, the PTS protein participates in the import of high-energy carbon molecules (e.g., glucose, fructose, or sucrose) into C. glutamicum, } and also may participate in one or more C. glutamicum intracellular signal transduction - pathways. Examples of such proteins include those encoded by the genes set forth in
Table I.
Accordingly, one aspect of the invention pertains to isolated nucleic acid molecules (e.g., cDNAs, DNAs, or RNAs) comprising a nucleotide sequence encoding a
PTS protein or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection or amplification of PTS- encoding nucleic acid (e.g., DNA or mRNA). In particularly preferred embodiments, the isolated nucleic acid molecule comprises one of the nucleotide sequences set forth in as the odd-numbered SEQ ID NOs in the Sequence Listing (e.g., SEQ ID NO:1, SEQ ID
NO:3, SEQ ID NO:5, SEQ ID NO:7....) or the coding region or a complement thereof of one of these nucleotide sequences. In other particularly preferred embodiments, the isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes to or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80% or 90%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence set forth, as an odd-numbered
SEQ ID NO in the Sequence Listing (e.g., SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5,
SEQIDNO:7....), ora portion thereof. In other preferred embodiments, the isolated nucleic acid molecule encodes one of the amino acid sequences set forth in as an even- numbered SEQ ID NO in the Sequence Listing (e.g., SEQ ID NO:2, SEQ ID NO:4, SEQ
ID NO:6, SEQ ID NO:8....). The preferred PTS proteins of the present invention also preferably possess at least one of the PTS activities described herein. .
In another embodiment, the isolated nucleic acid molecule encodes a protein or portion thereof wherein the protein or portion thereof includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of the invention (e.g, a sequence having an even-numbered SEQ ID NO: in the Sequence Listing), e.g, sufficiently homologous to an amino acid sequence of the invention such that the protein or portion thereof maintains a PTS activity. Preferably, the protein or portion thereof encoded by the nucleic acid molecule maintains the ability to participate in the import of high-energy carbon molecules (e.g., glucose, fructose, or sucrose) into C. glutamicum, and/or to participate in one or more C. glutamicum intracellular signal transduction pathways. In one embodiment, the protein encoded by the nucleic acid molecule is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, } 80%, or 90% and most preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous to an amino acid sequence of the invention (e.g., an entire amino acid sequence selected from those having an even-numbered SEQ ID NO in the Sequence
Listing). In another preferred embodiment, the protein is a full length C. glutamicum protein which is substantially homologous to an entire amino acid sequence of the invention (encoded by an open reading frame shown in the corresponding odd-numbered
SEQ ID NOs in the Sequence Listing (e.g., SEQ 1D NO:1, SEQ ID NO:3, SEQ ID
NO:5, SEQ ID NO:7....).
In another preferred embodiment, the isolated nucleic acid molecule is derived from C. glutamicum and encodes a protein (e.g., a PTS fusion protein) which includes a biologically active domain which is at least about 50% or more homologous to one of the amino acid sequences of the invention (e.g., a sequence of one of the even-numbered
SEQ ID NOs in the Sequence Listing) and is able to participate in the import of high- energy carbon molecules (e.g, glucose, fructose, or sucrose) into C. glutamicum, and/or to participate in one or more C. glutamicum intracellular signal transduction pathways, or possesses one or more of the activities set forth in Table 1, and which also includes heterologous nucleic acid sequences encoding a heterologous polypeptide or regulatory regions.
In another embodiment, the isolated nucleic acid molecule is at least 15 . nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising a nucleotide sequence of the invention (e.g., a sequence of an odd- numbered SEQ ID NO in the Sequence Listing). Preferably, the isolated nucleic acid molecule corresponds to a naturally-occurring nucleic acid molecule. More preferably, the isolated nucleic acid encodes a naturally-occurring C. glutamicum PTS protein, or a biologically active portion thereof.
Another aspect of the invention pertains to vectors, e.g., recombinant expression vectors, containing the nucleic acid molecules of the invention, and host cells into which such vectors have been introduced. In one embodiment, such a host cell is used to produce a PTS protein by culturing the host cell in a suitable medium. The PTS protein can be then isolated from the medium or the host cell. ] Yet another aspect of the invention pertains to a genetically altered microorganism in which a PTS gene has been introduced or altered. In one cmbodiment, the genome of the microorganism has been altered by the introduction of a nucleic acid molecule of the invention encoding wild-type or mutated PTS sequence as a transgene. In another embodiment, an endogenous PTS gene within the genome of the microorganism has been altered, e.g., functionally disrupted, by homologous recombination with an altered PTS gene. In another embodiment, an endogenous or introduced PTS gene in a microorganism has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional PTS protein. In still another embodiment, one or more of the regulatory regions (e.g., a promoter, repressor, or inducer) of a PTS gene in a microorganism has been altered (e.g., by deletion, truncation, inversion, or point mutation) such that the expression of the PTS gene is modulated. In a preferred embodiment, the microorganism belongs to the genus
Corynebacterium or Brevibacterium, with Corynebacterium glutamicum being particularly preferred. In a preferred embodiment, the microorganism is also utilized for the production of a desired compound, such as an amino acid, with lysine being particularly preferred.
In another aspect, the invention provides a method of identifying the presence or activity of Cornyebacterium diphtheriae in a subject. This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (e.g., the sequences set forth in the Sequence Listing as SEQ ID NOs 1 through 34)) in a subject, thereby detecting the presence or activity of Corynebacterium diphtheriae in the subject. .
Still another aspect of the invention pertains to an isolated PTS protein or a portion, e.g., a biologically active portion, thereof. In a preferred embodiment, the isolated PTS protein or portion thereof can participate in the import of high-energy carbon molecules (e.g., glucose, fructose, or sucrose) into C. glutamicum, and also may participate in one or more C. glutamicum intracellular signal transduction pathways. In another preferred embodiment, the isolated PTS protein or portion thereof is sufficiently homologous to an amino acid scquence of the invention (e.g., a sequence of an cven- numbered SEQ ID NO: in the Sequence Listing) such that the protein or portion thereof maintains the ability to participate in the import of high-energy carbon molecules (e.g, glucose, fructose, or sucrose) into C. glutamicum, and /or to participate in one or more
C. glutamicum intracellular signal transduction pathways.
The invention also provides an isolated preparation of a PTS protein. In preferred embodiments, the PTS protein comprises an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Scquence Listing).
In another preferred embodiment, the invention pertains to an isolated full length protein which is substantially homologous to an entire amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) (encoded by an open reading frame set in a corresponding odd-numbered SEQ ID NO. of the
Sequence Listing). In yet another embodiment, the protein is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90%, and most preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous : to an entire amino acid sequence of the invention (e.g., a sequence of an even-numbered
SEQ ID NO: of the Sequence Listing). In other embodiments, the isolated PTS protein comprises an amino acid sequence which is at least about 50% or more homologous to one of the amino acid sequences of the invention (e.g., a sequence of an even-numbered
SEQ ID NO: of the Sequence Listing) and is able to participate in the import of high- energy carbon molecules (e.g., glucose, fructose, or sucrose) into C. glutamicum, and/or to participate in one or more C. glutamicum intracellular signal transduction pathways, or has one or more of the activities set forth in Table 1.
Alternatively, the isolated PTS protein can comprise an amino acid sequence ‘ which 1s encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80%, or 90%, and even more preferably at least about 95%, 96%, 97%, 98,%, or 99% or more homologous, to a nucleotide sequence of one of the even-numbered SEQ ID NOs set forth in the Sequence Listing. It is also preferred that the preferred forms of PTS proteins also have one or more of the PTS bioactivities described herein.
The PTS polypeptide, or a biologically active portion thereof, can be operatively linked to a non-PTS polypeptide to form a fusion protein. In preferred embodiments, this fusion protein has an activity which differs from that of the PTS protein alone. In other preferred embodiments, this fusion protein results in increased yields, production, . and/or efficiency of production of a desired fine chemical from C. glutamicum. In particularly preferred embodiments, integration of this fusion protein into a host cell 1S modulates the production of a desired compound from the cell.
In another aspect, the invention provides methods for screening molecules which modulate the activity of a PTS protein, either by interacting with the protein itself or a substrate or binding partner of the PTS protein, or by modulating the transcription or translation of a PTS nucleic acid molecule of the invention.
Another aspect of the invention pertains to a method for producing a fine chemical. This method involves the culturing of a cell containing a vector directing the expression of a PTS nucleic acid molecule of the invention, such that a fine chemical is produced. In a preferred embodiment, this method further includes the step of obtaining a cell containing such a vector, in which a cell is transfected with a vector directing the expression of a PTS nucleic acid. In another preferred embodiment, this method further includes the step of recovering the fine chemical from the culture. In a particularly preferred embodiment, the cell is from the genus Corynebacterium or Brevibacterium, or is selected from those strains set forth in Table 3.
Another aspect of the invention pertains to methods for modulating production of amolecule from a microorganism. Such methods include contacting the cell with an agent which modulates PTS protein activity or PTS nucleic acid expression such that a cell associated activity is altered relative to this same activity in the absence of the agent. In a preferred embodiment, the cell is modulated for the uptake of one or more sugars, such that the yields or rate of production of a desired fine chemical by this microorganism is improved. The agent which modulates PTS protein activity can be an agent which stimulates PTS protein activity or PTS nucleic acid expression. Examples of agents which stimulate PTS protein activity or PTS nucleic acid expression include small molecules, active PTS proteins, and nucleic acids encoding PTS proteins that have been introduced into the cell. Examples of agents which inhibit PTS activity or expression include small molecules, and antisense PTS nucleic acid molecules.
Another aspect of the invention pertains to methods for modulating yields of a desired compound from a cell, involving the introduction of a wild-type or mutant PTS gene into a cell, either maintained on a separate plasmid or integrated into the genome of the host cell. If integrated into the genome, such integration can random, or it can take place by homologous recombination such that the native gene is replaced by the } introduced copy, causing the production of the desired compound from the cell to be modulated. In a preferred embodiment, said yields are increased. In another preferred embodiment, said chemical is a fine chemical. In a particularly preferred embodiment, said fine chemical is an amino acid. In especially preferred embodiments, said amino acid is L-lysine.
The present invention provides PTS nucleic acid and protein molecules which are involved in the uptake of high-energy carbon molecules (e.g., sucrose, fructose, or glucose) into C. glutamicum, and may also participate in intracellular signal transduction pathways in this microorganism. The molecules of the invention may be utilized in the modulation of production of fine chemicals from microorganisms. Such modulation may be due to increased intracellular levels of high-energy molecules needed to produce, e.g., ATP, GTP and other molecules utilized to drive energetically unfavorable biochemical reactions in the cell, such as the biosynthesis of a fine chemical. This modulation of fine chemical production may also be due to the fact that the breakdown products of many sugars serve as intermediates or precursors for other biosynthetic pathways, including those of certain fine chemicals. Further, PTS proteins are known to participate in certain intracellular signal transduction pathways which may have regulatory activity for one or more fine chemical metabolic pathways; by manipulating . these PTS proteins, one may thereby activate a fine chemical biosynthetic pathways or repress a fine chemical degradation pathway. Aspects of the invention are further explicated below.
I. Fine Chemicals
The term ‘fine chemical’ is art-recognized and includes molecules produced by an organism which have applications in various industries, such as, but not limited to, the pharmaceutical, agriculture, and cosmetics industries. Such compounds include organic acids, such as tartaric acid, itaconic acid, and diaminopimelic acid, both proteinogenic and non-proteinogenic amino acids, purine and pyrimidine bases, nucleosides, and nucleotides (as described e.g. in Kuninaka, A. (1996) Nucleotides and ) related compounds, p. 561-612, in Biotechnology vol. 6, Rehm ef al., eds. VCH:
Weinheim, and references contained therein), lipids, both saturated and unsaturated fatty acids (e.g., arachidonic acid), diols (e.g., propane diol, and butane diol), carbohydrates (e.g, hyaluronic acid and trehalose), aromatic compounds (e.g., aromatic amines, vanillin, and indigo), vitamins and cofactors (as described in Ullmann’s Encyclopedia of
Industrial Chemistry, vol. A27, “Vitamins”, p. 443-613 (1996) VCH: Weinheim and references therein; and Ong, A.S., Niki, E. & Packer, L. (1995) “Nutrition, Lipids,
Health, and Disease” Proceedings of the UNESCO/Confederation of Scientific and
Technological Associations in Malaysia, and the Society for Free Radical Research -
Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press, (1995)), enzymes, polyketides (Cane et al. (1998) Science 282: 63-68), and all other chemicals described in
Gutcho (1983) Chemicals by Fermentation, Noyes Data Corporation, ISBN: 0818805086 and references therein. The metabolism and uses of certain of these fine chemicals are further explicated below.
A. Amino Acid Metabolism and Uses
Amino acids comprise the basic structural units of all proteins, and as such are essential for normal cellular functioning in all organisms. The term “amino acid” is art- recognized. The proteinogenic amino acids, of which there are 20 species, serve as structural units for proteins, in which they are linked by peptide bonds, while the nonproteinogenic amino acids (hundreds of which are known) arc not normally found in proteins (see Ulmann’s Encyclopedia of Industrial Chemistry, vol. A2, p. 57-67 VCH: :
Weinheim (1985)). Amino acids may be in the D- or L- optical configuration, though L- amino acids are generally the only type found in naturally-occurring proteins.
Biosynthetic and degradative pathways of each of the 20 proteinogenic amino acids have been well characterized in both prokaryotic and eukaryotic cells (see, for example,
Stryer, L. Biochemistry, 3" edition, pages 578-590 (1988)). The ‘essential’ amino acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), so named because they are generally a nutritional requirement due to the complexity of their biosyntheses, are readily converted by simple biosynthetic pathways to the remaining 11 ‘nonessential’ amino acids (alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, and tyrosine). Higher animals do retain the ability to synthesize some of these amino acids, but the essential amino acids must be supplied from the diet in order for normal protein synthesis to occur.
Aside from their function in protein biosynthesis, these amino acids are interesting chemicals in their own right, and many have been found to have various applications in the food, feed, chemical, cosmetics, agriculture, and pharmaceutical industries. Lysine is an important amino acid in the nutrition not only of humans, but also of monogastric animals such as poultry and swine. Glutamate is most commonly used as a flavor additive (mono-sodium glutamate, MSG) and is widely used throughout the food industry, as are aspartate, phenylalanine, glycine, and cysteine. Glycine, L- methionine and tryptophan are all utilized in the pharmaceutical industry. Glutamine, valine, leucine, isoleucine, histidine, arginine, proline, serine and alanine are of use in both the pharmaceutical and cosmetics industries. Threonine, tryptophan, and D/ L- methionine are common feed additives. (Leuchtenberger, W. (1996) Amino aids — technical production and use, p. 466-502 in Rehm ef al. (eds.) Biotechnology vol. 6, chapter 14a, VCH: Weinheim). Additionally, these amino acids have been found to be useful as precursors for the synthesis of synthetic amino acids and proteins, such as N- acetylcysteine, S-carboxymethyl-L-cysteine, (S)-5-hydroxytryptophan, and others described in Ulmann’s Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97, VCH:
Weinheim, 1985.
The biosynthesis of these natural amino acids in organisms capable of - producing them, such as bacteria, has been well characterized (for review of bacterial amino acid biosynthesis and regulation thereof, see Umbarger, H.E.(1978) Ann. Rev.
Biochem. 47: 533-606). Glutamate is synthesized by the reductive amination of a- ketoglutarate, an intermediate in the citric acid cycle. Glutamine, proline, and arginine are each subsequently produced from glutamate. The biosynthesis of serine is a three- step process beginning with 3-phosphoglycerate (an intermediate in glycolysis), and resulting in this amino acid after oxidation, transamination, and hydrolysis steps. Both cysteine and glycine are produced from serine; the former by the condensation of homocysteine with serine, and the latter by the transferal of the side-chain B-carbon atom to tetrahydrofolate, in a reaction catalyzed by serine transhydroxymethylase.
Phenylalanine, and tyrosine are synthesized from the glycolytic and pentose phosphate } pathway precursors erythrose 4-phosphate and phosphoenolpyruvate in a 9-step biosynthetic pathway that differ only at the final two steps after synthesis of prephenate.
Tryptophan is also produced from these two initial molecules, but its synthesis is an 11- step pathway. Tyrosine may also be synthesized from phenylalanine, in a reaction catalyzed by phenylalanine hydroxylase. Alanine, valine, and leucine are all biosynthetic products of pyruvate, the final product of glycolysis. Aspartate is formed from oxaloacetate, an intermediate of the citric acid cycle. Asparagine, methionine, threonine, and lysine are each produced by the conversion of aspartate. Isoleucine is formed from threonine. A complex 9-step pathway results in the production of histidine from 5-phosphoribosyl-1-pyrophosphate, an activated sugar.
Amino acids in excess of the protein synthesis needs of the cell cannot be stored, and are instead degraded to provide intermediates for the major metabolic pathways of the cell (for review see Stryer, L. Biochemistry 3" ed. Ch. 21 “Amino Acid Degradation and the Urea Cycle” p. 495-516 (1988)). Although the cell is able to convert unwanted amino acids into useful metabolic intermediates, amino acid production is costly in terms of energy, precursor molecules, and the enzymes necessary to synthesize them.
Thus it is not surprising that amino acid biosynthesis is regulated by feedback inhibition, in which the presence of a particular amino acid serves to slow or entirely stop its own production (for overview of feedback mechanisms in amino acid biosynthetic pathways, see Stryer, L. Biochemistry, 3" ed. Ch. 24: “Biosynthesis of Amino Acids and Heme” p.
575-600 (1988)). Thus, the output of any particular amino acid is limited by the amount of that amino acid present in the cell. ]
B. Vitamin, Cofactor, and Nutraceutical Metabolism and Uses
Vitamins, cofactors, and nutraceuticals comprise another group of molecules which the higher animals have lost the ability to synthesize and so must ingest, although they are readily synthesized by other organisms, such as bacteria. These molecules are either bioactive substances themselves, or are precursors of biologically active substances which may serve as electron carriers or intermediates in a variety of mctabolic pathways. Aside from their nutritive value, these compounds also have significant industrial value as colonng agents, antioxidants, and catalysts or other processing aids. (For an overview of the structure, activity, and industrial applications of these compounds, see, for example, Ullman’s Encyclopedia of industrial Chemistry, “Vitamins” vol. A27, p. 443-613, VCH: Weinheim, 1996.) The term “vitamin” is art- recognized, and includes nutrients which are required by an organism for normal functioning, but which that organism cannot synthesize by itself. The group of vitamins may encompass cofactors and nutraceutical compounds. The language “cofactor” includes nonproteinaceous compounds required for a normal enzymatic activity to occur. Such compounds may be organic or inorganic; the cofactor molecules of the invention are preferably organic. The term “nutraceutical” includes dietary supplements having health benefits in plants and animals, particularly humans. Examples of such molecules are vitamins, antioxidants, and also certain lipids (e.g., polyunsaturated fatty acids).
The biosynthesis of these molecules in organisms capable of producing them, such as bacteria, has been largely characterized (Ullman’s Encyclopedia of Industrial
Chemistry, “Vitamins” vol. A27, p. 443-613, VCH: Weinheim, 1996; Michal, G. (1999)
Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, John Wiley & Sons; Ong, A.S., Niki, E. & Packer, L. (1995) “Nutrition, Lipids, Health, and
Disease” Proceedings of the UNESCO/Confederation of Scientific and Technological
Associations in Malaysia, and the Society for Free Radical Research — Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press: Champaign, IL X, 374 S).
Thiamin (vitamin B,) is produced by the chemical coupling of pyrimidine and : thiazole moieties. Riboflavin (vitamin B;) is synthesized from guanosine-5’-triphosphate (GTP) and ribose-5’-phosphate. Riboflavin, in turn, is utilized for the synthesis of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). The family of compounds collectively termed ‘vitamin Be’ (e.g., pyridoxine, pyridoxamine, pyridoxa-
S’-phosphate, and the commercially used pyridoxin hydrochloride) are all derivatives of the common structural unit, 5-hydroxy-6-methylpyridine. Pantothenate (pantothenic acid, (R)-(+)-N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-B-alanine) can be produced either by chemical synthesis or by fermentation. The final steps in pantothenate biosynthesis consist of the ATP-driven condensation of $-alanine and pantoic acid. The enzymes responsible for the biosynthesis steps for the conversion to pantoic acid, to - alanine and for the condensation to panthotenic acid are known. The metabolically ] active form of pantothenate is Coenzyme A, for which the biosynthesis proceeds in 5 enzymatic steps. Pantothenate, pyridoxal-5’-phosphate, cysteine and ATP are the precursors of Coenzyme A. These enzymes not only catalyze the formation of panthothante, but also the production of (R)-pantoic acid, (R)-pantolacton, (R)- oo panthenol (provitamin Bs), pantetheine (and its derivatives) and coenzyme A.
Biotin biosynthesis from the precursor molecule pimeloyl-CoA in microorganisms has been studied in detail and several of the genes involved have been identified. Many of the corresponding proteins have been found to also be involved in
Fe-cluster synthesis and are members of the nif class of proteins. Lipoic acid is derived from octanoic acid, and serves as a coenzyme in energy metabolism, where it becomes part of the pyruvate dehydrogenase complex and the a-ketoglutarate dehydrogenase complex. The folates are a group of substances which are all derivatives of folic acid, which is turn is derived from L-glutamic acid, p-amino-benzoic acid and 6- methylpterin. The biosynthesis of folic acid and its derivatives, starting from the metabolism intermediates guanosine-5’-triphosphate (GTP), L-glutamic acid and p- amino-benzoic acid has been studied in detail in certain microorganisms.
Corrinoids (such as the cobalamines and particularly vitamin B ;) and porphyrines belong to a group of chemicals characterized by a tetrapyrole ring system.
The biosynthesis of vitamin B,; is sufficiently complex that it has not yet been completely characterized, but many of the enzymes and substrates involved are now known. Nicotinic acid (nicotinate), and nicotinamide are pyridine derivatives which arc also termed ‘niacin’. Niacin is the precursor of the important coenzymes NAD - (nicotinamide adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate) and their reduced forms.
The large-scale production of these compounds has largely relied on cell-free chemical syntheses, though some of these chemicals have also been produced by large- scale culture of microorganisms, such as riboflavin, Vitamin Bg, pantothenate, and biotin. Only Vitamin By; is produced solely by fermentation, due to the complexity of its synthesis. In virro methodologies require significant inputs of materials and time, often at great cost.
C. Purine, Pyrimidine, Nucleoside and Nucleotide Metabolism and Uses
Purine and pyrimidine metabolism genes and their corresponding proteins are important targets for the therapy of tumor diseases and viral infections. The language “purine” or “pyrimidine” includes the nitrogenous bases which are constituents of nucleic acids, co-enzymes, and nucleotides. The term “nucleotide” includes the basic structural units of nucleic acid molecules, which are compriscd of a nitrogenous base, a pentose sugar (in the case of RNA, the sugar is ribose; in the case of DNA, the sugar 1s
D-deoxyribose), and phosphoric acid. The language “nucleoside” includes molecules which serve as precursors to nucleotides, but which are lacking the phosphoric acid moiety that nucleotides possess. By inhibiting the biosynthesis of these molecules, or their mobilization to form nucleic acid molecules, it is possible to inhibit RNA and DNA synthesis; by inhibiting this activity in a fashion targeted to cancerous cells, the ability of tumor cells to divide and replicate may be inhibited. Additionally, there are nucleotides which do not form nucleic acid molecules, but rather serve as energy stores (i.e., AMP) or as coenzymes (i.e., FAD and NAD).
Several publications have described the use of these chemicals for these medical indications, by influencing purine and/or pyrimidine metabolism (e.g. Christopherson,
R.I. and Lyons, S.D. (1990) “Potent inhibitors of de novo pyrimidine and purine biosynthesis as chemotherapeutic agents.” Med. Res. Reviews 10: 505-548). Studies of enzymes involved in purine and pyrimidine metabolism have been focused on the development of new drugs which can be used, for example, as immunosuppressants or anti-proliferants (Smith, J.L., (1995) “Enzymes in nucleotide synthesis.” Curr. Opin. ; Struct. Biol. 5: 752-757; (1995) Biochem Soc. Transact. 23: 877-902). However, purine and pyrimidine bases, nucleosides and nucleotides have other utilities: as intermediates in the biosynthesis of several fine chemicals (e. g., thiamine, S-adenosyl-methionine, folates, or riboflavin), as energy carriers for the cell (e.g., ATP or GTP), and for chemicals themselves, commonly used as flavor enhancers (e.g., IMP or GMP) or for several medicinal applications (see, for example, Kuninaka, A. (1996) Nucleotides and
Related Compounds in Biotechnology vol. 6, Rehm et al., eds. VCH: Weinheim, p. 561- 612). Also, enzymes involved in purine, pyrimidine, nucleoside, or nucleotide metabolism are increasingly serving as targets against which chemicals for crop protection, including fungicides, herbicides and insecticides, are developed.
The metabolism of these compounds in bacteria has been characterized (for reviews see, for example, Zalkin, H. and Dixon, J.E. (1992) “de novo purine nucleotide biosynthesis”, in: Progress in Nucleic Acid Research and Molecular Biology, vol. 42,
Academic Press:, p. 259-287; and Michal, G. (1999) “Nucleotides and Nucleosides”,
Chapter 8 in: Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology,
Wiley: New York). Purine metabolism has been the subject of intensive research, and is essential to the normal functioning of the cell. Impaired purine metabolism in higher animals can cause severe disease, such as gout. Purine nucleotides are synthesized from ribose-5-phosphate, in a series of steps through the intermediate compound inosine-5’- phosphate (IMP), resulting in the production of guanosine-5’-monophosphate (GMP) or adenosine-5’-monophosphate (AMP), from which the triphosphate forms utilized as nucleotides are readily formed. These compounds are also utilized as energy stores, so their degradation provides energy for many different biochemical processes in the cell.
Pyrimidine biosynthesis proceeds by the formation of uridine-5’-monophosphate (UMP) from ribose-5-phosphate. UMP, in turn, is converted to cytidine-5’-triphosphate (CTP).
The deoxy- forms of all of these nucleotides are produced in a one step reduction reaction from the diphosphate ribose form of the nucleotide to the diphosphate deoxyribose form of the nucleotide. Upon phosphorylation, these molecules are able to participate in DNA synthesis.
D. Trehalose Metabolism and Uses
Trehalose consists of two glucose molecules, bound in a, o-1,1 linkage. It is . commonly used in the food industry as a sweetener, an additive for dried or frozen foods, and in beverages. However, it also has applications in the pharmaceutical, cosmetics and biotechnology industries (see, for example, Nishimoto er al., (1998) U.S.
Patent No. 5,759,610; Singer, M.A. and Lindquist, S. (1998) Trends Biotech. 16: 460- 467; Paiva, C.L.A. and Panek, A.D. (1996) Biotech. Ann. Rev. 2: 293-314; and
Shiosaka, M. (1997) J. Japan 172: 97-102). Trehalose is produced by enzymes from many microorganisms and is naturally released into the surrounding medium, from which it can be collected using methods known in the art.
II. The Phosphoenolpyruvate: Sugar Phosphotransferase System
The ability of cells to grow and divide rapidly in culture is to a great degree dependent on the extent to which the cells are able to take up and utilize high energy molecules, such as glucose and other sugars. Different transporter proteins exist to transport different carbon sources into the cell. There are transport proteins for sugars, such as glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, or raffinose, and also transport proteins for starch or cellulose degradation products. Other transport systems serve to import alcohols (e. g., methanol or ethanol), alkanes, fatty acids and organic acids like acetic acid or lactic acid. In bactena, sugars may be transported into the cell across the cellular membrane by a variety of mechanisms. Aside from the symport of sugars with protons, one of the most commonly utilized processes for sugar uptake is the bacterial phosphoenolpyruvate: sugar phosphotransferase system (PTS). This system not only catalyzes the translocation (with concomitant phosphorylation) of sugars and hexitols, but it also regulates cellular metabolism in response to the availability of carbohydrates. Such PTS systems are ubiquitous in bacteria but do not occur in archaebacteria or eukaryotes.
Functionally, the PTS system consists of two cytoplasmic proteins, Enzyme I and HPr, and a variable number of sugar-specific integral and peripheral membrane transport complexes (each termed ‘Enzyme II’ with a sugar-specific subscript, e.g, ‘Enzyme [I°"" for the Enzyme II complex which binds glucose). Enzymes II specific for mono-, di-, or oligosaccharides, like glucose, fructose, mannose, galactose, ribose,
sorbose, ribulose, lactose, maltose, sucrose, raffinose, and others are known. Enzyme : transfers phosphoryl groups from phosphoenolpyruvate (PEP) to the phosphoryl carrier protein, HPr. HPr then transfers the phosphoryl groups to the different Enzyme II transport complexes. While the amino acid sequences of Enzyme 1 and HPr are quite similar in all bacteria, the sequences for PTS transporters can be grouped into structurally unrelated families. Further, the number and homology between these genes vary from bacteria to bacteria. The £. coli genome encodes 38 different PTS proteins, 33 of which are subunits belonging to 22 different transporters. The M. genitalium genome contains one gene each for Enzyme I and HPr, and only two genes for PTS transporters. The genomes of T. palladium and C. trachomatis contain genes for
Enzyme I- and HPr-like proteins but no PTS transporters.
All PTS transporters consist of three functional units, IIA, 1IB, and IIC, which . occur either as protein subunits in a complex (e.g, IASIICB%) or as domains of a single polypeptide chain (e.g., ICBAYMA). IIA and IIB sequentially transfer phosphoryl groups from HPr to the transported sugars. [IC contains the sugar binding site, and spans the inner membrane six or eight times. Sugar translocation is coupled to the transient phosphorylation of the [IB domain. Enzyme I, HPr, and IIA are phosphorylated at histidine residues, while IIB subunits are phosphorylated at either cysteine or histidine residues, depending on the particular transporter involved.
Phosphorylation of the sugar being imported has the advantage of blocking the diffusion of the sugar back through the cellular membrane to the extracellular medium, since the charged phosphate group cannot readily traverse the hydrophobic core of the membrane.
Some PTS proteins play a role in intracellular signal transduction in addition to their function in the active transport of sugars. These subunits regulate their targets either allosterically, or by phosphorylation. Their regulatory activity varies with the degree of their phosphorylation (i.e., the ratio of the non-phosphorylated to the phosphorylated form), which in turn varies with the ratio of sugar-dependent dephosphorylation and phosphoenolpyruvate-dependent rephosphorylation. Examples of such intracellular regulation by PTS proteins in E. coli include the inhibition of glycerol kinase by dephosphorylated [IA®', and the activation of adenylate cyclase by the phosphorylated version of this protein. Also, the HPr and the IIB domains of some transporters in these microorganisms regulate gene expression by reversible phosphorylation of transcription antiterminators. In gram-positive bacteria, the activity of HPr is modulated by HPr-specific serine kinases and phosphatases. For example, HPr : phosphorylated at serinc-46 functions as a co-repressor of the transcriptional repressor
CcpA. Lastly, it has been found that unphosphorylated Enzyme I inhibits the sensor kinase CheA of the bacterial chemotaxis machinery, providing a direct link between the sugar binding and transport systems of the bacterium and those systems governing movement of the bacterium (Sonenshein, A. L., et al., eds. Bacillus subtilis and other gram-positive bacteria. ASM: Washington, D.C; Neidhardt, F.C, et al, eds. (1996)
Escherichia coli and Salmonella. ASM Press: Washington, D.C.; Lengeler er al., (1999).
Biology of Prokaryotes. Section II, pp. 68-87, Thieme Verlag: Stuttgart).
III. Elements and Methods of the Invention
The present invention is based, at least in part, on the discovery of novel molecules, referred to herein as PTS nucleic acid and protein molecules, which participate in the uptake of high-energy carbon molecules (e.g., glucose, sucrose, and fructose) into C. glutamicum, and may also participate in one or more intracellular signal transduction pathways in these microorganisms. In one embodiment, the PI'S molecules function to import high-energy carbon molecules into the cell, where the energy produced by their degradation may be utilized to power less energetically favorable biochemical reactions, and their degradation products may serve as intermediates and precursors for a number of other metabolic pathways. In another embodiment, the PTS molecules may participate in one or more intracellular signal transduction pathways, wherein the presence of a modified form of a PTS molecule (e.g., a phosphorylated PTS protein) may participate in a signal transduction cascade which regulates one or more cellular processes. In a preferred embodiment, the activity of the PTS molecules of the present invention has an impact on the production of a desired fine chemical by this organism. In a particularly preferred embodiment, the PTS molecules of the invention are modulated in activity, such that the yield, production or efficiency of production of one or more fine chemicals from C. glutamicum is also modulated.
The language, “PTS protein” or “PTS polypeptide” includes proteins which participate in the uptake of one or more high-energy carbon compounds (e.g., mono-, di, or oligosaccharides, such as fructose, mannose, sucrose, glucose, raffinose, galactose,
ribose, lactose, maltose, and ribulose) from the extracellular medium to the interior of : the cell. Such PTS proteins may also participate in one or more intracellular signal transduction pathways, such as, but not limited to, those governing the uptake of different sugars into the cell. Examples of PTS proteins include those encoded by the
PTS genes set forth in Table 1 and by the odd-numbered SEQ ID NOs. For general references pertaining to the PTS system, see: Stryer, L. (1988) Biochemistry. Chapter 37: “Membrane Transport”, W.H. Freeman: New York, p. 959-961; Darnell, J. et al. (1990) Molecular Cell Biology Scientific American Books: New York, p. 552-553, and
Michal, G., ed. (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular
Biology, Chapter 15 “Special Bacterial Metabolism”. The terms “PTS gene” or “PTS nucleic acid sequence” include nucleic acid sequences encoding a PTS protein, which consist of a coding region and also corresponding untranslated 5’ and 3’ sequence } regions. Examples of PTS genes include those set forth in Table 1. The terms “production” or “productivity” are art-recognized and include the concentration of the fermentation product (for example, the desired fine chemical) formed within a given time-and a given fermentation volume (e.g., kg product per hour per liter). The term “efficiency of production” includes the time required for a particular level of production to be achieved (for example, how long it takes for the cell to attain a particular rate of output of a fine chemical). The term “yield” or “product/carbon yicld” is art-recognized and includes the efficiency of the conversion of the carbon source into the product (i.e., fine chemical). This is generally written as, for example, kg product per kg carbon source. By increasing the yield or production of the compound, the quantity of recovered molecules, or of useful recovered molecules of that compound in a given amount of culture over a given amount of time is increased. The terms “biosynthesis” or a “biosynthetic pathway” are art-recognized and include the synthesis of a compound, preferably an organic compound, by a cell from intermediate compounds in what may be a multistep and highly regulated process. The terms “degradation” or a “degradation pathway” are art-recognized and include the breakdown of a compound, preferably an organic compound, by a cell to degradation products (generally speaking, smaller or less complex molecules) in what may be a multistep and highly regulated process. The language “metabolism” is art-recognized and includes the totality of the biochemical reactions that take place in an organism. The metabolism of a particular compound,
then, (e.g., the metabolism of an amino acid such as glycine) comprises the overall biosynthetic, modification, and degradation pathways in the cell related to this . compound. The language “transport” or “import” is art-recognized and includes the facilitated movement of one or more molecules across a cellular membrane through which the molecule would otherwise be unable to pass.
In another embodiment, the PTS molecules of the invention are capable of modulating the production of a desired molecule, such as a fine chemical, in a microorganism such as C. glutamicum. Using recombinant genetic techniques, one or more of the PTS proteins of the invention may be manipulated such that its function is modulated. For example, a protein involved in the PTS-mediated import of glucose may be altered such that it is optimized in activity, and the PTS system for the importation of glucose may thus be able to translocate increased amounts of glucose into the cell.
Since glucose molecules are utilized not only for energy to drive energetically unfavorable biochemical reactions, such as fine chemical biosyntheses, but also as precursors and intermediates in a number of fine chemical biosynthetic pathways (e.g, serine is synthesized from 3-phosphoglycerate). In each case, the overall yield or rate of production of one of these desired fine chemicals may be increased, either by increasing the energy available for such production to occur, or by increasing the availability of compounds necessary for such production to take place.
Further, many PTS proteins are known to play key roles in intracellular signal transduction pathways which regulate cellular metabolism and sugar uptake in keeping with the availability of carbon sources. For example, it is known that an increased intracellular level of fructose 1,6-bisphosphate (a compound produced during glycolysis) results in the phosphorylation of a serine residue on HPr which prevents this protein from serving as a phosphoryl donor in any PTS sugar transport process, thereby blocking further sugar uptake. By mutagenizing HPr such that this serine residue cannot be phosphorylated, one may constitutively activate HPr and thereby increase sugar transport into the cell, which in turn will ensure greater intracellular energy stores and intermediate/precursor molecules for the biosynthesis of one or more desired fine chemicals.
The isolated nucleic acid sequences of the invention are contained within the genome of a Corynebacterium glutamicum strain available through the American Type
Culture Collection, given designation ATCC 13032. The nucleotide sequence of the . isolated C. glutamicum PTS DNAs and the predicted amino acid sequences of the C. glutamicum PTS proteins are shown in the Sequence Listing as odd-numbered SEQ ID
NOs and even-numbered SEQ ID NOs, respectively. }
Computational analyses were performed which classified and/or identified these nucleotide sequences as sequences which encode metabolic pathway proteins.
The present invention also pertains to proteins which have an amino acid sequence which is substantially homologous to an amino acid sequence of the invention (e.g., the sequence of an even-numbered SEQ ID NO of the Sequence Listing). As used herein, a protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence is least about 50% homologous to the selected amino acid sequence, e.g. , the entire selected amino acid sequence. A protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence can also be least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, or 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to the selected amino acid sequence.
The PTS protein or a biologically active portion or fragment thereof of the invention can participate in the transport of high-energy carbon-containing molecules such as glucose into C. glutamicum, or can participate in intracellular signal transduction in this microorganism, or may have one or more of the activities set forth in Table 1.
Various aspects of the invention are described in further detail in the following subsections:
A. Isolated Nucleic Acid Molecules
One aspect of the invention pertains to isolated nucleic acid molecules that encode PTS polypeptides or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes or primers for the identification or amplification of PTS-encoding nucleic acid (e.g., PTS DNA). As used herein, the term "nucleic acid molecule” is intended to include DNA molecules (e.g, cDNA or genomic
DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. This term also encompasses untranslated sequence located at both the 3° and 5’ ends of the coding region of the gene: at least about 100 nucleotides of sequence upstream from the 5* end of the coding region and at least about 20 nucleotides of sequence downstream from the 3’end of the coding region of the gene. .
The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated PTS nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived (e.g, a C. glutamicum cell). Moreover, an "isolated" nucleic acid molecule, such as a DNA molecule, can be substantially free of other cellular matenal, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized.
A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having a nucleotide sequence of an odd-numbered SEQ ID NO of the Sequence Listing, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, a C. glutamicum PTS DNA can be isolated from a C. glutamicum library using all or portion of one of the odd-numbered
SEQ ID NO sequences of the Sequence Listing as a hybridization probe and standard hybridization techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis,
T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor
Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
Moreover, a nucleic acid molecule encompassing all or a portion of one of the nucleic acid sequences of the invention (e.g., an odd-numbered SEQ ID NO of the Sequence
Listing) can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon this sequence (e.g., a nucleic acid molecule encompassing all or a portion of one of the nucleic acid sequences of the invention (e.g., an odd-numbered
SEQ ID NO of the Sequence Listing) can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon this same sequence). For example, mRNA can be isolated from normal endothelial cells (e.g, by the guanidinium-
thiocyanate extraction procedure of Chirgwin et al. (1979) Biochemistry 18: 5294-5299) ) and DNA can be prepared using reverse transcriptase (e.g., Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Petersburg, FL). Synthetic oligonucieotide primers for polymerase chain reaction amplification can be designed based upon one of the nucleotide sequences shown in the Sequence Listing. A nucleic acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to a PTS nucleotide sequence can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises one of the nucleotide sequences shown in the Sequence Listing. The nucleic acid sequences of the invention, as set forth in the Sequence Listing, correspond to the
Corynebacterium glutamicum PTS DNAs of the invention. This DNA comprises sequences encoding PTS proteins (i.e., the "coding region”, indicated in each odd- numbered SEQ ID NO: sequence in the Sequence Listing), as well as 5’ untranslated sequences and 3' untranslated sequences, also indicated in each odd-numbered SEQ ID
NO: in the Sequence Listing. Alternatively, the nucleic acid molecule can comprise only the coding region of any of the nucleic acid sequences of the Sequence Listing.
For the purposes of this application, it will be understood that each of the nucleic acid and amino acid sequences set forth in the Sequence Listing has an identifying RXA,
RXN, RXS, or RXC number having the designation “RXA”, “RXN”, “RXS”, or “RXC” followed by 5 digits (i.e., RXA01503, RXN01299, RXS00315, or RXC00953). Each of the nucleic acid sequences comprises up to three parts: a 5’ upstream region, a coding region, and a downstream region. Each of these three regions is identified by the same
RXA, RXN, RXS, or RXC designation to eliminate confusion. The recitation “one of the odd-numbered sequences of the Sequence Listing” then, refers to any of the nucleic acid sequences in the Sequence Listing, which may be also be , distinguished by their differing RXA, RXN, RXS, or RXC designations. The coding region of each of these sequences is translated into a corresponding amino acid sequence, which is also set forth in the Sequence Listing, as an even-numbered SEQ ID NO: immediately following the corresponding nucleic acid sequence . For example, the coding region for RXA02229 is . set forth in SEQ [D NO:1, while the amino acid sequence which it encodes is set forth as
SEQ ID NO:2. The sequences of the nucleic acid molecules of the invention are identified by the same RXA, RXN, RXS, or RXC designations as the amino acid molecules which they encode, such that they can be readily correlated. For example, the amino acid sequences designated RXA01503, RXN01299, RXS0031S5, and RXC00953 are translations of the coding regions of the nucleotide sequence of nucleic acid molecules RXA01503, RXN01299, RXS00315, and RXC00953, respectively. The correspondence between the RXA, RXN, RXS, and RXC nucleotide and amino acid sequences of the invention and their assigned SEQ ID NOs, is set forth in Table 1. For example, as set forth in Table 1, the nucleotide sequence of RXN01299 is SEQ ID NO: 7, and the corresponding amino acid sequence is SEQ ID NO:8.
Several of the genes of the invention are “F-designated genes”. An F-designated gene includes those genes set forth in Table 1 which have an ‘°F’ in front of the RXA,
RXN, RXS, or RXC designation. For example, SEQ ID NO.3, designated, as indicated on Table 1, as “F RXAO00315”, is an F-designated gene, as are SEQ ID NOs: 9, 11, and 13 (designated on Table 1 as “F RXA01299”, “F RXA01883”, and “F RXA01889™, respectively).
In one embodiment, the nucleic acid molecules of the present invention are not intended to include C. glutamicum those compiled in Table 2. In the case of the dapD gene, a sequence for this gene was published in Wehrmann, A, et al. (1998) J.
Bacteriol. 180(12): 3159-3165. However, the sequence obtained by the inventors of the present application is significantly longer than the published version. It is believed that the published version relied on an incorrect start codon, and thus represents only a fragment of the actual coding region.
In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of one of the nucleotide sequences of the invention (e.g., a sequence of an odd-numbered SEQ ID
NO: of the Sequence Listing), or a portion thereof. A nucleic acid molecule which is complementary to one of the nucleotide sequences of the invention is one which is sufficiently complementary to one of the nucleotide sequences shown in the Sequence
Listing (e.g., the sequence of an odd-numbered SEQ ID NO:) such that it can hybridize : to one of the nucleotide sequences of the invention, thereby forming a stable duplex.
In still another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence of the invention (e.g, a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing), or a portion thereof. Ranges and identity values intermediate to the above-recited ranges, (e.g., 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. In an additional preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to one of the nucleotide sequences of the invention (e.g., a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing), or a portion thereof.
Moreover, the nucleic acid molecule of the invention can comprise only a portion of the coding region of the sequence of one of the odd-numbered SEQ ID NOs of the Sequence Listing, for example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of a PTS protein. The nucleotide sequences determined from the cloning of the PTS genes from C. glutamicum allows for the generation of probes and primers designed for use in identifying and/or cloning PTS homologues in other cell types and organisms, as well as PTS homologues from other
Corynebacteria or related species. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 40, 50 or 75 consecutive nucleotides of a sense strand of one of the nucleotide sequences of the invention (e.g., a sequence of one of the odd- numbered SEQ ID NOs of the Sequence Listing, an anti-sense sequence of one of these sequences , or naturally occurring mutants thereof. Primers based on a nucleotide sequence of the invention can be used in PCR reactions to clone PTS homologues. :
Probes based on the PTS nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, e.g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co- factor. Such probes can be used as a part of a diagnostic test kit for identifying cells which misexpress a PTS protein, such as by measuring a level of a PTS-encoding nucleic acid in a sample of cells e.g., detecting PTS mRNA levels or determining whether a genomic PTS gene has been mutated or deleted.
In one embodiment, the nucleic acid molecule of the invention encodes a protein or portion thereof which includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence of an even- numbered SEQ ID NO of the Sequence Listing), such that the protein or portion thereof maintains the ability to participate in the transport of high-energy carbon molecules (such as glucose) into C. glutamicum, and may also participate in one or more intracellular signal transduction pathways. As used herein, the language "sufficiently homologous" refers to proteins or portions thereof which have amino acid sequences which include a minimum number of identical or equivalent (e.g., an amino acid residue which has a similar side chain as an amino acid residue in a sequence of one of the even- numbered SEQ ID NOs of the Sequence Listing) amino acid residues to an amino acid sequence of the invention such that the protein or portion thereof is capable of transporting high-energy carbon-containing molecules such as glucose into C. glutamicum, and may also participate in intracellular signal transduction in this microorganism. Protein members of such metabolic pathways, as described herein, function to transport high-energy carbon-containing molecules such as glucose into C. glutamicum, and may also participate in intracellular signal transduction in this microorganism. Examples of such activities are also described herein. Thus, “the function of a PTS protein" contributes to the overall functioning and/or regulation of one or more phosphoenolpyruvate-based sugar transport pathway, and /or contributes, either directly or indirectly, to the yield, production, and/or efficiency of production of one or more fine chemicals. Examples of PTS protein activities are set forth in Table 1.
In another embodiment, the protein is at least about 50-60%, preferably at least : about 60-70%, and more preferably at least about 70-80%, 80-90%, 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of the invention (e.g, a sequence of an even-numbered SEQ ID NO: of the Sequence Listing).
Portions of proteins encoded by the PTS nucleic acid molecules of the invention are preferably biologically active portions of one of the PTS proteins. As used herein, the term "biologically active portion of a PTS protein” is intended to include a portion, e.g, adomain/motif, of a PTS protein that is capable of transporting high-energy carbon-containing molecules such as glucose into C. glutamicum, or of participating in intracellular signal transduction in this microorganism, or has an activity as set forth in
Table 1. To determine whether a PTS protein or a biologically active portion thereof can participate in the transportation of high-energy carbon-containing molecules such as glucose into C. glutamicum, or can participate in intracellular signal transduction in this microorganism, an assay of enzymatic activity may be performed. Such assay methods are well known to those of ordinary skill in the art, as detailed in Example 8 of the
Exemplification.
Additional nucleic acid fragments encoding biologically active portions of a
PTS protein can be prepared by isolating a portion of one of the amino acid sequences of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence
Listing), expressing the encoded portion of the PTS protein or peptide (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of the
PTS protein or peptide.
The invention further encompasses nucleic acid molecules that differ from one of the nucleotide sequences of the invention (e.g., a sequence of an odd-numbered SEQ ID
NO: of the Sequence Listing) (and portions thereof) due to degeneracy of the genetic code and thus encode the same PTS protein as that encoded by the nucleotide sequences of the invention. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in the Sequence Listing (e.g., an even-numbered SEQ ID NO:). In a still further embodiment, the nucleic acid molecule of the invention encodes a full length C.
glutamicum protein which is substantially homologous to an amino acid sequence of the invention (encoded by an open reading frame shown in an odd-numbered SEQ ID NO: . of the Sequence Listing).
It will be understood by one of ordinary skill in the art that in one embodiment the sequences of the invention are not meant to include the sequences of the prior art, such as those Genbank sequences set forth in Tables 2 or 4 which were available prior to the present invention. In one embodiment, the invention includes nucleotide and amino acid sequences having a percent identity to a nucleotide or amino acid sequence of the invention which is greater than that of a sequence of the prior art (e.g., a Genbank sequence (or the protein encoded by such a sequence) set forth in Tables 2 or 4). For example, the invention includes a nucleotide sequence which is greater than and/or at : least 44% identical to the nucleotide sequence designated RXA01503 (SEQ ID NO:5), a nuclcotide sequence which is greater than and/or at least 41% identical to the nucleotide sequence designated RXA00951 (SEQ ID NO:15), and a nucleotide sequence which is greater than and/or at least 38% identical to the nucleotide sequence designated
RXA01300 (SEQ ID NQO:21). One of ordinary skill in the art would be able to calculate the lower threshold of percent identity for any given sequence of the invention by examining the GAP-calculated percent identity scores set forth in Table 4 for each of the three top hits for the given sequence, and by subtracting the highest GAP-calculated percent identity from 100 percent. One of ordinary skill in the art will also appreciate that nucleic acid and amino acid sequences having percent identities greater than the lower threshold so calculated (e.g., at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more identical) are also encompassed by the invention.
In addition to the C. glutamicum PTS nucleotide sequences set forth in the Sequence
Listing as odd-numbered SEQ ID NOs, it will be appreciated by those of ordinary skill in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of PTS proteins may exist within a population (e.g, the C. glutamicum population). Such genetic polymorphism in the PTS gene may exist among individuals within a population due to natural variation. As used herein, the terms "gene" and ’ "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a PTS protein, preferably a C. glutamicum PTS protein. Such natural variations can typically result in 1-5% variance in the nucleotide sequente of the PTS gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in PTS that are the result of natural variation and that do not alter the functional activity of PTS proteins are intended to be within the scope of the invention.
Nucleic acid molecules corresponding to natural variants and non-C. glutamicum homologues of the C. glutamicum PTS DNA of the invention can be isolated based on their homology to the C. glutamicum PTS nucleic acid disclosed herein using the C. glutamicum DNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Accordingly, in : another embodiment, an isolated nucleic acid molecule of the invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising a nucleotide sequence of an odd-numbered SEQ ID NO: of the
Sequence Listing. In other embodiments, the nucleic acid is at least 30, 50, 100, 250 or more nucleotides in length. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other. Preferably, the conditions are such that sequences at least about 65%, more preferably at least about 70%, and even more preferably at least about 75% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those of ordinary skill in the art and can be found in
Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to a nucleotide sequence of the invention corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g.,
encodes a natural protein). In one embodiment, the nucleic acid encodes a natural C. glutamicum PTS protein. :
In addition to naturally-occurring variants of the PTS sequence that may exist in the population, one of ordinary skill in the art will further appreciate that changes can be introduced by mutation into a nucleotide sequence of the invention, thereby leading to changes in the amino acid sequence of the encoded PTS protein, without altering the functional ability of the PTS protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in a nucleotide sequence of the invention. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of one of the PTS proteins (e.g, an even-numbered SEQ ID NO: of the Sequence Listing ) without altering the activity of said PTS protein, whereas an "essential" amino acid residue is required for PTS protein activity. Other amino acid residues, however, (e.g, those that are not conserved or only semi-conserved in the domain having PTS activity) may not be essential for activity and thus are likely to be amenable to alteration without altering PTS activity.
Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding PTS proteins that contain changes in amino acid residues that are not essential for PTS activity. Such PTS proteins differ in amino acid sequence from a sequence of an even-numbered SEQ ID NO: of the Sequence Listing yet retain at least one of the
PTS activities described herein. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 50% homologous to an amino acid sequence of the invention and is capable of transporting high-energy carbon-containing molecules such as glucose into C. glutamicum, or of participating in intracellular signal transduction in this microorganism, or has one or more activities set forth in Table 1. Preferably, the protein encoded by the nucleic acid molecule is at least about 50-60% homologous to the amino acid sequence of one of the odd-numbered SEQ ID NOs of the Sequence
Listing, more preferably at least about 60-70% homologous to one of these sequences, even more preferably at least about 70-80%, 80-90%, 90-95% homologous to one of these sequences, and most preferably at least about 96%, 97%, 98%, or 99% homologous to one of the amino acid sequences of the invention.
To determine the percent homology of two amino acid sequences (e.g., one of : the amino acid sequences of the invention and a mutant form thereof) or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of one protein or nucleic acid for optimal alignment with the other protein or nucleic acid). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in one sequence (e.g., one of the amino acid sequences of the invention) is occupied by the same amino acid residue or nucleotide as the corresponding position in the other sequence (e.g., a mutant form of the amino acid sequence), then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The percent homology between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = # of identical positions/total # of positions x 100).
An isolated nucleic acid molecule encoding a PTS protein homologous to a protein sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) can be created by introducing one or more nucleotide substitutions, additions or deletions into a nucleotide sequence of the invention such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into one of the nucleotide sequences of the invention by standard techniques, such as site-directed mutagenesis and PCR- mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g, threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a PTS protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a PTS coding sequence, such as by saturation mutagenesis, : and the resultant mutants can be screened for a PTS activity described herein to identify mutants that retain PTS activity. Following mutagenesis of one of the nucleotide sequence of one of the odd-numbered SEQ ID NOs of the Sequence Listing, the encoded protein can be expressed recombinantly and the activity of the protein can be determined using, for example, assays described herein (see Example 8 of the
Exemplification).
In addition to the nucleic acid molecules encoding PTS proteins described above, ~ 10 another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded DNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire PTS coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding a
PTS protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (e.g., the entire coding region of SEQ ID NO. 5 (RXA01503) comprises nuclectides 1 to 249). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding PTS. The term "noncoding region” refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).
Given the coding strand sequences encoding PTS disclosed herein (e.g., the sequences set forth as odd-numbered SEQ ID NOs in the Sequence Listing), antisense nucleic acids of the invention can be designed according to the rules of Watson and
Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of PTS mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of PTS mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of PTS mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An : antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5- fluorouracil, 5-bromouracil, S-chlorouracil, 5-todouracil, hypoxanthine, xanthine, 4- acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, S-carboxymethylaminomethyl-2- thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D- galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5- methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5- methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'- methoxycarboxymethyluracil, S-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5- methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5- oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2- : carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
The antisense nucleic acid molecules of the invention are typically administered to a cell or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a PTS protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. The antisense molecule can be modified such that it specifically binds to a receptor or an antigen expressed on a selected cell surface, e.g, by linking the antisense nucleic acid molecule to a peptide or . an antibody which binds to a cell surface receptor or antigen. The antisense nucleic acid molecule can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong prokaryotic, viral, or eukaryotic promoter are preferred.
In yet another embodiment, the antisense nucleic acid molecule of the invention is an a-anomeric nucleic acid molecule. An a-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual B-units, the strands run parallel to each other (Gaultier er al. (1987) Nucleic Acids.
Res. 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-0- methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res. 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue ef al. (1987) FEBS Lett. 215:327-330).
In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave PTS mRNA transcripts to thereby inhibit translation of PTS mRNA.
A ribozyme having specificity for a PTS-encoding nucleic acid can be designed based . upon the nucleotide sequence of a PTS DNA disclosed herein (i.e., SEQ ID NO:5 (RXAO01503)). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a PTS-encoding mRNA. See, e.g., Cech et al. U.S.
Patent No. 4,987,071 and Cech ef al. U.S. Patent No. 5,116,742. Alternatively, PTS mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J.W. (1993) Science 261:1411-1418.
Alternatively, PTS gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of a PTS nucleotide sequence (e.g., a
PTS promoter and/or enhancers) to form triple helical structures that prevent transcription of a PTS gene in target cells. See generally, Helene, C. (1991) Anticancer ) Drug Des. 6(6):569-84; Helene, C. et al. (1992) Ann. N.Y. Acad. Sci. 660:27-36; and
Maher, L.J. (1992) Bioassays 14(12):807-15.
SB. Recombinant Expression Vectors and Host Cells
Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a PTS protein (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional
DNA segments can be ligated into the viral genome. Certain vectors arc capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other } 15 vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host . cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniqucs are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector.
However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno- associated viruses), which serve equivalent functions.
The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control : elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185,
Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells.
Preferred regulatory sequences are, for example, promoters such as cos-, tac-, trp-, tet-, trp-tct-, lpp-, lac-, lpp-lac-, lacl®-, T7-, T5-, T3-, gal-, trc-, ara-, SP6-, amy, SPO2, }-Pg- or A Pg, which are used preferably in bacteria. Additional regulatory sequences are, for example, promoters from yeasts and fungi, such as ADCI1, Mra, AC, P-60, CYC,
GAPDH, TEF, rp28, ADH, promoters from plants such as CaMV/35S, SSU, OCS, lib4, usp, STLS1, B33, nos or ubiqguitin- or phaseolin-promoters. It is also possible to use artificial promoters. It will be appreciated by one of ordinary skill in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., PTS proteins, mutant forms of PTS proteins, fusion proteins, etc.).
The recombinant expression vectors of the invention can be designed for expression of PTS proteins in prokaryotic or eukaryotic cells. For example, PTS genes can be expressed in bacterial cells such as C. glutamicum, insect cells (using baculovirus expression vectors), yeast and other fungal cells (see Romanos, M.A. et al. (1992) “Foreign gene expression in yeast: a review”, Yeast 8: 423-488; van den Hondel,
C.AM.LL et al (1991) “Heterologous gene expression in filamentous fungi” in: More
Gene Manipulations in Fungi, J.W. Bennet & L.L. Lasure, eds., p. 396-428: Academic
Press: San Diego; and van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) “Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, Peberdy, J.F. ef al., eds., p. 1-28, Cambridge University Press: Cambridge), algae and multicellular plant cells (see Schmidt, R. and Willmitzer, L. (1988) High efficiency Agrobacterium tumefactiens —mediated transformation of Arabidopsis thaliana leaf and cotyledon explants” Plant Cell Rep.: 583-586), or mammalian cells.
Suitable host cells are discussed further in Goeddel, Gene Expression Technology:
Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
Expression of proteins in prokaryotes is most often carried out with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion : moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, : 15 and their cognate recognition sequences, include Factor Xa, thrombin and enterokinasc.
Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith,
D.B. and Johnson, K.S. (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly,
MA) and pRITS (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. In one embodiment, the coding sequence of the PTS protein is cloned into a pGEX expression vector to create a vector encoding a fusion protein comprising, from the N-terminus to the C-terminus, GST-thrombin cleavage site-X protein. The fusion protein can be purified by affinity chromatography using glutathione-agarose resin.
Recombinant PTS protein unfused to GST can be recovered by cleavage of the fusion protein with thrombin.
Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann ef al., (1988) Gene 69:301-315) pLG338, pACYC184, pBR322, pUCI8, pUC19, pKC30, pRep4, pHS1, pHS2, pPLc236, pMBL24, pLG200, pUR290, pIN- [[I113-B1, Agt1 1, pBdCl, and pET 11d (Studier et al., Gene Expression Technology:
Methods in Enzymology 185, Academic Press, San Diego, California (1990) 60-89 ; and
Pouwels et al., eds. (1985) Cloning Vectors. Elsevier: New York IBSN 0 444 904018).
Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gnl0-lac fusion promoter mediated by : a coexpressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident A prophage harboring a T7 5S gnl gene under the transcriptional control of the lacUV 5 promoter. For transformation of other varieties of bacteria, appropriate vectors may be selected. For example, the plasmids plJ101, plJ364, plJ702 and plJ361 are known to be useful in transforming
Streptomyces, while plasmids pUB110, pC194, or pBD214 are suited for transtormation of Bacillus species. Several plasmids of use in the transfer of genetic information into
Corynebacterium include plIM1519, pBL1, pSA77, or pAJ667 (Pouwels ef al., eds. (1985) Cloning Vectors. Elsevier: New York IBSN 0 444 904018).
One strategy to maximize recombinant protein expression is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., Gene Expression Technology: Methods in
Enzymology 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in the bacterium chosen for expression, such as C. glutamicum (Wada et al. (1992) Nucleic Acids Res. 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
In another embodiment, the PTS protein expression vector is a yeast expression vector. Examples of vectors for expression in yeast S. cerivisae include pYepSecl (Baldari, et al., (1987) Embo J. 6:229-234), 2 u, pAG-1, Yep6, Yepl3, pEMBLYe23, pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz er al, (1987)
Gene 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA). Vectors and . methods for the construction of vectors appropriate for use in other fungi, such as the filamentous fungi, include those detailed in: van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) “Gene transfer systems and vector development for filamentous fungi, in:
Applied Molecular Genetics of Fungi, J.F. Peberdy, et al., eds., p. 1-28, Cambridge
University Press: Cambridge, and Pouwels ef al., eds. (1985) Cloning Vectors. Elsevier:
New York (IBSN 0 444 904018).
Alternatively, the PTS proteins of the invention can be expressed in insect cells : using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith ef al. (1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow and Summers (1989)
S Virology 170:31-39).
In another embodiment, the PTS proteins of the invention may be expressed in unicellular plant cells (such as algae) or in plant cells from higher plants (e.g., the spermatophytes, such as crop plants). Examples of plant expression vectors include those detailed in: Becker, D., Kemper, E., Schell, J. and Masterson, R. (1992) "New plant binary vectors with selectable markers located proximal to the left border", Plant
Mol. Biol. 20: 1195-1197; and Bevan, M.W. (1984) "Binary Agrobacterium vectors for plant transformation”, Nucl. Acid. Res. 12: 8711-8721, and include pLGV23, pGHIlac+, : PBIN19, pAK2004, and pDH51 (Pouwels et al., eds. (1985) Cloning Vectors. Elsevier:
New York IBSN 0 444 904018).
In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDMS (Seed, B. (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBO J. 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements.
For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F, and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring
Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g, tissue-specific regulatory elements are used to express the nucleic acid). Tissue- specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988)
Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and
Baltimore (1989) EMBO J. 8:729-733) and immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and Baltimore (1983) Cell 33:741-748), neuron-specific promoters . (e.g, the neurofilament promoter; Byrne and Ruddle (1989) PNAS 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and
European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990)
Science 249:374-379) and the a-fetoprotein promoter (Campes and Tilghman (1989)
Genes Dev. 3:537-546).
The invention further provides a recombinant expression vector comprising a
DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an
RNA molecule which is antisense to PTS mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA.
The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. ez al., Antisense RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics, Vol. 1(1) 1986.
Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
A host cell can be any prokaryotic or eukaryotic cell. For example, a PTS : protein can be expressed in bacterial cells such as C. glutamicum, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to onc of ordinary skill in the art. Microorganisms related to Corynebacterium glutamicum which may be conveniently used as host cells for the nucleic acid and protein molecules of the invention are set forth in Table 3.
Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., linear DNA or RNA (e.g., a linearized vector or a gene construct alone without a vector) or nucleic acid in the form of a vector (e.g., a plasmid, phage, phasmid, phagemid, transposon or other DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE- dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (Molecular
Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring
Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.
For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the forcign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding a PTS protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).
To create a homologous recombinant microorganism, a vector is prepared which contains at least a portion of a PTS gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the PTS gene.
Preferably, this PTS gene is a Corynebacterium glutamicum PTS gene, but it can be a homologue from a related bacterium or even from a mammalian, yeast, or insect source.
In a preferred embodiment, the vector is designed such that, upon homologous . recombination, the endogenous PTS gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a “knock out” vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous
PTS gene is mutated or otherwise altered but still encodes functional protein (e.g, the upstream regulatory region can be altered to thereby alter the expression of the endogenous PTS protein). In the homologous recombination vector, the altercd portion of the PTS gene is flanked at its 5” and 3’ ends by additional nucleic acid of the PTS gene to allow for homologous recombination to occur between the exogenous PTS gene carried by the vector and an endogenous PTS gene in a microorganism. The additional flanking PTS nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5’ and 3’ ends) are included in the vector (see e.g., Thomas, K.R., and
Capecchi, M.R. (1987) Cell 51: 503 for a description of homologous recombination vectors). The vector is introduced into a microorganism (e.g., by electroporation) and cells in which the introduced PTS gene has homologously recombined with the endogenous PTS gene are selected, using art-known techniques.
In another embodiment, recombinant microorganisms can be produced which contain selected systems which allow for regulated expression of the introduced gene.
For example, inclusion of a PTS gene on a vector placing it under control of the lac operon permits expression of the PTS gene only in the presence of IPTG. Such regulatory systems are well known in the art.
In another embodiment, an endogenous PTS gene in a host cell is disrupted (e.g., by homologous recombination or other genetic means known in the art) such that expression of its protein product does not occur. In another embodiment, an endogenous or introduced PTS gene in a host cell has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional PTS protein. In still another embodiment, one or more of the regulatory regions (e.g., a promoter, repressor, or inducer) of aPTS gene in a microorganism has been altered (e.g., by deletion, truncation, inversion, or point mutation) such that the expression of the PTS gene is modulated. One of ordinary skill in the art will appreciate that host cells containing more than one of the described PTS gene and protein modifications may be readily produced using the methods of the invention, and are meant to be included in the present invention.
A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) a PTS protein. Accordingly, the invention further provides methods for producing PTS proteins using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding a PTS protein has been introduced, or into which genome has been introduced a gene encoding a wild-type or altered PTS protein) in a suitable medium until PTS protein is produced. In another embodiment, the method further comprises isolating PTS proteins from the medium or the host cell.
C. Isolated PTS Proteins
Another aspect of the invention pertains to isolated PTS proteins, and biologically active portions thereof. An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material” includes preparations of PTS protein in which the protein is separated from cellular components of the cells in which it is naturally or recombinantly produced. In one embodiment, the language "substantially free of cellular material” includes preparations of PTS protein having less than about 30% (by dry weight) of non-PTS protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-PTS protein, still more preferably less than about 10% of non-PTS protein, and most preferably less than about 5% non-PTS protein. When the PTS protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation. The language "substantially free of chemical precursors or other chemicals" includes preparations of PTS protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of PTS protein having less than about 30% (by dry weight) of chemical precursors or non-PTS chemicals, more preferably less than about 20% chemical precursors or non-PTS chemicals, still more preferably less than
S about 10% chemical precursors or non-PTS chemicals, and most preferably less than about 5% chemical precursors or non-PTS chemicals. In preferred embodiments, isolated proteins or biologically active portions thereof lack contaminating proteins from the same organism from which the PTS protein is derived. Typically, such proteins are produced by recombinant expression of, for example, a C. glutamicum PTS protein in a microorganism such as C. glutamicum.
An isolated PTS protein or a portion thereof of the invention can participate in the transport of high-energy carbon-containing molecules such as glucose into C. glutamicum, and may also participate in intracellular signal transduction in this microorganism, or has one or more of the activities set forth in Table 1. In preferred 1S embodiments, the protein or portion thercof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) such that the protein or portion thereof maintains the ability to transport high-energy carbon-containing molecules such as glucose into C. glutamicum, or to participate in intracellular signal transduction in this microorganism. The portion of the protein is preferably a biologically active portion as described herein. In another preferred embodiment, a PTS protein of the invention has an amino acid sequence set forth as an even-numbered SEQ ID NO: of the Sequence
Listing. In yet another preferred embodiment, the PTS protein has an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to a nucleotide sequence of the invention (e.g., a sequence of an odd-numbered SEQ ID NO: of the Sequence Listing). In still another preferred embodiment, the PTS protein has an amino acid sequence which is encoded by a nucleotide sequence that is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%,
99% or more homologous to one of the nucleic acid sequences of the invention , ora : portion thereof. Ranges and identity values intermediate to the above-recited values, (e.g., 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. The preferred PTS proteins of the present invention also preferably possess at least one of the PTS activities described herein. For example, a preferred PTS protein of the present ’ invention includes an amino acid sequence cncoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to a nucleotide sequence of the invention, and which can participate in the transport of high-energy carbon-containing molecules such as glucose into C. glutamicum, and may also participate in intracellular signal transduction in this microorganism, or which has one or more of the activities set forth in Table 1.
In other embodiments, the PTS protein is substantially homologous to an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) and retains the functional activity of the protein of one of the amino acid sequences of the invention yet differs in amino acid sequence due to natural variation or mutagenesis, as described in detail in subsection I above. Accordingly, in : another embodiment, the PTS protein is a protein which comprises an amino acid sequence which is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of the invention and which has at least one of the PTS activities described herein. Ranges and identity values intermediate to the above-recited values, (e.g., 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. In another embodiment, the invention pertains to a full length C. glutamicum protein which is substantially homologous to an entire amino acid sequence of the invention.
Biologically active portions of a PTS protein include peptides comprising amino acid sequences derived from the amino acid sequence of a PTS protein, e.g , an amino : acid sequence of an even-numbered SEQ ID NO: of the Sequence Listing or the amino acid sequence of a protein homologous to a PTS protein, which include fewer amino
S acids than a full length PTS protein or the full length protein which is homologous to a
PTS protein, and exhibit at least one activity of a PTS protein. Typically, biologically active portions (peptides, e.g., peptides which are, for example, 5, 10, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) comprise a domain or motif with at least one activity of a PTS protein. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the activities described herein. Preferably, the biologically active portions of a PTS protein include one or more selected domains/motifs or portions thereof having biological activity.
PTS proteins are preferably produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the PTS protein is expressed in the host cell. The PTS protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Alternative to recombinant expression, a PTS protein, polypeptide, or peptide can be synthesized chemically using standard peptide synthesis techniques. Moreover, native PTS protein can be isolated from cells (e.g., endothelial cells), for example using an anti-PTS antibody, which can be produced by standard techniques utilizing a PTS protein or fragment thereof of this invention.
The invention also provides PTS chimeric or fusion proteins. As used herein, a
PTS "chimeric protein" or "fusion protein" comprises a PTS polypeptide operatively linked to a non-PTS polypeptide. An "PTS polypeptide" refers to a polypeptide having an amino acid sequence corresponding to PTS, whereas a "non-PTS polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the PTS protein, e.g., a protein which is different from the
PTS protein and which is derived from the same or a different organism. Within the fusion protein, the term "operatively linked" is intended to indicate that the PTS polypeptide and the non-PTS polypeptide are fused in-frame to each other. The non-
PTS polypeptide can be fused to the N-terminus or C-terminus of the PTS polypeptide. : For example, in one embodiment the fusion protein is a GST-PTS fusion protein in which the PTS sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant PTS proteins. In another embodiment, the fusion protein is a PTS protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a PTS protein can be increased through use of a heterologous signal sequence.
Preferably, a PTS chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for cxample by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid } 15 undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.
Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al. John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A PTS- encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety 1s linked in-frame to the PTS protein.
Homologues of the PTS protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the PTS protein. As used herein, the term "homologue" refers to a variant form of the PTS protein which acts as an agonist or antagonist of the activity of the PTS protein. An agonist of the PTS protein can retain substantially the same, or a subset, of the biological activities of the PTS protein. An antagonist of the
PTS protein can inhibit one or more of the activities of the naturally occurring form of the PTS protein, by, for example, competitively binding to a downstream or upstream member of the PTS system which includes the PTS protein. Thus, the C. glutamicum
WO (1/02583 PCT/IBOO/0973
PTS protein and homologues thereof of the present invention may modulate the activity of one or more sugar transport pathways or intracellular signal transduction pathways in : which PTS proteins play a role in this microorganism.
In an altemative embodiment, homologues of the PTS protein can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the PTS protein for PTS protein agonist or antagonist activity. In one embodiment, a variegated library of PTS variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of PTS variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential PTS sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of PTS sequences therein.
There are a variety of methods which can be used to produce libraries of potential PTS homologues from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential PTS sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S.A. (1983) Tetrahedron 39:3;
Itakura er al. (1984) Annu. Rev. Biochem. 53:323; Itakura ef al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477.
In addition, libraries of fragments of the PTS protein coding can be used to generate a variegated population of PTS fragments for screening and subsequent selection of homologues of a PTS protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a
PTS coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal,
C-terminal and internal fragments of various sizes of the PTS protein.
Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of PTS
S homologues. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection otf a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libranes, can be used in combination with the screening assays to identify PTS homologues (Arkin and Yourvan (1992) PNAS 89:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331).
In another embodiment, cell based assays can be exploited to analyze a variegated PTS library, using methods well known in the art.
D. Uses and Methods of the Invention
The nucleic acid molecules, proteins, protein homologues, fusion proteins, primers, vectors, and host cells described herein can be used in one or more of the following methods: identification of C. glutamicum and related organisms; mapping of genomes of organisms related to C. glutamicum; identification and localization of C. glutamicum sequences of interest; evolutionary studies; determination of PTS protein regions required for function; modulation of a PTS protein activity; modulation of the activity of a PTS pathway; and modulation of cellular production of a desired compound, such as a fine chemical.
The PTS nucleic acid molecules of the invention have a variety of uses. First, they may be used to identify an organism as being Corynebacterium glutamicum or a close relative thereof. Also, they may be used to identify the presence of C. glutamicum or a relative thereof in a mixed population of microorganisms. The invention provides the nucleic acid sequences of a number of C. glutamicum genes; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning aregion of a C. glutamicum gene which is unique to this organism, one can ascertain whether this organism is present. :
Although Corynebacterium glutamicum itself is nonpathogenic, it is related to pathogenic species, such as Corynebacterium diphtheriae. Corynebacterium diphtheriae is the causative agent of diphtheria, a rapidly developing, acute, febrile infection which involves both local and systemic pathology. In this disease, a local lesion develops in the upper respiratory tract and involves necrotic injury to epithelial cells; the bacilli secrete toxin which is disseminated through this lesion to distal susceptible tissues of the body. Degenerative changes brought about by the inhibition of protein synthesis in these tissues, which include heart, muscle, peripheral nerves, adrenals, kidneys, liver and spleen, result in the systemic pathology of the disease.
Diphtheria continues to have high incidence in many parts of the world, including
Africa, Asia, Eastern Europe and the independent states of the former Soviet Union. An ongoing epidemic of diphtheria in the latter two regions has resulted in at least 5,000 deaths since 1990.
In one embodiment, the invention provides a method of identifying the presence or activity of Cornyebacterium diphtheriae in a subject. This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (e.g, the sequences set forth as odd-numbered or even-numbered SEQ ID NOs, respectively, in the Sequence Listing) in a subject, thereby detecting the presence or activity of
Corynebacterium diphtheriae in the subject. C. glutamicum and C. diphtheriae are related bacteria, and many of the nucleic acid and protein molecules in C. glutamicum are homologous to C. diphtheriae nucleic acid and protein molecules, and can therefore be used to detect C. diphtheriae in a subject.
The nucleic acid and protein molecules of the invention may also serve as markers for specific regions of the genome. This has utility not only in the mapping of the genome, but also for functional studies of C. glutamicum proteins. For example, to identify the region of the genome to which a particular C. glutamicum DNA-binding protein binds, the C. glutamicum genome could be digested, and the fragments incubated with the DNA-binding protein. Those which bind the protein may be additionally probed with the nucleic acid molecules of the invention, preferably with readily detectable labels; binding of such a nucleic acid molecule to the genome fragment enables the localization of the fragment to the genome map of C. glutamicum, and, when performed multiple times with different enzymes, facilitates a rapid determination of the nucleic acid sequence to which the protein binds. Further, the nucleic acid molecules of the invention may be sufficiently homologous to the sequences of related species such that
S these nucleic acid molecules may serve as markers for the construction of a genomic map in related bacteria, such as Brevibacterium lactofermentum.
The PTS nucleic acid molecules of the invention are also useful for evolutionary and protein structural studies. The sugar uptake system in which the molecules of the invention participate are utilized by a wide variety of bacteria; by comparing the sequences of the nucleic acid molecules of the present invention to those encoding similar enzymes from other organisms, the evolutionary relatedness of the organisms can be assessed. Similarly, such a comparison permits an assessment of which regions of the sequence are conserved and which are not, which may aid in determining those regions of the protein which are essential for the functioning of the enzyme. This type of determination is of value for protein engineering studies and may give an indication of what the protein can tolerate in terms of mutagenesis without losing function. :
Manipulation of the PTS nucleic acid molecules of the invention may result in the production of PTS proteins having functional differences from the wild-type PTS proteins. These proteins may be improved in efficiency or activity, may be present in greater numbers in the cell than is usual, or may be decreased in efficiency or activity.
The invention provides methods for screening molecules which modulate the activity of a PTS protein, either by interacting with the protein itself or a substrate or binding partner of the PTS protein, or by modulating the transcription or translation of a
PTS nucleic acid molecule of the invention. In such methods, a microorganism expressing one or more PTS proteins of the invention is contacted with one or more test compounds, and the effect of each test compound on the activity or level of expression of the PTS protein is assessed.
The PTS molecules of the invention may be modified such that the yield, production, and/or efficiency of production of one or more fine chemicals is improved.
For example, by modifying a PTS protein involved in the uptake of glucose such that it is optimized in activity, the quantity of glucose uptake or the rate at which glucose is translocated into the cell may be increased. The breakdown of glucose and other sugars
WO (1/02583 PCT/IBOD/00973 within the cell provides energy that may be used to drive energetically unfavorable biochemical reactions, such as those involved in the biosynthesis of fine chemicals. :
This breakdown also provides intermediate and precursor molecules necessary for the biosynthesis of certain fine chemicals, such as amino acids, vitamins and cofactors. By increasing the amount of intracellular high-energy carbon molecules through modification of the PTS molecules of the invention, one may therefore increase both the energy available to perform metabolic pathways necessary for the production of one or more fine chemicals, and also the intracellular pools of metabolites necessary for such production. Conversely, by decreasing the importation of a sugar whose breakdown products include a compound which is used solely in metabolic pathways which compete with pathways utilized for the production of a desired fine chemical for enzymes, cofactors, or intermediates, one may downregulate this pathway and thus perhaps increase production through the desired biosynthetic pathway.
Further, the PTS molecules of the invention may be involved in one or more intracellular signal transduction pathways which may affect the yields and/or rate of production of one or more fine chemical from C. glutamicum. For example, proteins necessary for the import of one or more sugars from the extracellular medium (e.g., HPr,
Enzyme 1, or a member of an Enzyme II complex) are frequently posttranslationally modified upon the presence of a sufficient quantity of the sugar in the cell, such that they are no longer able to import that sugar. An example of this occurs in £. coli, where high intracellular levels of fructose 1,6-bisphosphate result in the phosphorylation of
HPr at serine-46, upon which this molecule is no longer able to participate in the transport of any sugar. While this intracellular level of sugar at which the transport system is shut off may be sufficient to sustain the normal functioning of the cell, it may be limiting for the overproduction of the desired fine chemical. Thus, it may be desirable to modify the PTS proteins of the invention such that they are no longer responsive to such negative regulation, thereby permitting greater intracellular concentrations of one or more sugars to be achieved, and, by extension, more efficient production or greater yields of one or more fine chemicals from organisms containing such mutant PTS proteins.
This aforementioned list of mutagenesis strategies for PTS proteins to result in increased yields of a desired compound is not meant to be limiting; variations on these mutagenesis strategies will be readily apparent to one of ordinary skill in the art. By these mechanisms, the nucleic acid and protein molecules of the invention may be utilized to generate C. gluramicum or related strains of bacteria expressing mutated PTS nucleic acid and protein molecules such that the yield, production, and/or efficiency of production of a desired compound is improved. This desired compound may be any natural product of C. glutamicum, which includes the final products of biosynthesis pathways and intermediates of naturally-occurring metabolic pathways, as well as molecules which do not naturally occur in the metabolism of C. glutamicum, but which are produced by a C. glutamicum strain of the invention.
This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patent applications, patents, published patent applications, Tables, and the Sequence Listing cited throughout this : application are hereby incorporated by reference.
WO
01/ 025 583 w
[22] hE) se 2
AP :
NT 3 3 y PCT
Ls “T/IB : | (H)/ : [LI
Bz8u 32 3 ; 2i%s ov i s< = gLsu 53 ; i : Sw g i } C8 < 8053 ib 2g Th: 2302 EZ 28 2 £ = : of : 2 ee 2 & = ~~ S52 {ii 55 = © 7s} So oo 5K c EWG oe So ; : ; zuzs SF Noo ~ - oo < oo 5 So ~ ZW ww gw : 250% of] Do 8 oO wu ww ow
Fr] S ao. 00 = - : c @ S52 of EE QQ oz +: if
Sust a 2&8 == z : : : ! gE rig $3 w ww © i 8 T Zz ok wu Zu )
O35 2 QQ 2 w oO 1 3
E 3Esd 0g iE 22 $2 Nw 1 2d S99 = g & 22 2 o% 2253 wo o o Lo EE 3g 1 : pre = [&] [7] © m Q Oo og pag = 3 i ga) NO == 8 3 : : ! i : TH @ og § 2 Fy i 5 THEE 22 =z 585 oF § ; ak SHS) TT ~u ana og ny a o
Q wl HEPELE ur w 5 9 3 4: : ! oe = 55 8 Fa vf Ss 1%) ox ® : EH le NZ ee Ga a 3 gcolrol Wu & 5 > 2 55 « AW IN o » : Bod 233-88 ; o xg gx 25 a 9 8 rs (8) [7,] Sz g3r8 8 ou w S< 41; : | i zm EERE E 7] “ao a al 33 ot c sO Wow 55 tells) SEEEL : i : 1 -_— wl fEniine = 35 Ess : - . : 7] zegus EEE: £9 SuoSS 2 oo =] a < © [74 ipcaus 3 Z S$ ¢ 2 EE E > Biziis r « 25 2 J hE :
Q faEdsaneed x < ~33 & sEi 1 : c cioaceac s £3082 Fiat :
Ty w 2] 2S03sh = Ar x urtd : : [VS Re2e3 FHA: HELE: +3 1 3 £58 PLP wow Z8-23 w z2n58 wg a 1a ra pr} £28 xz S's 23 o 2 2 TEL HEE f . 7 £3322 w > 254888 Hg Sk : -— [= ok & 7) 4 FEE: 1318 :
Zz a = [77] SEIZE 2 Facas © 3 wl ER nz aa I 355646 3 w = 5 3 Tih £51 @ o 3 2 i055 ie i a & =] p aa azsit 1 : a nh pl 23 2 a. -
Oo 4 © 2 IN 3
M~ [ie] as 2 Ny ) z 5 a 5 8 Z gS 32 2
[32] ® Od 3 he ¥ ; 2 - « -— 5 3 [=] po | o < . ; : [+4 o g 5 pg : £2 21% a. : : : [=e] [Ze] < 38 ZEEE g 28 2 Lo = gg 825 § 383 > : , : = - : . > 0 < wn PI: a | : a 2 2 = 2&2 2 . he) w < Ng 22 . z% oS eo) 212 » 2 sgt : ) 2 <3 ] 11 [=]
R=1 pn . ©) g § 28 Bo >
I Pu 2 2 ag 22 Pe) a ~ 2 » 58 T 7] 812 ) ? HA no . o EE } - I © zl 0 Oo 2&8 3 &] © } a8 ree eo o = & Q nn aN
N [22] as pS [2d [y]
. L - 2 N S [5 o0-= = 3 I=3
I=] < O 0) S oO = = A = = 2 a py
Sp £= = . [5 |§ <= > =] os = £ o = £ = S 3 ~ = 2o@ c © [i $ > 3 [SI cS E & 2 un 2, [1 S 5 Q |= —_ =. 5 = = AS z E
SEG foi 8S F - 38 sme [9% SS Id £53 © .Oo wn 2 OY = 2 wT £ 2c cS 3 5 3 3 ° 8X 23 LS gx g ro 2 8 EZ —_ S 4 s ex £ ES <S 9 0 c 3s = 5b > ZOD LQ sPT |22 SSE |53°%
J— - 5S [23 TS le [35 ¢ 2 |e qQ » S = oc a I= 2 9. £ sv 53 EB a oo [F=J
SS w3D|D ES c « S eco=|s 8 SE |S ls8&
SZ oQ3 E se [© [222 = BERIT E 32 g BEF
OS = © oN O20 =
ES&@n|s Bz. [=RI6 23
FERRE aS (2c ES = Sc 3 s $5 =
SO £3S RP £28 |S 28 <c_53|8 2 £35 SEQ 3 co OqQ3 . [SI -] [3 = NID &
Z 8 neo O° 5510 0
Ocsg neon Y QE nl=% a i 5 ols LERIEQE 28 —E Sal S =CS le YZ 20
Ss E<il 38 Esl JPET. $0Z .. 82s oc. 8-2, . ) Elo Eo : 03 =le = E w c= el a oo |N 3 a 3 1 moo Sl% Zn = Selgin 8 & =e 3 5 50S « FES IPO I Gr iS J 51 c 8 wa
Yleg [Zc EXE 2 =
S| |EpsLEsy (8£225l558 ¢ |ESEES SY FEQIE 85 2 -~ Cc 5 5 =o & oO vlc 2 = QO
SE 8588s SE3SSESs - = @ oS LEE ER 2 HAZ [8S =
I] 18 4 s .
[5] 2 wv 8 3 |e ["] a] a £ ER ES = = 2 S |g 3 pd 3 € = 1B ol 33 on |=
Mm -£ « o |= dle]
L = lal
S m8 = E =|5(° © o PY g = g 2 218 >
SEE al E55 BJs [55 > = g 2 B ele f 3 alg 3 e [4 [R=] Se ol S [73 ol= = hel L oOo » Liv 1 => =] Fa > [51 22 = als = = = 1% = a = ad Q “= 22 EE gle Eilale|® 51 —_ [v] ole] ala @|s 8» gI5Is|e
Q S © igi E AER IM 3|5|g|3 = o Q SiS la |S 5lea 58 a Q = Elolg wills =? onl = ol¥|Elo [<9 Q = 2)= =|5 & o|= clot 2 = S|8[g S{2|B|8 E[2L[e(u| EES a. o S| Zlele Fs 8i§|2E|E|2|S = 172] [59 — | wn YiEaia 58 2islclamEIS 2 2 = NEE HE EE RE HE EE
Oo |E = AEC S(’|¢|= Bz 3[0|2|< [OA
N
© 8 3 g & lo a .- .- AS a0 £ °) Q = 5 flo ele lols @ an 3 El 8 =8 5 co. [En © |'c | Bol en 2 4) a g £ SEX |= 2 |8 fe=|88
S zs Z 2 xX 8 Io = — |= le oo |< [nn “ = .2 “ na 2s} oN [3a] Dad (ol Lond i=d oN |= |— 9 hagb adi fd fog
QS an ON =n nT [= pal vi [\D [en 10> hag I ng ot O | [non [nh [nn a 2 ~ 00 00 00 00D (a) =] 00 |O |en [<1 al lnd ind wy vio | |— |v leo y=} Vin n non | hong jong hone [oJ [mn Bl [a] oN [ed [=3 [= al sal [sal foal [aa 2 la nn nn nie = [= Qloloio =a i=3i=] = S lolaloio le ¥» QS << << <0 =a} fea] [eR[saR [sa] 1-2] mm |e a, [rig (TI [rig fly [rig Ig
QO << < <<a <|< < |< << |e (Cid |< [<i |xiC|]
. ] o =
R=] ES o [} @ f= ‘ © an | sg ©
[7] 0 1] [sa] . an = E a = — 3 ® = 8 =
E > a2 & bal £.%
I= ro.
Lo = 32 D8 ~
E % pa £5 S on 32 c E = 32 = 3 EP oh — Sa 2 = 9 ~ 2 0 ap ES
ES £3 S = 3 © T E ;
Ze c S 0X 0 Wn © £38 00 Pa 5 RQ 2 0 — <a 8 © § 2g og O eo >= Es S88 —- = 8
OX °c 2 oS Ax
Be no LX. oq = [= JR. =~ RT) DO = - Q Ear oc = = he = _= 2 = © © °° Ss Cc - OQ d IS oO
Lx E «9 = . -_ 1 °g E25 SS ©» cs © a B= = se 8a ow =a == c © = © gs 4 Sr yO : E - Qo» . 28 s £3 ERR =] =o 558 Hee - 0 RI, I) RE" Bad
Ca 3 ox —_ A= . E © © SOLS a
Ie, - = = T- 2 =a = So ER=N -— a =~ ZZ 0g on
Lo LE 0 Cc 0 —-
EQ SLE =5 = le § Yo C3 Bo elo = = O = 86 Ue
FEC 8 = 9 3 >n
E| ~~ ao Oc o— = he
Sj i | — H gl : ir » 3 Ie le 2 2 2 5 I oN © E’) £ @ IT E " o i Z i ow gl |= ££ & AREER 5 |B < _ a 5 = a a = = = =< Y
Li=5 a 3 E - = =D © a. u fd
RSE = o <5] © SlulE = @ 0 Lz fo a [22> = Sls? 5 8 ec |= = = sO 8 1258 Eu [Blew (8 2 [& |% £2 IER
EY a 5¥2 28 |=(8l28 |E 28 sg E |Z 5 oC © vlojls 8s. 58 [3|EIE « a S| uw |B = l= 3 —- slat of L o|ld|a a — © |e Pd = ad Z] oo Slaja 2 v~% 2|3is|ER p=] lal. IR = <0 ote clS|es cv £ s{2|=2[2 > =|cla. 8 2 = gE 2 82 41 [BIDE EEZ 3 aE[REE |B [EEE SIE |B 2 1258 wn 3 ‘= = NS 5]
IRE 8|SI2IEEE=Z 8 2 2|5(8ley |g lols 51E |= gE 2F 5S E|GIRIEIES 2 ES SB ElERIS< 22 |= >E a. v|S 8 © epXltielSIsgE cas Elgg [© HEHE EE ERS 5825/5188 Ew E8328 E 2 (E5828 [3 HEE oz BElE|lalmy 5S = 3 2|12|8EE QE gigft &e |S S|= &E
TE8I2GlEp ERs EE|S|E2RRlE (EEE Eas Sel5ea = o — .-— | = 1"
Fr HE EERE EE ES Ca EE EE EA ol 353% ad Sl dlaefe = 8 LC 5a a & =15(qg £5 (<Q 3 £2 £2 = Sa CIT EY MME 2 ole wis la SY ) OS ©
AE A<|E|<lz 58 ES 55a | 2|T ABE BW == AOS & i & x 5 so 20 = = 5 < F< & GT woo oo —
ES 80 20 ob 2 |g af <Q © 3 [5] < [nla so < < m < a [UD |<<
EE BEEEE 23lE 1B [gE [8 °c [28 [E|2 o GlEIB|s & ® Elcie £ 828 ES | | a [ELE -_ 0 [00 jr |e oo [eo [on] — [00 |= on ht co = ~~ [00 a) [3 [\O [on ONO a) nico on 00 — = [SAR {oA 0 <T [ON | [00 -— | — [oO 0 [=2 172% | od oy — Lal \O QO [GO 0 — [1 |oo | oS |o|—= ~ - lo ho - 2) - <r nn 2 EEE 222 8B BEE EE SO SI - — = Z| 2 , [rig [rg [rly 15 [rig [2 [oH ow [23g [reg [and [1% [£9 [5 [So a jo < < |< |< |<< < |< |< < < |< |< < < < |< << |<<
PCT/IB00/00973 > 85 52 = E - = 3s — = a. . So = eb 2 = = oF g I= a
SN = - = — Q >
Si .E lon 5 S ca (Eg = | |B 029 [~g - B ° = S23 —- |S S - 202 = J £ Q hl 5 SRS CIET oz I > w 8 » E 3 2 oO o >Re wld 228 Id Ee) 55s |» 2 2d o 2 5 oF car |* 0 22g |8e gE £ Swell STE F 5
Oo = = o = a BD 4 < Ly > = 5 = ~= E S — .2 NS nS << = = © = 30 woe 8 hd S = Ex|A|3 2HI(E I=
Zz SE ar|>S ER oO g oS |= SE mo ‘Oo SE 2 <£ n 2 a0 © = Sng eg = Oo oO . © 2 ot SE = hit eg en 3 oS 2
Teh (E XY ES k= Sa |ETEgE |B Ss == SE 2 S& === 3 222 © 03
RB. O N= 3 ‘= N Q = Nc - = 7] Pr Lo ao = —|® 3 ‘= «© To ~~ R=] —lT Oo QT = SS B8 52 go|lET oN EN) = SA [EE ETE ) o 2 20 ®gl=Ego = c Ss 2a s Elms gal 2 sa : ose Xian 9 Ton aa SE 80 Sg swlw |v o © =2Wnicg s & g CS £ Ae ZS BYE 872 on © ole 8 £ SR Ss 82 i rr S ac “9 glg 8 ee EO en SelB SEZ gle °o ° 9
ESSESE 553 | [SS] [2FRCS|EE SE IE S63 38 -~Nls Sv = Lo 2. Is S 8s = ood 25s 3 S22 | [E82] Belial I8 | REs
ES E36 ce O A gc g 5 ss 3lee gis ° Spe
SERRE —ES 8h B= 52 2ESES £8 = oS
SEE NEES S82 2g = E §|8. [5EE3 = Id e2§3|E32 Sic | BEE| EES e230s 5 | [BES zd alE SY aR = oF | |e QS 2|E E = = a
Eo old ®me Pc = & els =z|le 3 8i8 |e gcd 5 3x Slo <3 = = E og E §5- |2E EGE cis Povd [BPN = = Ql& ™ c = oR LU .= I=] cS olo - [<3
SO SL. TS 3 -X 2c Rr elg ee [33 Ss Ot
Oo A Als 2D 223 Ss 3 Cc 82 2&2 W033 = 2%
Sg Sa ER ®> 8 SES SEZ R EEL Be|Bw| [£22
SE 2h. Bo £95 SEQ BEEBE E|ES| [EE cE25alSEa ZES D8 FLEES SESE S| [2682 : TES -°%=% = 39 = S58 CFCREEF SSIES] FL 85 — Dolo = Oo oO” =e a -
ERNE: 283 529 [SC 31885 EES<«|5<] [FE8 555 EES: SE | Big CeELesEISalte SS. c= 23S us = 2: oo 83 Ue eld EE gD Ss
IT » a 0.2 ca gs 5 = T fa Q “able n= ; Ss
Eo BEE} “5f | [BES| |PESIsSEEER|EE| [£24 1 = = Oo == Ss Oo £ a A Qlag™= %X lg = © o Se 8B ° 5 = Ql od tS] ~ ~ ® 2 lg EC Ser gy FEB = EE Eo egl8 3 ll2nlan a28e
Ble 853% 2a S25 S82 CSOs sas SRR s=8 £ wm [DFESESS25IT] [E85 EF =
[3] . [=] = > 0 = = z [%} = Ss © o = eal os w— 23 0 2 cs [5
YRS 2.5 ‘= == Q TR Es a Q 8 Q
S| 4 ges gaged 8g |E 3 <2 = £28 [EEE EE E |8 Ss al IP R= »>2y [2 80ola|s — gs |E c = [3 os 29 = = algl3 Pa) 2 = r=} on) ‘5 Q o oo >5 R=] =) < on bed
Q 3 £ L= 26 vl - 0 = Hy > a § x LE X|=15 «|S 8 18 =! = Ss x a= %=lS [+ Q =)
Ts pt > 25 |82E gly © 2 |[& cs 3 = o S £3g a3 Pox 2) — = 2 [5] S
LE 22 ge8 [298 glo 5 |= o © Lo =) = EQ 580 ES|e S = S 8 = 2 3 228 Pg=23l5 ob E IS 3 |=» [815 3 ‘a Fl =) — = E18|¢e Io) [TV] - - © ols
R=3 oé = > © 2s ps4 ° 5 L S|.- a 5 |5 3] gc SIE S ° 0} 2 8a 5 n 5 E = 2 0 EIG|3 > Q 5] ° - b= © °8 |sE? |E§> EET = = [2 0 5 o|2f= 8 E-E-N oo = xs|Sy 3 sg 18 Z SIS(8 a Q £ = EE 2|05% 2 E12 © 4 = © £ ol=|2 ac = SE g|l>22>>282 - 8 |a 8 sol gl 128 FS [BEciEZEEEl: Ble |Z [B [EsEzlEs
Eg BE FEEx|zEREEIE Els Ss [8 |ES|ZEE3
TC [AW OoE S30 s0O|= Zz |2 = 7 S .Ela.E |S oN xD X= |= = e [32 n 5) Je g 2 < a0 0) foo) 2 £ w a CY a us T et < < E = — 0
A - a ja 0 |\O o len = 2 ~ 23 |X QR = = S S © or 0 00 a 2 tS NE Ad bd =] P=% S 0 (eN [en <r — pl ~ |r = = = =4 — | ae ~ < [a] en en len < < < < << wl = [2 = le ala <|< on Q im |@®
WO (11/02583 PCT/IBO0/00973 .w a. 1 © © = I") = = EIS B 2 18 |Z 2 |= I= = = a. 5 EN : =
Sle o 3 S = £ S = o k~) - < < " 80 on |» n oo z os Q © © . > cla — f — I] o = oo [-% o [=1 \O =) = a8 o x a a. & c = 2) In = £ s ho ©
D © ole < OU [YS = j= 17] c i sa > oD I ed x = [== I br oO Ys I El 4 uU a | o
SC O32 [ZR Oo = FER n EN bs E IS] o Ne) Ne) £% |«~-|S5=2 [§= [5 [8 [§ 8 | |= I [2 |e |= 8 |2 2 sec [C-|1Eg 159 [2 [2 8 [2 [5 [8 |B (2 |e le i= & §
VO L «clea 25 - KC) Q « < = = = =] fa) I= 38 8 Ee Sn 5 o- o- = 3 oe 3 IZ 8 3 EN —-
SS Bx|EQ [EQ [= < |< 2 lg | |s® = S 5 lv | |& co Sols a ae) I$ I RS = Q EY E E [3 Z = ‘Ss 2 © 0g ~~ |g—- NN Z Z © © gS [= 7] Q = = i] o ~ [= = = [34 = QL OO a o o «< c c a. Oo ao. TN-9 = Qo a S = & & 5 fy I © ENE] 8 = > co |E =] » |& po = a oo — — = ob an me) [ i=] = = > > x [] < a. aos [eu |g = c a |B la | [2 |& 2] a Ja o 8&2 E == se |= [= i] [> SomiQm|h © Ss | z cS g®|c~|c 8 cu < |5 | [EE |E [B2lE2|e cS = 3 vo
EI =a lon ta NR] o o = 2 Slee B=] ££ Fa) Q © 2 30e jo ge 4 E P= © SHE QE j= [=4 = = j=
LaQl="g A | & 2 13 c |= e |Eaiselc a < [=] o o =A — a [54 «< © BES = = - a0 =D
ZS oC|g Elwes. wi. |E S 8 I= a S85 =|8 o [= o : = 2 =| = oO o PS S026 oc) = Onl [=9 ac ac < [<8 ah fad Vv oO Xx—|Q 25 6 oo a. co co |= bn = an > > < Dla 177) > [3 3=1 2 2 I} = - — |= = = =| < . 5 SE = = “ [=] 2 Rd c — ~| = [Raw <= a |= Eg ~ = = = B «|S <lw Oo o 20 85 ILS c
Q Ss E 8 EN = = [=H a0 © o = = =
Sedlg:lsS |s= | 1 [2 ' 2 [e2lgdle [2222s qd |B -~ — —_ 1 —_ = 2 cw|E gl2= = = = a 3 — 5 < ~|QsT AAs —]e t gomimws®s (BF (8B ££ (Eg (8B F228 LEX |S = oc I (SE a a, o I= = [33 IZ SC © © iS «| F [5 os SE lg £ c Zz = < c a < [] No =] @ gE 5 = Sc |< |g |& |Z “ANZ le leg ois 3 c QQ = b=] f=] a = Q en an lZ ono S Lie pos £8%9>Z|8 2 9 [ZZlem|lew|TalZmlEaizaag sis Ils a ad PE od agile eERZRIR KZ 2520 S18 «(8 «2 RE S 25a 22 |S @ ERE CERES elPals=lB2B8Lls3E [2
Sl= vo & 8 Sorel ls Qs SF. SE —|2 0 wl Tis 7 a." BP so |©O% Gola alfFsosE ilu olf laa e2Rf 2
E2ElssE PE [FemOEolLo Os EIR El «F SF. SEF |=
Let else |w E ym elem Beal —| 88 2% T= oml= 00 T= -
I SESE DR go EEIl<|icisc|Sfae Esc EsRIZQISRE XE (2 : wild RAE [Y] elo Sl Te Sg Sar Ealosls Rs R= Tl .
Ses [gO 8 = LQ ~ No a |? old: o ping |S = 0 .8 < B= 2 S| QZ . LI DSN RI = \ clE SX g Y= oF 90 | of © [Val OE 4 [9 f— - = " v E c e ce >a ~ ~ Z l= 8 00
EES 2 8 = Sos am lS a ar a. alo lg o
SES n|dogida gl RIS elswl 25g 2|dQl Sls Flee
SEED PE CRIEC SZ RNEQIEL SEE RV aS n|lExS |S cE alle =z 8 2/35 E SEX SscXZR|ZRINERZRES|EZTE|SS|S ESE ~. |Ex|E ols BS BIE SESSA IEEE Place n= 212 5|2 §|22 (2 4 — —_— — R ? A
SES ETB SCENE ETA TE ZT SM SEEN AMEE SRSA S
- ptt + £ ! = © 2) 8 - i
Ls = | : od : o : : «3 “5 i £ o l= > s £0 3 = r= ze I @ 2 13 £5 - & 17] [3] [ [m= «<2 Q o 50 PZ] 3 wv P= — - < QL wn f= c R=] od © 2) = @ 2 = £ £ |S 8 i s =) E = > 2 oo [5
L he] > |= > [2 2 - 1 [9] o 0 wv (3 7 = -— «©
I. Q a - 7 TY © @» Ld s v j=} a = 3 bod a © > 32 1 0 < © = = [33 © Bd [sd 2 [<] c o Q © 2 cs pL. = = YY }) [4 = A = < 3g =
Q c c oO 9 wn © = « < o pi o = ag S g a ad 2 o Qo Ig > |S & =] oO a a so «3 > > Fs = = r= = 26 IE IS £ s = l= [© |2 12 IB |2 I |& |¥ |g |& < 3 © 2 lo oS Q ce Ig |= © = e 3 a = 4 4] P=] po] -— = he} a. [3 -— a. o i < 58 > lo o s [x : o c =] x
E52 212 [2 leg BEEBE E18 BIE BB
Sg |g [IE = 5 |E IE 2 58 IIE 8 | 18 |e |§ Is
E < = = = g S S a. < > = oO a. hd o> 2 8 sx [2 |2 3 = [8 |8 lo [& | 8 [EE |& |B |S |& [2 2 EE mm |o a BE 2 2 El B&B FE & 2 |< |< |= ~~ ~ > ~ ~ © ~ < 00 ~ ho Io =] — 4 wv bd ~ pa b= < os ~ Joo o - |= ~ Ea < Io [8] en on oO (a) on on hd — — ~~ ~ — —_— —_ [= fd — a b-4 < «+ |< - < EE a I) wv o |o Bb © |e
I= o |= [= o |e <Q o |e P= P= P= P= P= S = = (3] mn m mw [a3] 3%} i) m 33} 13] 1) [3] [9] om w mo =
Ww
PCTN
. » 60 - B00/00973 . eg
IE 62158 2 13 ES|IES o © ~ g |§ HEE = |g g [Ble » o = wv 2 8 82182 o E ERs &l3 ..
S |E 2 el I] S = Ze Lian H u — bd P| < Q = = 88% lL Ss a o . = 0a 3 a (es e a Ql |S a gE =
BS. 288 © LT = co asEaly IS - o = = = we TS a DO o 1) = a ECR= Fl [= « — QL [+ . IEE = [= acl a I] —- [*] = = SESE =] S [3 [=] ee —|2 ~ 2 a. JS) - c °ZlZgiE 9 = > 2.2 8 |s 9 — jon = = Ss I
S cases g (8 ZnS nS S <Iz <|= S ar 2 &
E EERIE £ |E S&S &c SIESE [8 £ |g |g :
A 2855S 5 |= ccs = ®is 3 a 5 |5 - = s&s & A Baa i= Re] ERIS EIS a 3 2 5 P= i 52|52|22 2 8 2812812 S203 E 2 g 1g |g 2 = a. = 7] 11 | on = a 2 o s ERM 5 25|2 35 EISEN Z |g |2 a
S IEelFulr 2 15 [Ez|EzlE 2olESE 5 |e g [2 |g © 8S EEE FS = E <|§ — EEE < = E s & 2 EEBERE x [8 ENE eof 5 = |= R= = 238 E88 L 3 23l23|EsEelealE = Ss Is = |= £ E Zl & Od oo — a0 © De call = =] 2 g
Kv] Eze ss > 7) =5[=5 Bgl]: © = [15] [3 ‘5
Q ERP be = g HEHE FR FEE © b= ‘g = = hd S22 82 o [=] s < eg RN Slo ELE a0 «8 © -
I= 53s 85 5 - bE =f NE © el 5] © 8 15 c.2|8 2 51 - ES[Eg|aS[EEE 2 £ ob | oo © a
[7] a |S 8|2T 2 Fle HEHE EEE 2d .E8 I<} en 4 a8=1s os le x18 2(3 . = © LS ae 3 7» = I= [V) - SIS E(S 2 Sx|2g(E EE 58S si © 3 a a = g < El E = ERERERIE z<EL5%E c © b+] a 8 Zz 8 Sl 5 S25 ale sl3 218 [7 [5] = Q 3
SZ 3 Sle SIE Sle glo 8 ah <3 3 [a ni Q = SIE =|8 [= PU gle [ = Ww gla = «0 3 S2+ EA EA I - Ie ob Oo Q = ° sin = |e sles 8 S|E 55 §|5 r=] hay 20 Oo S g 2s oT < Zc 5|< 8/68 S215 £5 = 5 0 {80 . 2:2 EIR E 5 <[$ Zz 8 sla £<|5 c = |g . — oO o = S E-EEERER Ese R= c [= b= © Seg c|Ec STEERER cs t=] ~] = lz |e
S N 8|S 5|G S oo = ad i 2 [7s NEESER: < = 2 = c “80 = ° I _ E|_ << = « <4 Q ~ o py = =
Ss EF : Os FAE-E 4 — E «< N RK] Tole SIS = = pos Eu Fy EE = RENEE 8 i 0 EI HSER ER SIZ Z| aX SRE IE SIS gS ES £ 3 oa 508 IF ~|5 8568 5% = 6 I= 3 I: SES ) = = = 518 8° gl a3 £= r= EES s_.|Z a3 2 c TELE sll SI. BF s pa] S2E2ERES
PR & {4 HEHEHE 22 ESESESES
SIE 3 s =p 8p 3 sols ZIE o L SSS als a . , << 23|23|23|83
SHEER 8 = alse |S ENE . Ss ols af = 2 Ll” <ol<o
HEELERS =} s mR Elx* -1A] = = Sls Th = 17] 2 [ela=] =| SSIS r = » [|e =n — Lr. < 1 S12 iE |B HERE LEZ 38 2 [TRY pot c — " . << 81 HERR IS EEE l= ES a Salszls ales = & ie EE EE 28812 5S ; © Ql &ls 3 5 2/8 218 28 EZE8l58|23 o Ss = : © ae
Ea |S =< 8|o = = s : oN a gL E HEH oo Sls 8s >} u EE EE EEE oo = TO 5=5 1 2 EERE EEE salfziSa "© al RS sls Ble EERE ols 2 isa =} 282328 -ls rs] - so S25 rE alSalgalga = < 8 .2 2 = 3 2 S 9 2 ~ b= a . . o @ gS < Ks a 0 1 a > OQ 3 <= EH] 3 o u 1) = hed £ 8 =| a x o R= [3 = = 5 - 2 S 3 I] £ S 3 = > = ‘ap © 2 < IV] 2 [3 .© -= cS © 3 3 |] = I] g = ° o = k=} 3 = b=] Ss 3 5 o |B 2 85 2 18 [5 ° 5 2 17:3 =] = << SB Be PS 7 he] 2] = v 5 9 i] R= > a ® i = |E > S 219 g Is IE sg 2 = 9 < [3 8 Zz 5|8 Ee [° | 5 |g ° = 8 < = S| = Q g £ ® 5 8 $= Q ° ols ° [5 E 32 &
El} o 0 > 2 u|E .Q © fn > ale s aig = g 2S a £ 3 a 3LE .2 a o S cs 37 Q 5 = = < 28 ec . < I& © EZ 3 a a [Z 2 Z 3le °
Q <8 © [=] > a Zz 8la IN © < tla 5 |E = la 2 <|E a [2
ESE a |Z £ o [8 =< 33 £ |Z [=¢] < br k= .E o >8|5 iv - [a] la) o I= c 9% Q o 72} ad ol = =] b= ld = < >
Ze |g [8 © [a] > (
QL
£7 0
Oo wa 5 8 I=
SRE 6 of © 8 I= SIZ 2 18 «0 RRE= 2A < om oo oo 50 0 50 % |= ~~ [an] a) EERE IX o 3 3g [=
SRI82R 3) od 2 < o
Wj oo oo O o> — on S 0 P=S [=] <x ~~ 2 18 1K A . [53 p= 0 ve 0 93} oo 00 eH ANS ~~ 43] > o~ ~~~ \& o [£3] 0 — oo r~ = on o NNN ~ = 0 mm ola (9) t~ ww om x o~ wm
PCT/TBOO/00YT
I] R . . ! 2 A u ° £ 3 jo) N 2
E=] ~ on o 9 = o = jut | = J 0 f 3 = : nn 2-3 E = EQ S o SO =O a o ih ew IR = a 3] ba v4 © © < E ou gE > 3 oA 1 un ~~ H =
Oo 00 3 c 3 ~~ ab ~ = j=} IZ <I © To ; 2 0 Oo ~ Oo % o =. < — =) = 9 [= EE < v0 5 oa = ° D5 a0 ce oO - > < 2° 2 5 Le 3
Zz |E8 [8 Ew geo sE |ES [29 SY CERNE] 86S YN a) 5 2 3 Ze © 552 Bs [TRY =m uals L2 Le !
TEX BE 27 |E2Egg |8T Bc | |4% |EglE £8 £5 = =~ r= By» — ~ a. c & > x — S = = © ~~ 9 S S RS = ® £0 EO 2 [z= [22 [ER IS853Eqiea [2° | [28 (3512 Eo Ew b4 ~ I=) 3 a = 220 848éx Pair « a oe Q = s~E8 [G& (28 vo=SR oo Sao a3 SX 2 _:|E ©-3 © 3 5358 [g£€ |28 |E8=m=g|®T [v2 sEG8 LIES [53
Ep - oc qa [3] ~~ <= S OPE Tle g|2 Padi] ol, S o a ss X RIT 2T wn -8 |a 9 coz sieR|s 2 Cc 2
Salad ee |B essen (2g os g [plas (28
Cola x c £ v oO Qo ETI a 23 = at A I CJ © 2215s BF 15 [053 BES|ES [FF | (ECE s|ae [ow
SLED |3% |§E EE8® 85a 5 255200 2|Eg [Eg
SEE 82 [08 S855 agzles S68 <EFe E22 s 23
SCE5 |gSnzg |BdS gases. [E3 zs glass E [EE ve gO £ .= © 7A sxe o hd UO Su E w £
So(58 [© 5a PE 9=~S E [2 & O clas Cc = °c
Tl = A DIU) [Y Riad a) © wr 3 - 0) ET £2 ©
F31e Soins 2=%,5%|83 © ah 3 QE &%[2 = cs [= org Ss 235 v= gexec Eh = C oie 2am [f® <£ ~|2 5 Cc 2ols’y 55a vo 0 E = ZVI <|w ols = $e» (28752 (38: 55538 mY | EESCEERE [E- o Z| 2 B= FANE aed, — wl83 =38 SS ly & EE SE c E QU om = vw a. = < ES « QO ~ [= “— [Ve bd Nod = EO ~ 80 T [SRT RE ell he ‘= 9 2 3
An -— 3 = = [TRIS = = E Sc o|l3 Elgg =lo 0 oS
Oo |e = ® =| | = DO ~|0 FE hd —_ = LQ Tle = [== -. i o lg > 5 a © E C3 oo oS 3le & o cleo 0-3 =o = SS =3 3 Qlw 3 EY 3 SIL 0g Js <Q
Z 5128 |ES2|2T |ZAESERsS|sEs |B eS Slee|lmele E © E
CRA: = 8S =O a0 8s03g8 SE 29 8is Ele 85 § EE
Elst [BQ gl8F [Ec S595|BT |ES sz2afF £x25¢ [22 . 3 RI Ye — a 0 = [72 00-4 . = 3 —_ I= [3] = = wu © ~~ 2 == lle = Sis = ==
SEE 2 SEC Se EZ E328SF 0 LEDER |IESolES = — 1%) — —_— = -— = hed -— —_—
SEIS [F838 |» 8 So EQ: £2= & © 2G Els gl Zo - x ale O > © Ole A z EEG R= . ~~ le 3 - 5 E 3s GF. EST. ES
MX |e ae PER —% 0 3 gRfg oo PSE EESTI ;e|l29 WJ E Im 2EZ ESCM § i § Eg 2 BISETISET
Esdy |sESCSSsE=F E88“ 3 SS5=gx 3588588
[3] 2-4 ET ar, ¥ | and 1 fof PEI + 8 Lo SE ~ WN PERS TN oN
SESE [025858 «Sev iEdgg=s | [gEElgEE SET uD
CS BR -En|8E 3 -BEBESTRS Ise [REEE c"« SS D|lsT a ~~ OT NST ESE Qenl|D 2 =] -C iD >a 3 = O|&2 pd - - "l= 82 > g3= 2 Ry SEER RE | gS = ZiS RISERS
So [*] -— [= ==] v3 oT c= 5 20 Qlo O lm iS = NS SE ™ dfs J18 5 le 3s 2oP|os X RA el I OS ol El d AlB mA
Hr BETO RW ERI BS @ 3d FBO =
Ef =H =e b>] = S i 2 2 ! o£ 3 2 232 i
H ’ wy
LR ~ v3
Rg N v= = 205 2 ob ®@ 3
CE od s ES - f= | © = —_ ng 9 - = Q uu 5. [] © a a un Ll — = > = 9 9 gen o - KY) = = < £ = a 0 ha on 3} 2 == E|Z a - © w a. EE 9|2 © 3 u oS 7) EA = nn lle Q E] < @ = J] = « oO 4 < = o = < ol eR [ere = © = = 5 Ew S033 8 = > g c 3 5 © ERE AR 2 3 oz = x > =] = R= >a < < 218 2 ° I) (3 Sn |X x X52 £ = Se bo! - a. © Tn coos . = RY bond K] L S Bd v=) I} Oo oo o|lo & > © I's < ‘= 5 } = 8 [>> x29 in L 1 = g S 2 EG x £ £5 Sas 2 S == 2 £ = o Q oo a o OO Co < Sls [=%
Ss 8 °2 |55wlda = g gle o © = 2 |= = QOL Yess by a a2 (8 a < = © = na |[<<<lana -
Q
2 wy ST = Z = < ht 3 B] 812 vw |B E = mn = < « (O a =
Tr |v 0 3 hel [==] ~ 0 \D ra I=] > - = a I R= == © 8 b-bd 2 IN = ~ = oo |v AT =O od S = ~ |e = |e < S - o ~N = m pus a hos i] —I = - | = |=
[= []
EI - oN > Q 2% les [08% SEP |28. § . IY EY) E <S — = = « o 50 [88 |as®8 eo x 52 |EEE = - = wn Bas o © 2 bE] ~ ~~ $ £5 ISS |9253Y (ne |80 [9m 2s 23 |23 |2% 2. LQ. © 0 ge 80 2 = g ESE S cx Es 2 £2 ge c ~ r=1 - ox Ly a = = LQ Cc =o — A — A — A [73 7) > = - CON v Y LU °c 8 oS oN 3 oa co 9 =.= LE 8 2S 2 232 = = ooo ==
Z oz oc 2 cE£5E ao = EEG = ® aR al aR oO oO o QL 3 0 ow 0 [=3 <Q © 3S a S ~ ©] O [=] = = wn vn = © =~ Eq Ex Ex g | |F0 12a [228 0G RE EAN 3 3 3 28 95 [©= SERRE 2388 [22 (EES |B [BS 12 — ard - -~ r3
Se Is% [£2 0S =T8 I8F I2es¥S) Ba |B [Ea © p|& = Zw 0 6 = EES Lz Z 532 wun So se Eg
So | a SY = = GG 0Z2=835S EE S52 =] gReREL L SG =e 2 3 3c 58552 @”° [2 [©
Ue [=| P00 _|&EQ x 25 28 aS a
I= ~ ~ En . g oS 3 . < < <
Z| “ob Pools ES 0 WV |= .20 Suv Es [Eg ES 29s} = 5 3g ERIE § & ca? sno R 25 |823 [2x5 = X “SRB © 5“ 2 2 2 geqets |°= EsEeClE2§ seS82SSFem So [So |Sa su5Ee [Ee |E€3aa[e@2 (Exile 2ass| (B32 [82 (8S
TO QZ E x = IC a~|2 ES CA=IRS52 6S o% (£6 |o% = 2” = = SE 2Fomise EQ 10x Alo gegT ed © © © © o ©
So .E Ales 2 © ° one Lea ju 2 — 2g < 0 cw I=] e soc 3 | 3 Za—0WEx [oN ZS E SH wR J a a sexlEc [Ez EEQR0Seg: Fu3lgssmesd| [EE [S88 [58 3 93 oS oS 8 SE Eo NR PY I SOSEIEEERZED 3 5 3S 5 S &
Jesse Sls =m Flo SS = ole c= O33 O23 (SF sug EcQlstETHETI2G 2 (TF Sc EZ ent. Q Q w
EN Q RN LAY 2 ~~ LX|= © RY) [= =3s) = = = cs = VD ARP an = L = = = = Fa] ="
E XI 223 22S 6 els po 2 4 bBo = on = Cl - — wXOIZEC|IZEC|REqE~|S8T [CE2S22=EE| [2 (22 |e23 £E8:.|2 5x2 Sn|SES 2<E|PO 0 Ql? 20 @ vo Ela Bala Ea ce gq Qe Qe C=R=ZSlEd 5 £=20(e§ aQ ES = Sie ie 2
SSR ECZ|SECIST RESETS |SEE22553 (2g egg <]
Coo|EELIEELQsnESSeg [e58leese Sa] [Buss ns ) HN —i8 owl ov vs 2502 I= nL) = T= = =) | © ~ o
S80 ZG ZSESS RSL Ee 22S EERE £22522522 3 = —lz oT = Z|. = 2 = 2 = p : SEE real SR ESS ws [REEL 2S5E LEINSTER ati g RR" FE T.E SIP E£ SED >E 8 TS = SAE dE a4
Se gles = -m~ 2 Sle 8 a dot EsSRES - 9 == =o =
SSIS RHEE R8T Pgs SEsl<z2e8Y| EEE 2ES ce dal ug e~=xsS8s.ln ocx . 8g 5 5 8 = GL ml eles DA
Ss 2-= 23S E33 Veo 59 a] aw Sse § EAC ESCES wa Ew QF Q(B Se dle cEl®R n> e2 wc EVER . = a SY 8 LY 8 Ise Es EQS Sls Gen. 3) = ATE AZ| AT
Bl Ec 58s 5 8|88-cBE ESE GEES ERE] (EERE E SESE = = £5 5 EY = |= QO = m™m Oo [5 =~ =~ 2 ~
BoE SE GIR SI 2SOSTFESOOOBE=303 <8 Z|<B Z|<B =
Ed rd
El
H . °c [o.
S gz 2 r= p Cow : ~ 25 8 a " a
PN £ 5 a =) 2s zz [5% § | =: EE =] £ 5 2 = ©. 2 3 =
Si 3 3 = 2 i EE 9 ==)
Bll 5 g g SS = 229 p E35
Q a 2 GR] > ¢ ov 279 8 a 8 = = = 5.0 2] = Zo. 2 = go s S S = — 2 25 Y 8 2 83 ° £ £ 5 2 5 5 2587 A £3 $F 15 |g (5% g 2 [pdfs eT OEE 3 = = ss £ o Rv 3c hd = £ 8 5 2 A 28 a = 2 2 5 & £ = 8 8¢ a Eeog [=¥ [vy ['v) wn b= Se’ a. oo 2.2 « «= = = s o x) © TE] ER © =F 2 = ego Zz — 0 a & < < = kg s ks 25d wu 289 8 Z @Ro hod = vo ESL 2 Sg = of Ow Ie < > v= = Eg. 2 a. rot rs ~ o = = 2 = = 0D
A << 9 t= SSE oo [= Ex 2 a A 3 a 3 = Sogo iy 835 «© ~ ~ a3 = < a eg i] S29 = = — 5 20 5 = o Ad > Fd j= & = =
E E 2 £ AES a 2 = S 2 5 [vt E=}
EF] & 2 a G3 [=a] 0 I 0 = wv o~ wv | vy [= — S [==] on < ~ 0 | ~ re] © - — = | S A oN Q N I o n n nn on IN hit} - = |= a e ~ oo oo 00 0 2A pt — — len Ie) Poa) = = == |= A) o > ja jo] jo 2
PCT/IBO/00973 o £ ’ c = = Ey | s 3 ° 20 Oo wv : Q = )
P35 Rg |Z 8 = T 8 |8_F 5 § c o & = ox - 8 < O ol < 2
S = 3 0 El c ‘a r= so. ow» E ab 2 Zz = E oc 3 I= go 3 oo 2 v 0 3 =F ox
Og == 2S EE [52°55 228 | gl35s [2 _. 0 [oy : rd . ir 5 S : ne (22 23 gx [£3 SS sAlgEg Qo 2° g§= = wn SE ER QO rp wi 5/ews Sle eX L 3 OU a QU k= DO oa. STovEn|5 wu Zig oo 8 =< = eS $3 Ss = © x REN ENR = 0 = no. & = oO = 8 s © oo z=2~|3869 ~~ 23 ool
Sale [89 a= |& $3 E558 03 Bo 2 80l¥ x o ex [£2 2389q(2 3S e3m sg L 3 soles |e R= fain 28 3x3ud= S28 [Et
El i] £ x E ¢& © © 28-298 & J EEYE [23 n= |e 8 &= 8 6 |©e do NEE i] » Nig 4 oS = J 3 = o Ele DH 3 w|0 Ew &|o = ou E I © 9 2 Cc 2d <|8 3 p= FEE s 5S 9 ] EO a |= SEXES T|2 FE xy 8°. |S
D5 NEE = So 0 © Sal end g 03 oF Poli coves |g 3 £3 SST ETIZ ES <dlg2e gS 20 Z|EB — a] Ee] = Sa 2 Cc gL 3383 g 8 =
Ss ° LEB |§.2 SE |®8 SEQ 05le 5S = Ss |E- tm Pp [=D = OQ. [SRnErTEN af I o= a > EE 0 Es > 2—=[3c So ° 8 <« E 2503 1s 2 glows € oY nn Dog © = = g <= fw Eod de ] uv 39 Peal rp Yule, Sled i a |>38 2.2% 38 EY 238s TE So
EY) = wn \O I © [3 add >= - <|g £3 Bn 2a SSIES em se Lo o ~ XG .2 s £€ © © = 2032823 3 T= [EE ST2320E% 33512883 S 5 52°55 8 Ss E EEE3TETEE 8 vy 3583 o on
E RERREES o 2 c2%|l=28X =z 8 le g|® o = = gle 8 S cx S 38g 8 > © = 09 « Ee oY = as o lo 8 NE fa SE
Fd SIS 248 2 3 Q old © <|27% B= 32Z|5 _ Q 52 =38 528 9° I=: 25 veg . 2 Ss £E€ S(T 5 Ow g 3 2 B-= qc |o E_|E82£EY¥2S Sle =.13.© o.2
LElg © [2 a0 ~ ou LEG =~ 3 2ST FE bd a © 34
EEE EEE 2587S a dS EF SES|cEIgge a E
EERE 282 FialfidELRS EI is ae S 5 = = 20 SD —- 5 <= EBTles =f EVE l[0EZ EEE 3 gle |< =~ oO SEE SEE HS I SH
Qo 3 = ~~ |= wy > EE NE Eh = = S| E 4 3 . 3 Lo 2 a< [11] 0 =| © % : 21 avn. 2
Y 225 8s=d ER=) EE - Te ol 80 ~ : PRE 3 = ~ S58 =5 ss Q LES gS|s ERR: 0: |= WZ BENZ © = asiSE 2|BED S22 aP EXl=m2x8 0 ’'2J Gi Elg EB call 2230 ES|I0 03 352=% as ge 5d 85555588
ERE <a C8 FEE EE RE = SE 8 ced 2EF oN J25|s 5 Elgg E SIE Eig EZ = a
Sis 2 Sis s 5 = iS35|53 3435 ESCS aT ) BE 2 NT Eo lS SS lg Sn Zoe EDS @ SExlyglgs ER =
SHEE EERIE A 3 fe ESET Eh EE Eat 3x 2 Wo Llp ORs SE cE $o 555-8288 8 She 213 30|S aS 25] HEHE ER NT = Eis = x 9 <|5 5S E lz 25 ETS oo ZT £ = $i5lzfesgls EERE ES 58 = . © LOH as & - 2 BC CaS=T = lo 9 [=] t H ~ 3S plas 2 rf . o = 2 = 25% 3 = = > gis 3 & bg E ! : g c|E(5 5B c » J] = ft = SEZ 2 ‘E @ = se a = sl=ele 2 a = uv ce 4 8 elals .E = > 2 = ‘= iy [3] al» © ~~ x be} sd o 8 c 8 2 gle 2 3S [2 < s 1 <4 we|g 2 ~ re) e n = a sa. 2 FE ™ Re jn) gS - = a Cc UV — « — QL s o S|3|5 E~ [© «© El Ey = 2 ElC|E E ST |e © = ]
S = olo|e0 c o = = = 8 © = 3 wk: ES ° pa Ng Ss I=} 5 7] = * alolE ¥ e a O > = 3 Q = 2 2 £23 2 8(& =@ IE & 2 E = 0 © L <|@|S SC [8 re 2 3 2 =] = La Slg zw co [= = ° 2 o > <8 ob x|21{5 E 25 28 |o °o Is is 7 SS = glEl8s S12 - = =4 2 = “v = 2 c o = FEE = 2 ks] < c 3 x £ Q hed 17] = > = = SQ va 0 x o 0 > 1 od 88 |B sg §E[2 $3 | $ S |S = mn = 2 = =a as [= 3 ooo = x 9) £8 |= Sw|s gil 5] a < alin EY
TlmlO 2 8 << OQ o [53 | a 0D wn OLf= as = 2 ~ ie == © a. AES BES 5S [499 . o 9 — <r [<< <3 .- =]
B
O Qa 3 EE
Q ao -— 2 Q ae) a <0 EE = o ee - m |< PRR = PB o = E a5 <a |< < Ea
Cc Es |2 Q - < i” - = om 5 [= 9 [72] 2 5 Sd a — fae) 00 Lal
I] Oo [r~ al a nla \o 2 \0 pi. ™ en pag nag bo = a [ve] [aa] Pe) Jon oD > ho 4 <t |v [00 <r ~ ol - te ~ fd = SDD A S 3 pag pA Ng ~ > — AB BS =x > > NH Vv
N; NS vv) >
Ww 0 01/02583 PCT/TB00/00973 = . = £ = em = — Ew vy ce QO 2 = o 2 ° on 00 : 212 Se. (338% oo 29 | § |®Ez 5 lex
E 233 [ECT oO FE = = [52a 5 3 2
E =ES [ESB eR 28g |E= = 18 — © es |2z = pc] TR) 5ST 25a 88 Sm: EX SEE [=I 2 EO = 3 om oO O ce uf. 9 3 ~ = Cc = 3 = 83 a - — ~~ @ ~ aN ~— ° 20 = = A SS 5c cE 0 SS [1 Boe 8.9 8S... 8 a O 8 ond an OO, 5 = 5 -= ‘0 ~ QS = =
EBS 2718 28s 282 T [ge gees |B AS ==
E [E883 [ZnB EQi5325 [ES (8% (5:8 [52 | KAS Ip = : — j= ty = £ . o Eh By = HF 0 F2 = S oh W038 25 w= ET § 2928S [Bz2gglEda [BES |2% [3S Es | [5% [53 |8RIECA SOS SRBEEEC [3D [eg |832 (Ed 2s |g: 2 BIlzis [5WE2Q8 AT BS [SS [p83 | 25 [BY a og 8s. |Z ST e8F OE o— c= —- E32 2alg 2 5S 19% 3 v e¢=soqle ty © SE 2 cos § oo ES £o5|521288% |Z3E3RN|SpEy IE [ES [scelis® | 23 |BE =l2 5 : = | ~E S
OOS 2F SSS X§|lgs § 1 (OR Ss: PC 92 £5 221228 [S505 S23 2y |25 |2¢ [ECSQ8E § Oo
STEFF E s52338lss 88 £% [8% |SSEREYS RS [=% cole Te [E2230 |833838 |« 8 3s 3 EQ|2 ES a 2 . = sole cfs [E-aC8il8c2x [68 |§8 |T2GA|03Q] |9 [88 o~|e SIE 2 8 COO E Slo 5 : nw 5 c 3 nS no REC Q QS oo 3585588 |ESE53(8880 [85 [sz |sg€23|dec| EE £2 ng © 0 O - \ = mo. > O =. b=] ~~ oN = AD
SRS EE [3 2i2lsSsy 152 2% [TEEdlizg| 35 [22
EIR ERS ceg2s3|g225 EX [32 |8v 225% |g oo eZ =I6 CL. |= 3 5 Eo 582 © = 2c [22s PT S 3 °zZ 2 eS|88% [E252 |2%g3E [58 [SS [88c=%8c| [EL |S§°% = ERE cESEESES? [Be ST [Egolpi= SE = g f= = = = -— g [o_ - I=] © 2 =n z= uo 3a 3 Co Oo © = TU eo wIl2 gn 5 S ce
PECTIN A 28 09 Ln = -= — © Pol|E so I=} =o 23s ulz els meg 8 a Ss E = 9 Ss 25l85¢Q 5S [E83 oC 3 JZ 5 £5 we El ESS Ss = 5m 8 s s ST
SSIEENESRV Ee osSEERS =E [gE |¥ITHPo- Sz 188
Zl BC Ec ET 25|E528 [3 [Ze |[sEESL ed [5 Bis
EN sso l=E2xC glen S — 0) [= 5 E — S oO .E =D = — sl 2l= SIT §R 2 No Uo TH © op : 9, o Q |= 23 ele oc
SSF. Els E2QssszEF.EEE |B5 [$= ©223185878 BRIS ES : Do l= a] Il = [= ~» = pg = = O° ~
SIRE, E2ST-S<825282 8 (42 [2% Z28| [scsi - SIZ & al m0 LL om © 5S TQ —_— <> gf lms Tw —0 Ex
S: oa 8 Exnlg sg EG 2 = w s em 3 = 3 Von yo
JE ad s 9 hv] 29.0 oO = E~-ls Q XIE I > QO vw
AaSlhelgesW Lev ELEeS |g S3a|®2388lag:] HFS TL s|“c882v|zo258lE08S [8 [225g g Erg IToLlRES
SGM ES 2 ES|SC EES EE uals geo SS EERE [545502
Belg Ele EEg SEs cE EndR|EogaSaE edt FE ESAS re =[S 23 8 E OI o 2d Elo Die BSc ni DENTE
ST EIT EPO MAK EX FOROS T@ BIG WR|ISEFER@ SS & Armee a mb = o ol 3 o g = = o3 Q QQ wl s 3
L(= S r= [= I oO [2d .o .~ 8 Q = = 3 u 2 A po = = 8 2c sS = = E—1 3 = -—
HH] SE & = To Is So 2 on oD 38 aw “a Sle £ 1 5 0 20 a A e =] el [Y) 22 n>E 2g bv} le rt == <Q Vo < = ob = 85g = g > [4 2) 2s 5 ni -a =I LoS BS a £12 © = al LQ v Ta CT o © fan) S 4 = 8 5 ec |= RE Rg oo 5 ES) a Flee 3 2 El [@ a a3 >3 5} E = Ol =]
I ER-3 4 - [] £ 3 << = = | O t=
DL Sfo s EE 2 =o Q 4 R= z Sf > - o 2lE |B <x = = © 2 > 3 [= 2 vgs IE ChE = lz |B z Bls |= 2 =18 2 8 s.8 Lae I] ‘a a 2 = |e > 18 g Oo @ = NE -
Sele S.oe $8 E 3 2 E he 5 512 |B LES =e 8 = = = IE fa) a aE |< << 3 [CRS ©] ~ a (8) o (on 2] g 2 0 2 % 5 Ea he} “a = wm & = = g - 3 oy 2 £ $ 2 - oD ®} a — 0 ley
BIE [E 23 = 5 20a gE |= |= Ealt ab 2 <3 < (=~ |» =) a fm = x 3 bX o 2 N pong 2] I a lo |e a = = o = T= <
IPAS V-S IV: ~ = on P= ve] ) EY x vy 8] hd wv) vy i N= A
Zor (2 7) " N= OS © [© © < >< x eS bes [= x
PCT/IBO0O/00973 = : a |v © £ 2 3 [1 £5 = Z - o - «8 = = oo ag RY) er. EX : Jd s & gs 3 2 85x [gf |g= |8= E os SN > ° S © = - - ec ac 9 £0 y = § | [£5 |g° |Ew |ES [EZ 2 Es |.F | = lg 2 = 8 |g EE [98 oD E so (wR = lE £ = ~ = 5 3 © a 2 o 3 Sc: gen SS © 3 9, 2 € 28 |e 9 @ Sd |S > °
Oo > 2 ws, Sp Ec < Sw Sg = > oO <r 20 3 = == sR Y sk 3 |S |S% [23 wy [84 ~ |Eg 2
Eo EE 3 = < - - » oe 2 oO wn S = 8 0 Allg = < 2 © QQ gO o © EXE Oo 3 J Q Q — SF 3 ISIE =] TaN] qs vu = E=] Bs] ~~ o — 3c =] [SE A = = S 2 R=] = 9 ~~ Ss © 62a & = Tofu O Se 18% |g |&E—=|§ oo = c . 2531588 | BESlss 2% 122 [28 [B3Ei: EY 5% £2
ETL wo Qe Low == Ji Rr aio 2 LIEN Fa = cw > ac £ AD IE S 7 EE AEE ASSIS G EQ 25 0 Ww 2 oe — = > ~ 2 o TU NS Sei y 0 Y =a I
Co TT = = B(s E = 2 5 ae TR PTle 3 Se 5.2 E «=
Lc So D NRE 0 © ran dle T = © = E = ce 0 -O [= = oO ral [8 I=) O o z [3] «
QZ m2 = oS OTC - = Eo Ele fal oo. a Sw
S “ma 50 S278 [28 |e Ts er gx|5?” Bs nE |€a oO «ee .2 EsSsnigs = SL wn|d Cn A0 o.XL G2 |S
LV 3 =o FT aS » 0 ogo <Q “wo Olwo O © 0 wn Lr = 0 0 Oo £82125 8 SZzRNIS8FSE |EEREETSTIES [55 Le [Be
S o's SiASsa|6 § = 8 AE ®A|C Le 2 o th 5 [apg 2 53 Q CRS 0 ~~ [5] wn Soom 3 00lY ofa v 2.2 — =
Oo 2 sw o = HTe © Ze 5 cto ce lle Sse RE -] ay = c = bls 2g Sc E=e®PolS 818 225 Edlgs 1238 (22 |EE = 2 SIS ES ED QISTRIEEIIIE SE 23 S228 [2% |= nwa = 3 = 3 S fn oanl=g © = l= 3 F|23 9 = 3 =
LZ BD w|io3G 838 lege AN Do oe wlw 2 w|DZ[E EL c= Q « D = = vo 28 2 “ £ %|.S HET EIEEEYIBT|E ESS 28 52 [BF $ofl8cs | [csySeflasslec les anita iz oF (55% © & oe .- on {= = 2. a ~~ = es o© Fre) ° JT8 v oo
SSSIESE | 555 eelsEe|Es ies EEE Es E22 158 13:2 53 S58 wg EN EERE EEE HE HERE Fh SL [25% c 2 O [33 OQ oo 9 gE <|e MEE 0 = EE = < .2 Oo = L&E *n : 3.2 — 0 26 an = [= [77] os gs 3.328 PES acl ESE 33287 EL Eze “ERE 3585558 FaslhesconfFssfFos.acsaf as Seg sd - [Tab EE = = 5 Slo. A Is 8 ZTE. 3X
T3x|88 EY EE 1S EEN EN Ca I EE ERA EA — 9 X50 0d SEQSE SS ECR 3S 2 ola ElmOTI=D 5 A vd PEE a sXe aR C-= Qs 8 SB Ole nl 23 32 - 2 wo zx ~|% 3% - EX[([a eg a TSX gF/R ET 8S EIBST EB C08 xl®2s =| 2
SE. .0E%| [E58|w3 SETIVES CESSES Rc: [50S E® os SIE Sal C8 LHe == 8 = S Elz § Els olv 891 IE 0 IP = > E3508 Do FIZ5 R288" wx? 8l5 S32 E >0 REZ “=O - = - [33 = a5 = =o [S) er MER SEN PH VEE FEE BEE
Ole SS clo o NO SIE ole 28 Iw ole ® 5 13 ho] wv £2 ® 0 NEw Dr uo REZ Se 3 Fel3 slE gE THER EQIE EIS 8
Sls sF@ss— ERR CCIE RS EA SC CES CER CESS CCE £| ZR olf aio aS Z ESE MF O= 2 | : oli . i of gy ~~ 2 = ¥ | 1d ir) a. a = [ a) a = i fame << <|o bd
I= 3
Zz <2 1723
ITY ~~ ws EH] wn [%] a2 ~ hd < a ‘a . = o = 3 AS E 2 © o = = 2 — 2 = [=] © = 3 @ Qo > & ols ES € = < > £ » = BS |= = 3 =z tA £ - © >| & Q 0 =) [5 o.
S 2 SE 5 2 & y 3 2 < Ola, | 1 1 a] ~ =
E < NEE 3 8 S = 2 3 £ = pe z2lE =] 3 = ] =] 2 R=} a = <> 2 .2 a br z hel = gl Q - 7] [= © — eS — © > = = 35 = 2 3) 0
Qo. 0 =| = oo oh = = R= 9 [=] 3|E jt = 5 = Q w = = oO a
QO
2 oD = < os] < = pd 3 < 5d < |< Q ho 2 bs als 3 © - < |9 fo <Q [|W — = O|E 2 3 3 8 8 So 232 1&8
EA [oA nen = a 0 \n joo oo pad S = hed < —_ = — a = <x wo |S nn > r= I «© ed =A) o~ P= ~ —_ Nin © [r= VAY > fd on =x N=} — en x ® SEE EE KE BE EE EE IB = >¢ I= oo 0 a = a > x |x > > >
PCT/BOO/00973 . : o ~ [723 ‘ ton [3] fd
A 1% [23 QQ vy —
ES [8 2 EI > s e8 [3 EB S20 E & 8 & oa |e: E~ [g<s 8 8 s 2 - oo _. 2 84 Ex|® & vO 5 or A ou © = 8 = NE LS = @ EEN od - 3 ES ec ANES: =H c —-2 x = fo) “
Ie a 5 E 8 giles L|@E E wig |= R=] 2 ab $2 188 (88 ERLE ERR Sg 5a |5 £
Eo |B 82 [B5|2E8sES ged [eS Se 158 [8d 23 |g §%< ESE scl S S wD ES [gS 8 |°o8 - —— Sea o — - ng Phd pi .e 5: |§8 |g= cF8 Sess c2xi2: SF ES [Ef ES 5g [DE BE STEs&8 a3 838 4SR [8 33 [23 [2S 88 log a0 .E ry RCE pe E820 E 8 S [£38 EE
S55 [3% [3% 2352 BES Seda £8 = [£8 [88 > 5 <2 dq © 2sle33(8 Ra old 3 = =] SI gs
To |= = go -Al8 o SESE E or |o04 3. 3 co Q BD on > wSlea nls S3 2 983 3 = D0 Ws |e es 2.
O° c 3 vw |S ° Ale LT. 2.90 x 3 E 3 = = BD ws pa cq|3. 52 hs £8 5lgT ° £ pe, 0 So & oc © Ce o = SEX © RO 2 E 5°¢ £2 £5
ZZ 29 [29 =s|5sSks 8 S°oSlsf |B Sg [22 [38 -_ Nn = (7 Lo - oc Q - Vv nn br ed
Ho TREES ERA 52 (23 (33 5g 0 & SRE NIE s i gl8% SS |8§ 532 (832 = E EE EERE A - QO Ss 8 dic E © wn 13) = 5 Qc 2 =O Frogs le a3 328 2 aclsE ce = QQ QL 5 s 2 F22|32SIE EIT ESE EE = e=|8% S86 E56 22 |23 52 2522583" SHEE BEEP £3 |§% |8¢C S5 lr=1 Era © Q 3 25°:
Fa = =) Slo a b=} = ~.2 < ES = o
C= §eRIFC8zd=ES|55% we E15 2 £8 oO 2 o © 8 = a0 = HEISE ER EF bE £ o|C .E < ES = o E EINEEINEY EE IEEE ZS glued =) = eS [. = = snl sn Sls=w~[(8 82 s S29 = 5 Qo Ss“ EL _|2E£512E512¢(8 8" 2 82 S 2g Ss [ES = Ss
ZB ol 2 Re FE C®e|eE ng 2 = G Ts £Eaal EAL sQi22|s es oo © hs gle =glE 8 [I] wk “—
SEEN Ee EEE £5 |85 (£8
T=ZEadEE3L 21: a 5. og CT EsSSSiEeglEE = «0 o Q
SECs ESS ERE & "ERs SE LEiPsiEtgigEget
ERNE EE SLR SIEESEEREEEEES
— Rd l= Ra = Sle = . QD < wa eis Oo <A CO . . o<|g © 8 = a0 —_ 8 YD 0 DUE yw» D&E a og 23% & fe @ oO SlL.= 5 : £ 318 .=28F ein 0 DUE on DE = wn x 2 Jl BE ; Z E> ans oO PI] IE SE dd 2 DUE oS
LOI |>8 soulug|ES® 2 Uw CREED . > » Z|: = : ~8228 |g = 2|ESB|g8E SE EEE
SIF2552 852 §(58 ERE el SEs hE bl El ett EE HE Seiad sale Sls 52g RF eH HET 2S slid Ens Es 3 821g 82
I=} << |B oo 3 = S E(2 0 ao Ss 0 ~~ SRi=s=25 hm
Q | = = ~ al B= 3 png pf ay = §S8Es33EFEE 22S EClY ES 3a SEE 2n = th (0) 5B YEE HER EE - 2 & o ES EEE ER EEE EERE o~ ECE EXE dl2c digs yg
J - a. E [3] dig eg
Ty , © SIfESS EX ~ s 7S < oc Q — 2 c @ gE = a = 1) 5 EE -S < . < <4 3 ~~ 50 E. ’ = Sd © - = SZ <= 22 > zou |B .~ -—
QL 2 2 gy yd8 Q
Pi £ g SESE |g [V] “on o 3 E Zz 5 ad u > 3 a 382 4 = = 2 a v3 Ew |5
Zz 3 a < [2 SES IS ol r=] = Zz Q EE Q 2 —_ < r= 2 Zs5EeES [EB w oN = “ £ Q [oN
E s — |£ wt dE ols - Le boy [ S < 28S 3 = «= e © @ = = 5 6p 2 32 e - a : = E E £828 S8 @ 4 S = -
Q y on [=] < == Slo = [= bv} <3 2 8 - 2 |e SEEE%|5 @ cb E £ : © = - — 5 £ 2 |= 2 LE 258 =] £ «© ob =
A Q £ N= s wg 2 ES ] = £ o ed a 5 on £ > E=2 EIS £ 5 bm & - < o £323 [= = P= OQ L. oO ° |= 8282528 3} °© 5 8 5 < 22835 8s at E £ o Ss cs 0 = =] £ © [Ow < = g 8 E a. an = [=] a a
Eo) = a
O < w ce 2 2 < 8 (&% [3 = Ia) I=] 20 on wn \ oo < = © =I) ve Le] ES [- - 8 £ a |B aa 3 a © |2 20 60 = = 8 s aa) a = 1 o> 00 <Q AN 8 [pn “ny ~ 3 I2N wv ° ~~ «© 0 oN oN [«} ["g) -t > 00 <r fre — oO [=] © > > 0 0 O fo had wr ~~ xX [> 00 I % “a a) x I= > 0 A = o - “= >< = I= oc [2a > > [9 I=4 [=
4 ; S_2g
Kd 3 _—
FS =F 521 E 4 - 3 ~| nn - - - - > 9 “0
EN) 50 3 oe ab 20 tb ad 20 5 = =F N ~~ ’ £ £ SE = £ £ £ E 3 © ESI s&s = a [= Neg = [= Cc .- = a = a - <a |= 53 [E38 |5Cl5% |S 52 | |Ea ley |E TEs x
So RS) S ono D SO SQ SS SD SQ v5 NT 2T|= ~ — oO Lo SX a ~ — — = in CARIN T= = EE) Lo S S 5) = 2 ks) ks) Es =v |e wt |o
E 2 E = LAER EZ E = E = E 3 E 3 PE = 6 D|= Zen = 32 El oS —|3 3 Er Er 3 3 o = ww alle := = |5 & 82 |22 |Ex|2L [28 2% |28 {8% |8% |e |829eBI|z § 8 S “on |ES [ES RY KR] S 8 [5 gc 52% «3a = = ah ~~ = = =~ -— -— = 3 Oo = ta —_—1 = 5s |S |#218S |BS ES [BS |8S |Bs [23 |SERaZZ|mi 35 57 [EGE IBS ED BET BT 157 NE |BzzlEiziz s aD a0 or ERIE I BO GT 80 67 20 60 30 uT ab Gr 5s £s x 5g ES L 3 “= = 23 = *= =] he b= “= [ 52 3
Eo £5 © EB Eo EB E © Eo Eo g 32 5275.2 |= 0 2 E 2 E E BZ E 2 E 2 E 2 E Z E 2 E ge SIE E Ele E
Q » Qo »v S02 |u wn QU 9 u un Q © ov wv SE oe 21S g JF 3 = 3 = 3 038 3 3 = 3 a 3 = 3 3 i] 5 oils x C
Qn QD nn = RE ve QL QL wn Q on 9 A Qn = Cc Sao Ev
Qc QS = EQ|E = So oo Qo Qa = <Q = 0 = ET SE EE 0D Eo ENT] SL » Do LD Do 0D © DO =o c "RG SZ 3°
QD «a Q ©» S Plo a Q «a D «a ® » Q wv © wn SS cu Sg gE =
St |25 2858 |SE [58 |5E [SE [58 (25 [25g 5t|as = 8 5 £8 |28 1=s(cf [28 (28 [2% |28 lod |B [SESE Zj3E
N fo . [33
Se B® |U:jd= [C= I= [O° [O° [0° |v& [Bajo 28|EE 5 “lg B 5 5 5 5 5 |S5 |ss¥s82ESe
E& ES EZ|ES ES E& Ea Ea EZ lr go E85: < OX
I=] = [1 RC R=) = = = wi = £5 1B |EB|185 [85 |€5 (85 |86 [65 (Eo |SeglEEgasl a 5 Pr -] nn ale 8 an 5 v5 wn 5 wa no 5 © | 20S olas > 59 5 9 5 3s © 59 53 58 oO © 5 o ZS =o 208 3 En 0
La Low Lal a La Ya La Ya 2 a oRolcsg cl2EOE To
So ~|2vAi2E|8 uv Aju 82-808 v|EER|CSSolzx 233%
E =0[lE cE YE SDOEcCcDO|IEs0|EEOEEQ ESO ST|IES XE 0 2b 2n oS doc sac Elo SP |0on|5 fr|o S60 dro S(O 22NE 2 ols I=
Sa DE aE SIE aE pS aE ADE aE aE gy DO Wg § 2 ) [SURES | WS-< nd f D of [- DO< Rpn | D [ W [I [TIE Ep [Ba pe BE av a = [7] |= =| p= 3 WD ws [ad FRR 7 RN 7 [V JER PY = ZR) wn os ry i= E <= |[¢ 5 Ql = xa 2a 2a i Dal Pas Demos Dale En 33 a2 E22
ST SOF BO|d 5" SOc SOW EO|B SOW SSW BI SiS E0® © 4" Xd wo Eno Ena ENla EMfu SEM|o SEMfu EN EM AIC 8 No - TN
DRT SS =D C0 WD 8g Fd 8d @ =] BF fang oe S(Y 0 de Eo Se [= [3 Eo) ob . . —_ . EE -— iSite Oe Oe 8 |e Go © le og > o IN|. 8 [4 LS
SiolESalEEESg=ESgESaE SESE Sa ESE SER OBR ES coat 3alL Sls oalc3all Ens 2al 89,30 5 285 2,28 {of =| =I Aix Gd =| GG =| DQ —|£D—|¥ ST == ald ¢ =e EZ 2 £2) I EE IEE i eR EE Re sR A RE Er HEE = 5 gls ol= 5 olf oQ|EedIE Eel |E eds eds eds els elle Exlzs SEF ZTE
SE EE EIR RA ESS ENIR ESE ERR ESR Emma O89 E>2=
El =i [=F 1
P
1 i : Hl i =| g
E
3] 2 fd! £ = R=] © o> ES
J— + = > «2 — = I= S 2 p= - o~ < ~~ wy << wy — — — on Q jo] o ae} Ia tr Oo ~~ fe ww. tr = ao ‘Ss [7 [5 [2% [4 [2% [75 a on a 5 a 2 = po = |= po po — pol po 3 8 S = = = = = = | = [= o = 7) o o 5 o ° D Oo I] 2 = oe £ E E E E £ E £ £ < o o's &n ab ap ob ah ab 5D =) 8b = £ = gg |g IE £ ® 8 g 8 ce |S Eo = = [i=] = 3 = [= = = <& D a.
J — oe I" = — - — R= = »® a
Q [¥3 [%] [] L Q [%] [73 7 c © 0 5 - -— -— -— - -— - ~- P=3 -— [=] [<] o Qo Q © =] Q Q =] R= 2s
E E E = £ = = E E E 2 = =
I] S Io) S S S 1] I<) I) = =) 2 6p.
Te [9 13 Je Ty Sp pe. — Se 'y) [= a [-® [-¥ a, [ou [9 a. a. < ©) — =
Q
[7]
Ea g 4
S 2 =) — ol fon) < wn N=) ~ 00 [2] <t [= —_ = Nd 0 \O N= N= DO Oo v=1 — — = r~ sa) on [sa on «© [sa) [sa] [2a] [oa] vy Ua) 0 NS o o = o o = =] o =} Io) a) wv
I= = => > = = I= x I-28 f= = = I= = ~< =< >< = =< x > > >< 3 >< >
PCT/IB0O/00973 2 E [28 £ 5] 2 Lo g Q QL es . £ WE [90D 2 v2 © z SH" ec LU Nl oc 2 on S & 2 5 3} o o |@ I) I =e het 2 8 = 3 © ESBS 3 Nl = Ss = oc .2 3 2ESEql. 8 |84 [52 [ES | £ (58 359
E 8 ~ oc SlE8IaS fant £ oO Q ob Q SN O = >
Eco | [E2228RT (28 35 [55 | 8 12% | Bgliis
SSR S NR Ale oe | oo. 8g a a 2 ERs EY = 2 ve g RIB 3 3 2 3 2 E » 18 a S 388 oh = = Ss == Fa ™ .O E 2 E Loe 5 E gE = CL LERIZS [B83 c 3 Se e 22 Eg wlels £ oo RECS 2E CS I< SS es x _|§ £ TC tol Re ° ~~ a Qe 0 3 Ia _ 9 = 2 Es Fal [3 =id
TAS 22a 822 |2% (E& |°E Saxles [ZF 2lE SER o —_— — © = KY = = Eel N y 32 £52 | [552|8€[Ze (38 [82 TE E3228 B|RAB LET 2S“ a ec 258 glE 3 Sz |2~ - 5 |S E—=|SE ESI2S|gE 80 8 a §= YES 2 £: ES = 8 oO Snip © >alelt22no3 2 2 = |g 8 ha o cS 8 a boc l8|RE |(o = |e f= Z |5¢|22[282°8
S85 | [BES12R(2E [2F |: [Se |ETogE SEEL|8E2a
Oo = ft ~- lou 8 = o 2 Se 1 zx|E 8 = 3 8
QC £8 geile gle2 |e [£85 [EE Q 3 =>. EX|S Sie 85 8 x 0 ~[= IE = o Ss oO VL = S|o 2-210 e @ TS 0% = eg (BB 2 PEE 2 3S r § 2 £75 | |E5858ze [58 [58 [28 [3c3es SOE ER 2g 2 982 ,2E3 [08 oo [S82 [0585 = 23s g[e E48 723 <2 So |= = 8& 8 = ols = § SE 86S $= —~|2=, = om c =o S © SO = 252 weo|EE[CE [58 |s% [828 (2823 SSEIEEES = 738 ces E88 8 |SE =E fal- EB SIE: SEALE £3 E20|23|88 |22 (2% |g4 [FIs 8 RIG 2E > w= 280 els Q a E =] SR3lze23lgsl™s § 5 2s O 2 E = 8 SD .=DI3 goo Jie 5 o ~ [TIRE So < == wg = as Ol: — 34 © 23
FERS S28 EIT 82 18% SS [23X05 ®EelEC- gE £85 g=EZSS|%s [28 |2€ SESE eg cCIESIR [EET
Qo 2 w E 38 = a = = = wool SEF gle 2% ls & 3
Zc > 52/8300 |g 535 [EERE s5<[-s<[sal52|835L 3 o> = © Sila Rat OO £ oA 8 l=-2|9|iIg=|o 3 £58 | 2B 8Bs [58 Bi |Ba8icsfinblaildgaats = EE g|32[8s 3s 4 2 =l8 S| R92 §|2 5le a8 gS 5 Ee3Zegict |£2 Zz FL2zIEE= fob S|d Pee sy
S58 | SSS EBe Lagf3 RES: REEF E|n2 Ee
Oo s = 215 5 al=, ols 00 oo ewe 8RSEPEIEEES ale=1P TL EIR G1 REC RR g soles 8-83 8p ={S 8c %® - Leis df vlc Els E [PER EEE SL SREP Ese 50.8 285 : Bs 8 = Le = a. © ~ 2 =laG = 8 = | ££ 0 -
Qf | [588528858 SeEFed Eads ze Eee : 853 <S8l533|% Sia c8l08 = Sls Eels ESS Els Sls 55 E 2% S22 2528208 [g/d 3s E80 z ees
Pd . 5 ‘a - 8 = N ela < : 9 et A EE Pe EE RE SESS EZE[Fese ec > O a. Q | a 3 - > Qc > = ou © £ = gleg=l= N= oN wie = SK s|e 2 = o Q = 5 le =O [sN S S E|8 5 918 55 E28 = = S32 SS 2 Qe CS Ale Eno © cs ws|3SEES8zg3|es5[8 ES § = 2 Se = £ nN = fn v= olo= T= 7) S
Yr [= 8 . 2 © 8 bi [%) [t) =
TS 3 a c a 8 ~ 2 c= = v= o 2 oS S 3-2 £ hd =
Q o a ob) “ > - ‘0 — = < (=) o B= 2 - 2 = s © hed £ — 0 [7:9 » — — e Bb wo UO — > 17] = 2 bo g ° 2 2 = e g ls = 2 8 © ye ER: Ss |& |g
Sq o uv 8 5 £818 w ood S 4 a a = 22% 2 Z o (a) a 212 8
Ss dE |S c = bE Blg Ss |g |5
S 5x |— 2 7) = s 2 g5|E > 12 |e gE a = & 2 ES cle es [5 [8 [2
Seca o. [ 5 S 3 g
SEZ slr 3B BB BB 1Efgs EE fz IE |B
EER |2s 128 15 IF IEEE: FOE I is
Tm = oS =.= .2 = I
SZy (38 [Ele [5 [3 [2EElz EB OEE IF |5
Saag |8e 2 E —= pA Le Ss =|& = £ - =
Ea g £ = |E = Oc oS > |g 3 = |=l2 = = = ®-= OS 229 [81% S |5< |8 8 bo fE g ER = = = I=} vo @ 2 r4 = = = E S
TERE 2 18 (By [FEES 2 IE JE IB
ESE 28 E gv |5 EE 2288 g 5 8 Is : = ale hee} o a 2 = + e & v— etm bm > v £
Fe |S T =8 |= TX DD aT a RY a
N
<< «@ .~ 3 [a] > > o & 1 2 2 -~ £ =
ES) = } 5 i < E 5 Q Ss g £ = =] 2 > 2 = = E a a
I= ol [on I= © = © < “ © 2 BR EE FE B B EB EB EB ER © 0 |» os |e S = So a R EA & SIZ S [S S S = = = s 2 |=
SA > = =. > > => > [>
PCT/IBO0/60973 " ° oo = 5
S 2 = 3 3 Is 2 [Z |§ = ~|e ° a g : — [=3= 3 js El 2 = & pt 2 S bul E803 oa |B a |E 8 [2 [8
Leo [ne ww gT 92 8 is ge &
S| |HZ|E = san (2d = E z |& g
Wo! |= 2 E ~38Q [E | = EE - 5 : =I8 gn = ~ |E - 4 |S <2 Bale: moo [C= R ao — Ss |. E < 2 Sn 2 a3 °S ~~ E =~: UV oq : L > == Tole E a = py 3 = E ~ ES aly 2F| |S SBN (22 2 [RF 28 SEER [Pe anja E h-] —~ EN EE QL ZR 2 =I
E — o o 3 a 2 58 p S
B == & 2a sp ON Ca he 3 ES = ls EN 5% > ) 5% 2 23 2 = 0 oo 2 = ce [SR A 38 5 = Yo 8 22 = 8 = 52s 2: ~.8 = YS Sa <= QS = 60 c=
E male 2 J e - ~ = =o La 03 =e wn Ss 9 E=IN] 2 y % 8 ‘> h — ‘ag
Ss |EQ|Z>Z EE (j°o3< Sf [35 [Bs [33 2 2 3 ~~ oo ~~ OQ ~ oc = [4 = =
ER 2 |< EE <2 8 < = QS ou [EE = OQ 23 3 2RZEL (283 $8 =% 5% ig IEE |52
EQ leds |85°% © s@ 55 lew 5c [28 323 SEES [298 (53 |8- |B n= 5 o cS ee nll 8b i= e.2 272 8 & 5 3 Q O = vo =] QOL 5S |[eg[»8 |8% 22) 15% BE 58 22 [&&
QO © = LE 3 oS eT HENS 3 = 1% = JE &% 8g] 8232 Bg. [E353 £3 125 |fE [8 [2 - = 5
V ( REIS FD © = 2S 2.2 ° 2.2 5 £5 c < op on LV ~U 5 ss Qo» 8 2 Qn o £5
S| |E Pd aol os 8S |25 (8s |@8& £ =. EP¥ceRE2E |v [£3 c 8 [8 ga aE
Sa vat ov v= oc ES bd © 2 © s 3 Ee 3 Lalo v= 5 = ov 2 ~|9 cS == o £ 2/3 = ca As gE o [€=) = = a. 5 al |x eel REN a3 EERE S = 2 ©
FA = Sg Sols 3c a2 25 EER o £o~ cL ow Sloe 3Alg 5 2 al] = gc|s 8 55 5 52 |28|25SR|gge (24 Bs wESlsd [52 [58 = © > hjw = 515 2 8 & Sle sg 2s 5
Sa Seln=cgBEZ <F [2% [FEST E& 52
SH Eolcz2B<es LX) BE i2g2f BZ 5% sg fSfLswAl80 [2 ES ESSE 53gl8 3g
El els 2 ®N=Sy 38 RY REciER 2sglz
SE sstsES5EE 2 52 [FEE C5 SIE a
R=} Ia = < E Z 55 23 ER . 3B p= Q 5 os E=|g E © Tle ¥ 2 Belg ¥OEIK ED |g 2 |g Egle ET 3 = vs E == 5 8 ao |< & = ule 2 SOx g an — 5g e HE EE EC Sali eR i . a cS3|ge> (fe HSER TSH Boi LR E >. 2d gE o|lESS |EE LEQ SO: EQ faze y= sci§S8=E5isL2ae|Es ge 2 i 5 (SSIS 2ATE
SE IE m5EE SES oR|ES JoeZi§2o: [F825 5528
HEE SE2Ep8EEEe|ae SSIS TUS SSE BYE 2
Sg Ed Se dla == = Bo Alo E 5s R Sls 5 z= Elo Sead p= 9 RA SERA GER 2 SSE] Chom Ho = RUS g 2 - 88
I<] . = ; 5 2 i = Ex x ig 8 3 E EE 7] H ao g oc 3 r= ol 2 I+ 2 2 E ££ a |S = pA = 3 ] © E 52 83 £ [Tae [Sa = Slo |S ¥ S$ ¥ =
LHS yg < Se 3c = |= rey SS = is sa (3 = 3 5 = 2 _ Z| 5 Eg S = 5 a =e So = E e To = = S = 53 = 2
[7] Ile = = I E a ; 2 8 © SE Le 2 a.2 §3
S 2S € E = IY 2 [= ES QQ = z 3 €s Ss 4 Sl = Do ° c QL = i=] bd oe =r < ale £5 Q o = £ gl == < |[z=|o 2 S s § gE |§51F £23 8's c = 8 8 |: 5-2 2 oigle B= 58 > 18s £5 |B 2g = 25 - > 5 = 2lg 8 & 2 $ .£ o|lg |= 8 Bo 2 =~ E oY |® 3 EE
E ISIE 2.28 go = S|.o 2 hi 3 53
EEE 22 BE [5 IEF zis |B 2 s S [Ef S ° EXE a La 5 Ze mo 3 22> v 2l< s £ 8% a oa oo Bl 3 = 2 = |B sScl@ £3 < a 0 © = 61177} S 8 5 = v3
[77] QO als ~~ 23 < a k* c
Eg o = [VI 5S £3
[22] < = < <7 2 k= Zz x [B zo < zi < Q ca z2
Tel BF REE 5 FE 5° = | 2 8 = = °F E E 2 - ~ ln ad o wn © = .2 = 2 —
Q
2 > a gg — |e |= = a ~ - Lv .2
SN 212 = o 2 ™ | [2 oe ER 8 BRE IB 3 2 RE OE & B [5%
SEER OR REE FB BE FB Fs:
N N N N +s
TABLE 3: Corynebacterium and Brevibacterium Strains Which May be Used in the Practice of the Invention
Brevbacteriom _Jammoniagenes | 20054 [ [| | [
Brevbacterium Jammaniagenes | 1930 |_| |] [
Brevbacteriom _Jammonagenes | 19351 | [| | [
Brovibacterium [ammoniagenes | 1932 | | [
Brevbacierium Jammontagenes | 1935 | | [
BrevbacieriomJammoniagenes | T0359 |] [
Brevibacieriom [ammoniagenes | 19355 |] [
Brevbacierium [smmoniagenes | 19356 [| [| 1
Brevibacterium Jammoniagenes | 21055 | [
Brevibaciertum [ammoniagenes | 21077 | | [
Brevibacterium Jammoniagencs | 2153 | | [| [1
Brevibacierium _[ammoniagenes | 21580 | | [
Brevibactertum Jammoniagenes | 39101 [|| | [
Brevibasierium [butanicom | 219% | | [| [
Brevibacterium [Givaricatun | 21792 [P| | | [|]
Breviacieriom_[favom | 7 | | | TT
Brevbacteriom Jfaem | 21 | | [
Brevibacteriom [Ravam [B® |] | [
Brevivacterum [lawam |_| [ena]
Breviacterum [loam || [Bm
Brevibacieriom_[favem [2027 || | [
Brevbacteriom Raven [2028
Brevibacterim [Maven | 21 | | | [|]
Brevibacterion _[favam [ows || {
Brevbacterion [Ravan | 25507 | | | [
Brevibacieriom __[favem | 21% ||| [
Brevbacterum [Maven [255 |] | TT | _]
Brevibacterom [Maven [| Jew] | [
Brevibacterum [favom || [Bum] | [
Brevibacierom [fam | 2127 || | [
Brevibacterom Jaam || [BE]
Brevibacterium [heal | Te [ [
Brevibacterium _[ketoglumeun | 2100 | | [
Brevibacteriom [ketoglutamicam | 2109 | [|| | [
Brevibacteriom [kewsoreducm | 21918 | [| [
Brovibacteriom Jlactofemertum |] [0 | |]
Brevacterion_[lactofermenm || [A [
Brevibacteriom _Jlacofermentom || | [77 | | | |]
Brevibactertum [laciofermentum | 21798 || [| [
Brevibacterium actofermentum | 20799 1 [
Brevibacteriom laciofermentum | 2180 | ||| | | |]
Brevibacterium _[laciofermentom | 21801
Brevibacterium Jlaciofermentom [| [BAW] | | 1]
Brevibacteriom _[laciofermentum || [BUA] | [| |]
S71 -
Brevibacterium __ lactofermentum | 21086 | | [ [ [TT]
Srevbactriin Jcatemmenum| 2100 ||]
Brevibacterium _ flactofermentum | 21086 | | © [ | [
Brevibacterium _lactofermentum | 31269 | [0 1 | AT]
EL ZS I I ES NO
SrevbacierumJimers [Tos] — TTT —
Ts te Ss ms .11 0 BS
Bracerm pee TT TT oar retro ——— | a [Brevibacterium spec. [ 1404 | | 0] | | [ revamps me |]
Beever pee ower [
Brevibacterum [spec | 21865 T | 0 [ 0} [
Brevibacterivm _ Jspec. ~~ J 2186 | ff 2 | [
Brevibacterium spec. [ 240 |} 0 | 0 0 | =]
Corynebacterium _[acetoacidophium | 21476 | | [| [| J [ [Corynebacterium _[acctoacidophium | 13870 [ | [| | ~~} ~~ { [
Cory ebacerum ~|acefogtanmioam —| | [BIAS]
Commebasterum Jacetoghatamizam || [Btw] |||] [Corynebacterium _[acetoglutamicum | 15806 | | ~~ [ [ |] | 1
Corynebacterium _Jacetoglutamieum | 21491 | | [ [ | [| [ [Corynebacterium _[acetoglutamicum | 31270 | | | [
Commebaceram Jsceophtan |e |]
Corynebacterium Jummontagenes e877 || ||| [mo
Corynebacterium _{ammoniagenes | 15511 | | | [ F } |] [Corynebacterium _[fujiokense | 214% | | | [~~ [ | [
Corynebacterium [glutamicum [ 14067 | [| [
Corynebacterium [glutamicum | 39137 | | 1 | [| [
Corynebacterium [glutamicum | 21254 | | [TF
Corynebacterium [glutamicum | 21255 | | | 1 [ | |]
Corynebacterium fglwamicom | 31830 [| "1 ©
Corynebacterium glutamicum |" 13032 | | | I [
Corynebacterium glutamicum | 14305
Corynebacterium _Jghwamicum |” 15455 | 1 1 1 F
Corynebadiertngosmien | 1088 || {| [|]
Corynebacterium [ghtamiesm | T3089 1 [Corynebacterium _|ghutamicum | 13060 | | [| I [1
Comebacirtim|ghtamieam | 2vasz | [ [Corynebacterium [glutamicum | 2053 | | 1 1 1
Corynebacterium {glutamicum | 21526 | | | [FT [
Corynebacterium Jghamiaim si _[ [
Corynebacterium [glutamicum | 13287 | | | [1
Comebacertun |giuamioom 21851
Corynebacterium Jghamiom 27 | | [1
Corynebacterium |ghtamioan | 21518
Corynebacterium ghia | 2151611 | 1
Gorynebacertm[ghwamicor | 2199
Conebactriun Jgwamiesm 7300 |] 1 | 1
Corynebacterium Jghtamicun | 9968 | [| | [TT
Corynebacterium _[ghwamicam | vss | | | {
Corynebacteriom glotamicum | 216
Corebacterium Jgltamicun | 2160 | [| [
Corynebacterium [glutamioun | 1923 | [| | [
Corynebacterium _[ghwamican | 189 | | | | 1
Corynebacterium [ghwamioan | 207 ||| 1 | 1
Corynebacterfam [ghvtamicum | 21158 | [
Corynebacterium [ghwamicun | 211%
Corynebacterium [glutamicum | 21355 | | [| [
Corynebacterium [ghwamicun | 31808 | [
Corynebacterium [glutamicon | 2067 | | | [
Corynebacterium [glutamicum | 21562 | | [
Corynebastertum _glotamicum | 21563
Corynebacterium [gvtamicun | 21568 | [| [
Corynebacterium [glutamicum | 2056s | || [
Corynebacterium [glutamican [21566 | [|| 1 [
Corynebacterium Jglutamican | 21567 | [| | [
Corymebacterfum glvtamicum | 21568 | [|| [
Corynebacterium Jglutamicam | 21560
Corynebacterium [glstamicum | 21570 | [| 1
Corynebacterium [glutamicum | 21571 | [
Corynebacterium glvtamicam | 21572 || [| | |]
Corynebacterium Jgluamicon | 215% |] |]
Corynebacterium gloamicum | 217% | | [
Corynebacterium [glutamicum | 1908 | | [
Corynebacterium [glvtamicum | 19050 | | | | | | |]
Corynebacterium [glutamicum | 19051 [| | [| |]
Corynebactertum elwtamicum | 19052 | [| [| [
Corynebacterium [glvtamicum | 19053 | | [| | 1
Corynebacterium [glutamicom | 19054 || | | [
Corynebacterium Jglutamicum | 19055 1 | || |]
Corynebacterium [glvtamicam | 19086
Corynebactertum _[glwtamicum | 19057
Corynebacterium [glutamicum | 19058 || [| [
Corynebacterium glutamicum | 19059
Corynebacterium [glutamicum | 19060 | [| | [
Corynebacterium _glotamicum | 19185
Corynebacterium Jglutamioam | 13286 | [
Corynebacterium glutamicom [21515 | [| [1 |]
Corynebacterium [ghuamicum | 21527 | || [
Corynebacterium glutamicam | 2158 || | [
Corynebacterium _|ghutamicum | 22
Cormebacteriom Jghutamicom || [B8WI[
Corynebacterium lglutamicam | | [B82
Corynebacterium [ghtamioum || [Bal]
Corynebastertum [ghwtamioom [JB] [
Conebactertum [ghtamioam || [Bmalg] {
Conebacterium [glutamic || [BtW6] |]
mew | [| [1
Connebacterun [lon | [Pm
Corynebacterium _|nilophilis CALTEIN IN I NO NLLEC I
Conmebacteriom spec. | __ [pass]
Corynebacterium spec. | ___ [Pads]
Cormebacteriom [spec 3088 [| | | 1 so |_| | [|] si | | ||]
Corynebacterium [spec 31090 [| | | | [
Corynebacterium [spec | 3100 || | | | ||]
Conmebscterium [spee. | Tosa | [|| | [ms
ALLA I I A I NE SA SN
Corynebacterium spec. | ame |__| | | |] |]
Conmebacterium spe | 28e |] | | | | |]
ATCC: American Type Culture Collection, Rockville, MD, USA
FERM: Fermentation Research Institute, Chiba, Japan
NRRL: ARS Culture Collection, Northern Regional Research Laboratory, Peoria, IL, USA
CECT: Coleccion Espanola de Cultivos Tipo, Valencia, Spain
NCIMB: National Collection of Industrial and Marine Bacteria Ltd., Aberdeen, UK
CBS: Centraalbureau voor Schimmelculiures, Baam, NL
NCTC: National Collection of Type Cultures, London, UK
DSMZ: Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany
For reference see Sugawara, H. et al. (1993) World directory of collections of cultures of microorganisms: Bacteria, fungi and yeasts @r edn), World federation for culture collections world data center on microorganisms, Saimata, Japen.
WO
© 5g 2 74 P ol» - -
HE [+4 02 x CT/1B00/0 9) oR oo 2 0973 33 LH on [=] S © D> © = Ww o [2d ~ * & 23 = pod
RY L 2 o & © © 5) r~ E) b= - ~~ < 7} 4 © 4 2 © a bry < a XX
El % © © Ss & <P : 498 8g 5 © 9 a o A
RY [gd 58 ~ [72] 3 w 5 © z S ©g 85 ¢ 2 3 5 3 2 2 55 z 88 #9 g 8 SJE 5 3 3 033 g 08 8s 3 5 8 FA ? $58 % 3 @ ee © ~ g = 2 & 2 Ee 3 2 ~ 3 58 TS % 5 : 3337 2 2
OO [7d EY 7 - oo 4 coal w Q be 8 oo I 9 3) < “uw S 7] 0 ES £2 7 © I) gq °c 9 E 23 22 5 hs © hR ® 3 fa] e © B® [4] on 3g p< < r~ [=] << 8s €< 22 g 5 w 2 59 hs © oO © 5s ao @ w 2 3 = = [4] hed 8338 =) » = 28 33 a 8 9 3] os 2 2 NON °° Q 5 $8 5 a s 2 =) g 8 = 559 zs = @ I] ge a a c © o > ® 9 ag a ~ 2 oo EE 2 2 o 2 [4 I £2 = a g 2 £2 E 2 2 E Ea § = a I [=] » » c > oS 02 S 2 £ x w= n E 2 © gS a 5] a ss 8 2 g o nw 3 5 05 = 8 20 oc 5 5 — 9 Ex [1] o © 3 re i E [4 e832 5 2 os 2 2 8 (7) s o E 9 a 3232 g 3 s g & 2 ow 2 E - ° Z Ep Se 3 = EA 5 ° n a ® = S - a I) Ss -— 3 Y a - wn gcc 2 ‘= : a a] on 0 q © I} £ 2 ESE ed 3 - Zz ~ © £ © 2 8 oc =} = o © © BE ° Ww o~ L 2 € I [3] eg 2g 838 7) > 3S SE ec © Eo cw 2 [v4 HHMI a + E c ~ £ 20 £25 sole w (a) - O @ © ow 2 © = zo § E2258 @ o 3 w NC oO sg £ S 3 o < S5% 8 £ al 3 225 py Tz 2 58383 © w ~ c nw © £ © = —_ o~ 4 8383 = 5 : Eo Ss ¢ ~< 3 S Q ~ 22 ® [a] * 2832
Zz =] oN a £2 4 ° c £508 £ [3] 3 ©
Ww 2 £8 238 2a JEE ? 3 £882 E a 2 = 2 SFE ov @ , E 2 E 4 SEs 2 a 2 4 B428883 Loa ° » ace Ez 2
Zz s sEfzeiss £24 = I) 882% so % g (G} o 0igiisy 233 Pi] € Fy 5 58K oO
Ul = g Hite SO 2 Ki} S s32r 83a 3 § So az 4 SEPT . 3 25 Es cg8 § ;
PrdR- [2] Hii oS o 2882 o*g < £ . € « SHEE Sg83 80 © > ST ® eg e S
Ld [3 22855 ¢ Eg WE S38 -— 2< Tr ns? g S «| © 3 EEE8R SE Ewids Lod Q 82 yg 2 © 0 6 a a
S 2 88a 3 sizizizis a ages ealcts ° wl © EE E 5957 SEEaf 2 0 gS 2 oI 2g SEELEY: <a 9 o I 2 E832 E . Ss ls BS2E) HHH o £egol 58:5 = ol o 5223 » O FHI — 82S $idgsgas 4
SHIT ob = ga i” £8358 t,o BERRY ge «| E HEH I<} 4 59 2 p53 NE 5 c soft wae 2 $3s535% = gga 5% £ ~ s 3 Hiei 13 59 > 9613 sO %® 2 BRE £c °
Z = ee sv 8 VI & 183383 3 a >> SOEEZ E g 2.558 08 IEEE © 2522 Sp EEE33 E a 3888 HEHE HRIHH El 2 5 Hint g HITE 2 — reg sepdlel E Epc Eg ELSES £Es ° © .
I" Te) ht 5 HELHIE E c a ~ T0532 a5 = Po 352335 ss End 8 hd = S ~ $s2822 > EEEESTE sad 8 5) [ 8 2 f2EzizEB o B23 af 55895 = 2 g oS 5 28 2Q 255858 oes sechzh ce 8 2 < S 88 38 5 Esk i] HH HEE 3: 38 8s oF © =» o HLH 5 < Oo S 3 4 = §224gs oS ~ © E £ = S85 © o QQ HE Q 3 8 a] at jy o oo HEH = e c < [a] S S $< ~~ Hua 2] FH
S < s S 2 < SHH ° 3 [] - 2 [= ~ Q o 3a © ~ w so 3 EEE] g ~ © oy < a [= 3 [22] £5gzt 2
S 33 2 < @ - o 3385 > » andl 24 © < J © 5 © Q 177) @ $ ha <3 o~ < 3 2 8 I) ~5 5 B 0 © 3 5 D 2 ~ ~ 3 + © © a x ~ = 8 Rr g Tr = s s £ ha} 3X £ : 58 22 & : EE: ° = 3? % $888 § = oO 38 af hd] 3 < ~ o © << 2883 2 © g 29 28 3 fa a ° SSF 14 [oS 2 : eB 8% ¢ g 8 5 3 B XO § 3 zk eB s EB ? 8 8 33
O [} “«< T 2a 0 < =) < rs ~ oO © ~ [¢7) } ca [72] © P= Py — > _ < EES £ o o © 0 id 2 8 8 pe z 9 seo Q 5 00 @'o ° 5S 8 gs @ 2 08 < EN Q & ° 38 9 a 9 9 a 3 S I 8 8 8 INN
IE - oN Oo , = 6 = Oo e Rr fa) r~ [+] x «© < © ~ le} ” © i : 2 3 5&8 = 23 2) ~ & 8 > = < I < 20885 2 x 3 8 bo ca 3 Ex3 3 a «© = oO [od] | < «- ou 5g¢gg ad
S 3 N 3 8 Ss & [> £SSQ gS
S 3 © g @ ad © = 2 bo] < oO py @ BEC EZ & 5 - o «© < © a S oS o | rxx D Ww [] [*.] ~ [CG] [a2] o £3 -— ha 3 ad S (OU oa h-4 < o - ® 833 ,& x 8 g 3 3 & S ” @ Q m = < © Q n + ~ & o o 3 8 3 [3 © 3 o a sg [= [3]
~75- fe) @ . « © 3 Los 3 0 3
Zz 0 5 = oo
N Oo 9 N o
SS nn ©
SS ww vw [=3 o w g 8 a 2 E28
Q 22 0c
TEggt 3S © 00 COE oes 8 [T= cEL2@ co >8>02>E 023 2T GE
Co Bf0w 4) = o _ o = ©]
Ss 3 2 3 n a » © - 2 ud I) 2 un
HEEERR
Sjs25ed cS S208 gp . = 8 EE£ao - Sago cl50a§3
Qs§<8°®
Olcz%o ag E © c
EEZ2&Z 3S. 28
Lesage
RHELELCS
© 2so 8k 2 o
ETERS
© ®
Sess
E2325 w
TS58T3
TEI Ew 0 ©9Vo al
OE Oc on caf acy
C8abCTE
Oeo 80 8 2 82 & [3 © 3 8 2
J IJ < 8 3 3
Te} — 2
N oN 5 3 = = —_ 2 o eg 3 3 [o] id w 0 @o < z < o, © © [ie] m m [U] [&] [V] ~ ~ ~ © p: § . by
Exemplification
Example 1: Preparation of total genomic DNA of Corynebacterium glutamicum
ATCC 13032
A culture of Corynebacterium glutamicum (ATCC 13032) was grown overnight at 30°C with vigorous shaking in BHI medium (Difco). The cells were harvested by centrifugation, the supernatant was discarded and the cells were resuspended in 5 ml buffer-I (5% of the original volume of the culture — all indicated volumes have been calculated for 100 ml of culture volume). Composition of buffer-I: 140.34 g/l sucrose, 2.46 g/l MgSO, x 7H,0, 10 m/l KH,PO, solution (100 g/l, adjusted to pH 6.7 with
KOH), 50 mV/1 M12 concentrate (10 g/l (NH.),SO,, 1 g/l NaCl, 2 g/l MgSO, x TH,0, 0.2 g/l CaCl,, 0.5 g/1 yeast extract (Difco), 10 ml/l trace-elements-mix (200 mg/l FeSO, : x H,0, 10 mg/l ZnSO, x 7 H,0, 3 mg/l MnCl, x 4 H,0, 30 mg/l H;BO, 20 mg/l CoCl, x 6 H,0, 1 mg/l NiCl, x 6 H,0, 3 mg/l Na,MoO, x 2 H,0, 500 mg/l complexing agent (EDTA or critic acid), 100 ml/l vitamins-mix (0.2 mg/! biotin, 0.2 mg/l folic acid, 20 mg/l p-amino benzoic acid, 20 mg/l riboflavin, 40 mg/l ca-panthothenate, 140 mg/l} nicotinic acid, 40 mg/l pyridoxole hydrochloride, 200 mg/l myo-inositol). Lysozyme was added to the suspension to a final concentration of 2.5 mg/ml. After an approximately 4 h incubation at 37°C, the cell wall was degraded and the resulting protoplasts are harvested by centrifugation. The pellet was washed once with S ml buffer-I and once with 5 ml TE-buffer (10 mM Tris-HCI, 1 mM EDTA, pH 8). The pellet was resuspended in 4 ml TE-buffer and 0.5 ml SDS solution (10%) and 0.5 ml
NaCl solution (5 M) are added. After adding of proteinase K to a final concentration of 200 pg/ml, the suspension is incubated for ca.18 h at 37°C. The DNA was purified by extraction with phenol, phenol-chloroform-isoamylalcohol and chloroform- isoamylalcohol using standard procedures. Then, the DNA was precipitated by adding 1/50 volume of 3 M sodium acetate and 2 volumes of ethanol, followed by a 30 min incubation at -20°C and a 30 min centrifugation at 12,000 rpm in a high speed centrifuge using a SS34 rotor (Sorvall). The DNA was dissolved in 1 ml TE-buffer containing 20 ug/ml RNaseA and dialysed at 4°C against 1000 ml TE-buffer for at least 3 hours.
During this time, the buffer was exchanged 3 times. To aliquots of 0.4 ml of the dialysed DNA solution, 0.4 ml of 2 M LiCl and 0.8 mi of ethanol are added. After a 30
AMENDED SHEET
® BGI-122CPPC min incubation at -20°C, the DNA was collected by centrifugation (13,000 rpm, Biofuge
Fresco, Heraeus, Hanau, Germany). The DNA pellet was dissolved in TE-buffer. DNA prepared by this procedure could be used for all purposes, including southern blotting or construction of genomic libraries.
Example 2: Construction of genomic libraries in Escherichia coli of Corynebacterium glutamicum ATCC13032.
Using DNA prepared as described in Example 1, cosmid and plasmid libraries were constructed according to known and well established methods (see e.g., Sambrook, J. et al. (1989) “Molecular Cloning : A Laboratory Manual”, Cold Spring Harbor Laboratory Press, or Ausubel, F.M. et al. (1994) “Current Protocols in Molecular Biology”, John Wiley &
Sons.)
Any plasmid or cosmid could be used. Of particular use were the plasmids pBR322 (Sutcliffe, J.G. (1979) Proc. Natl. Acad. Sci. USA, 75:3737-3741); pACYC177 (Change &
Cohen (1978) J. Bacteriol 134:1141-1156), plasmids of the pBS series (pBSSK+, pBSSK- and others; Stratagene, LaJolla, USA), or cosmids as SuperCos] (Stratagene, LaJolla, USA) or
Lorist6 (Gibson, T.J., Rosenthal A. and Waterson, R.H. (1987) Gene 53:283-286. Gene libraries specifically for use in C. glutamicum may be constructed using plasmid pSL109 (Lee, H.-S. and
A. J. Sinskey (1994) J. Microbiol. Biotechnol. 4: 256-263).
Example 3: DNA Sequencing and Computational Functional Analysis
Genomic libraries as described in Example 2 were used for DNA sequencing according to standard methods, in particular by the chain termination method using
ABI377 sequencing machines (see e.g., Fleischman, R.D. er al. (1995) “Whole-genome
Random Sequencing and Assembly of Haemophilus Influenzae Rd., Science, 269:496- 512). Sequencing primers with the following nucleotide sequences were used: 5°-
GGAAACAGTATGACCATG-3' (SEQ ID NO:35) or 5-GTAAAACGACGGCCAGT-3' (SEQ
ID NO:36).
Example 4: In vivo Mutagenesis
In vivo mutagenesis of Corynebacterium glutamicum can be performed by passage of plasmid (or other vector) DNA through E. coli or other microorganisms (e.g Bacillus spp. or yeasts such as Saccharomyces cerevisiae) which are impaired in their capabilities to maintain
: B -78.- the integrity of their genetic information. Typical mutator strains have mutations in the genes ) for the DNA repair system (e.g., mutHLS, mutD, mutT, etc.; for reference, see Rupp, W.D. (1996) DNA repair mechanisms, in: Escherichia coli and Salmonella, p. 2277-2294, ASM:
Washington.) Such strains are well known to one of ordinary skill in the art. The use of such strains is illustrated, for example, in Greener, A. and Callahan, M. (1994) Strategies 7: 32-34.
Example 5: DNA Transfer Between Escherichia coli and Corynebacterium glutamicum
Several Corynebacterium and Brevibacterium species contain endogenous plasmids (as e.g., pHM1519 or pBL1) which replicate autonomously (for review see, e.g.,
Martin, J.F. et al. (1987) Biotechnology, 5:137-146). Shuttle vectors for Escherichia coli and Corynebacterium glutamicum can be readily constructed by using standard vectors for : E. coli (Sambrook, J. et al. (1989), “Molecular Cloning: A Laboratory Manual”, Cold
Spring Harbor Laboratory Press or Ausubel, F.M. ef al. (1994) “Current Protocols in i 15 Molecular Biology”, John Wiley & Sons) to which a origin or replication for and a suitable marker from Corynebacterium glutamicum is added. Such origins of replication are preferably taken from endogenous plasmids isolated from Corynebacterium and
Brevibacterium species. Of particular use as transformation markers for these species are genes for kanamycin resistance (such as those derived from the TnS or Tn903 transposons) or chloramphenicol (Winnacker, E.L. (1987) “From Genes to Clones —
Introduction to Gene Technology, VCH, Weinheim). There are numerous examples in the literature of the construction of a wide variety of shuttle vectors which replicate in both E. coli and C. glutamicum, and which can be used for several purposes, including gene over- expression (for reference, see e.g., Yoshihama, M. et al. (1985) J. Bacteriol. 162:591-597,
Martin LF. et al. (1987) Biotechnology, 5:137-146 and Eikmanns, B.J. et al. (1991) Gene, 102:93-98).
Using standard methods, it is possible to clone a gene of interest into one of the shuttle vectors described above and to introduce such a hybrid vectors into strains of
Corynebacterium glutamicum. Transformation of C. glutamicum can be achieved by protoplast transformation (Kastsumata, R. et al. (1984) J. Bacteriol. 159306-311), electroporation (Liebl, E. et al. (1989) FEMS Microbiol. Letters, 53:399-303) and in cases where special vectors are used, also by conjugation (as described e.g. in Schifer, A et al.
(1990) J. Bacteriol. 172:1663-1666). It is also possible to transfer the shuttle vectors for
C. glutamicum to E. coli by preparing plasmid DNA from C. glutamicum (using standard : methods well-known in the art) and transforming itinto E. coli. This transformation step can be performed using standard methods, but it is advantageous to use an Mcr-deficient
E.coli strain, such as NM522 (Gough & Murray (1983) J. Mol. Biol. 166:1-19).
Genes may be overexpressed in C. glutamicum strains using plasmids which comprise pCG1 (U.S. Patent No. 4,617,267) or fragments thereof, and optionally the gene for kanamycin resistance from TN903 (Grindley, N.D. and Joyce, C.M. (1980)
Proc. Natl. Acad. Sci. USA 77(12): 7176-7180). In addition, genes may be overexpressed in C. glutamicum strains using plasmid pSL109 (Lee, H.-S. and A. J.
Sinskey (1994) J Microbiol. Biotechnol. 4: 256-263).
Aside from the use of replicative plasmids, gene overexpression can also be achieved by integration into the genome. Genomic integration in C. glutamicum or other
Corynebacterium or Brevibacterium species may be accomplished by well-known methods, such as homologous recombination with genomic region(s), restriction endonuclease mediated integration (REMI) (see, e.g., DE Patent 19823834), or through the use of transposons. It is also possible to modulate the activity of a gene of interest by modifying the regulatory regions (e.g., a promoter, a repressor, and/or an enhancer) by sequence modification, insertion, or deletion using site-directed methods (such as homologous recombination) or methods based on random events (such as transposon mutagenesis or REMI). Nucleic acid sequences which function as transcriptional terminators may also be inserted 3’ to the coding region of one or more genes of the invention; such terminators are well-known in the art and are described, for example, in
Winnacker, E.L. (1987) From Genes to Clones ~ Introduction to Gene Technology. VCH:
Weinheim.
Example 6: Assessment of the Expression of the Mutant Protein
Observations of the activity of a mutated protein in a transformed host cell rely on the fact that the mutant protein is expressed in a similar fashion and in a similar quantity to that of the wild-type protein. A useful method to ascertain the level of transcription of the mutant gene (an indicator of the amount of mRNA available for translation to the gene product) is to perform a Northern blot (for reference see, for example, Ausubel er al.
(1988) Current Protocols in Molecular Biology, Wiley: New York), in which a primer ’ designed to bind to the gene of interest is labeled with a detectable tag (usually radioactive or chemiluminescent), such that when the total RNA of a culture of the organism is extracted, run on gel, transferred to a stable matrix and incubated with this probe, the binding and quantity of binding of the probe indicates the presence and also the quantity of mRNA for this gene. This information is evidence of the degree of transcription of the mutant gene. Total cellular RNA can be prepared from Corynebacterium glutamicum by several methods, all well-known in the art, such as that described in Bormann, E.R. ef al. (1992) Mol. Microbiol. 6: 317-326.
To assess the presence or relative quantity of protein translated from this mRNA, standard techniques, such as a Western blot, may be employed (see, for example, Ausubel et al. (1988) Current Protocols in Molecular Biology, Wiley: New York). In this process, : total cellular proteins are extracted, separated by gel electrophoresis, transferred to a matrix such as nitrocellulose, and incubated with a probe, such as an antibody, which : i 15 specifically binds to the desired protein. This probe is generally tagged with a chemiluminescent or colorimetric label which may be readily detected. The presence and quantity of label observed indicates the presence and quantity of the desired mutant protein present in the cell.
Example 7: Growth of Genetically Modified Corynebacterium glutamicum — Media a and Culture Conditions
Genetically modified Corynebacteria are cultured in synthetic or natural growth media. A number of different growth media for Corynebacteria are both well-known and readily available (Licb ef al. (1989) Appl. Microbiol. Biotechnol., 32:205-210; von der
Osten et al. (1998) Biotechnology Letters, 11:11-16; Patent DE 4,120,867; Liebl (1992) “The Genus Corynebacterium, in: The Procaryotes, Volume II, Balows, A. ef al., eds.
Springer-Verlag). These media consist of one or more carbon sources, nitrogen sources, inorganic salts, vitamins and trace elements. Preferred carbon sources are sugars, such as mono-, di-, or polysaccharides. For example, glucose, fructose, mannose, galactose, ribose, sorbose, nnbulose, lactose, maltose, sucrose, raffinose, starch or cellulose serve as very good carbon sources. It is also possible to supply sugar to the media via complex compounds such as molasses or other by-products from sugar refinement. It can also be advantageous to supply mixtures of different carbon sources. Other possible carbon sources are alcohols and organic acids, such as methanol, ethanol, acetic acid or lactic : acid. Nitrogen sources are usually organic or inorganic nitrogen compounds, or materials which contain these compounds. Exemplary nitrogen sources include ammonia gas or ammonia salts, such as NH,Cl or (NH,),SO., NH,OH, nitrates, urea, amino acids or complex nitrogen sources like corn steep liquor, soy bean flour, soy bean protein, yeast extract, meat extract and others.
Inorganic salt compounds which may be included in the media include the chloride-, phosphorous- or sulfate- salts of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron. Chelating compounds can be added to the medium to keep the metal ions in solution. Particularly useful chelating compounds include dihydroxyphenols, like catechol or protocatechuate, or organic acids, such as citric acid. It is typical for the media to also contain other growth factors, such as vitamins or growth promoters, examples of which include biotin, riboflavin, thiamin, folic acid, nicotinic acid, pantothenate and pyridoxin. Growth factors and salts frequently . originate from complex media components such as yeast extract, molasses, corn steep liquor and others. The exact composition of the media compounds depends strongly on the immediate experiment and is individually decided for each specific case. Information about media optimization is available in the textbook “Applied Microbiol. Physiology, A
Practical Approach (eds. P.M. Rhodes, P.F. Stanbury, IRL Press (1997) pp. 53-73, ISBN 0 19 963577 3). Itis also possible to select growth media from commercial suppliers, like standard 1 (Merck) or BHI (grain heart infusion, DIFCO) or others.
All medium components are sterilized, either by heat (20 minutes at 1.5 bar and 121°C) or by sterile filtration. The components can either be sterilized together or, if necessary, separately. All media components can be present at the beginning of growth, or they can optionally be added continuously or batchwise.
Culture conditions are defined separately for each experiment. The temperature should be in a range between 15°C and 45°C. The temperature can be kept constant or can be altered during the experiment. The pH of the medium should be in the range of 5 to 8.5, preferably around 7.0, and can be maintained by the addition of buffers to the media.
An exemplary buffer for this purpose is a potassium phosphate buffer. Synthetic buffers such as MOPS, HEPES, ACES and others can alternatively or simultaneously be used. It is also possible to maintain a constant culture pH through the addition of NaOH or : NH,OH during growth. If complex medium components such as yeast extract are utilized, the necessity for additional buffers may be reduced, due to the fact that many complex compounds have high buffer capacities. If a fermentor is utilized for culturing the micro- organisms, the pH can also be controlled using gaseous ammonia.
The incubation time is usually in a range from several hours to several days. This time is selected in order to permit the maximal amount of product to accumulate in the broth. The disclosed growth experiments can be carried out in a variety of vessels, such as microtiter plates, glass tubes, glass flasks or glass or metal fermentors of different sizes.
For screening a large number of clones, the microorganisms should be cultured in microtiter plates, glass tubes or shake flasks, either with or without baffles. Preferably 100 ml shake flasks are used, filled with 10% (by volume) of the required growth medium. The flasks should be shaken on a rotary shaker (amplitude 25 mm) using a speed-range of 100 - 300 rpm. Evaporation losses can be diminished by the maintenance . 15 of a humid atmosphere; alternatively, a mathematical correction for evaporation losses should be performed.
If genetically modified clones are tested, an unmodified control clone or a control clone containing the basic plasmid without any insert should also be tested. The medium is inoculated to an ODgg of O.5 — 1.5 using cells grown on agar plates, such as CM plates (10 g/l glucose, 2,5 g/l NaCl, 2 g/l urea, 10 g/l polypeptone, 5 g/l yeast extract, 5 g/l meat . extract, 22 g/l NaCl, 2 g/l urea, 10 g/l polypeptone, 5 g/l yeast extract, 5 g/l meat extract, 22 g/l agar, pH 6.8 with 2M NaOH) that had been incubated at 30°C. Inoculation of the media is accomplished by either introduction of a saline suspension of C. glutamicum cells from CM plates or addition of a liquid preculture of this bacterium.
Example 8 — In vitro Analysis of the Function of Mutant Proteins
The determination of activities and kinetic parameters of enzymes is well established in the art. Experiments to determine the activity of any given altered enzyme must be tailored to the specific activity of the wild-type enzyme, which is well within the ability of one of ordinary skill in the art. Overviews about enzymes in general, as well as specific details concerning structure, kinetics, principles, methods, applications and examples for the determination of many enzyme activities may be found, for example, in the following references: Dixon, M., and Webb, E.C., (1979)
Enzymes. Longmans: London; Fersht, (1985) Enzyme Structure and Mechanism. :
Freeman: New York; Walsh, (1979) Enzymatic Reaction Mechanisms. Freeman: San
Francisco, Price, N.C., Stevens, L. (1982) Fundamentals of Enzymology. Oxford Univ.
Press: Oxford; Boyer, P.D., ed. (1983) The Enzymes, 3" ed. Academic Press: New
York; Bisswanger, H., (1994) Enzymkinetik, 2" ed. VCH: Weinheim (ISBN 3527300325); Bergmeyer, H.U., Bergmeyer, J., Gral}], M., eds. (1983-1986) Methods of
Enzymatic Analysis, 3rd ed., vol. I-XII, Verlag Chemie: Weinheim; and Ullmann’s
Encyclopedia of Industrial Chemistry (1987) vol. A9, “Enzymes”. VCH: Weinheim, p. 352-363.
The activity of proteins which bind to DNA can be measured by several well- established methods, such as DNA band-shift assays (also called gel retardation assays).
The effect of such proteins on the expression of other molecules can be measured using reporter gene assays (such as that described in Kolmar, H. er al. (1995) EMBO J. 14: 3895-3904 and references cited therein). Reporter gene test systems are well known and established for applications in both pro- and eukaryotic cells, using enzymes such as beta-galactosidase, green fluorescent protein, and several others.
The determination of activity of membrane-transport proteins can be performed according to techniques such as those described in Gennis, R.B. (1989) “Pores,
Channels and Transporters”, in Biomembranes, Molecular Structure and Function,
Springer: Heidelberg, p. 85-137; 199-234; and 270-322.
Example 9: Analysis of Impact of Mutant Protein on the Production of the Desired
Product
The effect of the genetic modification in C. glutamicum on production of a desired compound (such as an amino acid) can be assessed by growing the modified microorganism under suitable conditions (such as those described above) and analyzing the medium and/or the cellular component for increased production of the desired product (i.e., an amino acid). Such analysis techniques are well known to one of ordinary skill in the art, and include spectroscopy, thin layer chromatography, staining methods of various kinds, enzymatic and microbiological methods, and analytical chromatography such as high performance liquid chromatography (see, for example,
: Ullman, Encyclopedia of Industrial Chemistry, vol. A2, p. 89-90 and p. 443-613, VCH: ’ Weinheim (1985); Fallon, A. ef al., (1987) “Applications of HPLC in Biochemistry” in:
Laboratory Techniques in Biochemistry and Molecular Biology, vol. 17; Rehm er al. (1993) Biotechnology, vol. 3, Chapter III: “Product recovery and purification”, page 469-714, VCH: Weinheim; Belter, P.A. ef al. (1988) Bioseparations: downstream processing for biotechnology, John Wiley and Sons; Kennedy, J.F. and Cabral, J. M.S. (1992) Recovery processes for biological materials, John Wiley and Sons; Shaeiwitz,
J.A. and Henry, J.D. (1988) Biochemical separations, in: Ulmann’s Encyclopedia of
Industrial Chemistry, vol. B3, Chapter 11, page 1-27, VCH: Weinheim; and Dechow,
F.J. (1989) Separation and purification techniques in biotechnology, Noyes
Publications.)
In addition to the measurement of the final product of fermentation, it is also possible to analyze other components of the metabolic pathways utilized for the production of the desired compound, such as intermediates and side-products, to determine the overall productivity of the organism, yield, and/or efficiency of production of the compound. Analysis methods include measurements of nutrient levels in the medium (e.g, sugars, hydrocarbons, nitrogen sources, phosphate, and other ions), measurements of biomass composition and growth, analysis of the production of common metabolites of biosynthetic pathways, and measurement of gasses produced during fermentation. Standard methods for these measurements are outlined in Applied
Microbial Physiology, A Practical Approach, P.M. Rhodes and PF. Stanbury, eds., IRL
Press, p. 103-129; 131-163; and 165-192 (ISBN: 0199635773) and references cited therein.
Example 10: Purification of the Desired Product from C glutamicum Culture
Recovery of the desired product from the C. glutamicum cells or supernatant of the above-described culture can be performed by various methods well known in the art.
If the desired product is not secreted from the cells, the cells can be harvested from the culture by low-speed centrifugation, the cells can be lysed by standard techniques, such as mechanical force or sonication. The cellular debris is removed by centrifugation, and the supernatant fraction containing the soluble proteins is retained for further purification of the desired compound. If the product is secreted from the C. glutamicum cells, then the cells are removed from the culture by low-speed centrifugation, and the supernate fraction is retained for further purification. :
The supernatant fraction from either purification method is subjected to chromatography with a suitable resin, in which the desired molecule is either retained on a chromatography resin while many of the impurities in the sample are not, or where the impurities are retained by the resin while the samplc 1s not. Such chromatography steps may be repeated as necessary, using the same or different chromatography resins. One of ordinary skill in the art would be well-versed in the selection of appropriate chromatography resins and in their most efficacious application for a particular molecule to be purified. The purified product may be concentrated by filtration or ultrafiltration, and stored at a temperature at which the stability of the product is maximized.
There are a wide array of purification methods known to the art and the preceding method of purification is not meant to be limiting. Such purification techniques are described, for example, in Bailey, J.E. & Ollis, D.F. Biochemical
Engineering Fundamentals, McGraw-Hill: New York (1986). : The identity and purity of the isolated compounds may be assessed by techniques standard in the art. These include high-performance liquid chromatography (HPLC), spectroscopic methods, staining methods, thin layer chromatography, NIRS, enzymauc assay, or microbiologically. Such analysis methods are reviewed in: Patek er al. (1994)
Appl. Environ. Microbiol. 60: 133-140; Malakhova et al. (1996) Biotekhnologiya 11: 27- 32; and Schmidt et al. (1998) Bioprocess Engineer. 19: 67-70. Ulmann’s Encyclopedia of Industrial Chemistry, (1996) vol. A27, VCH: Weinheim, p. 89-90, p. 521-540, p. 540- 547, p. 559-566, 575-581 and p. 581-587; Michal, G. (1999) Biochemical Pathways: An
Atlas of Biochemistry and Molecular Biology, John Wiley and Sons; Fallon, A. ef al. (1987) Applications of HPLC in Biochemistry in: Laboratory Techniques in
Biochemistry and Molecular Biology, vol. 17.
Example 11: Analysis of the Gene Sequences of the Invention
The comparison of sequences and determination of percent homology between two sequences are art-known techniques, and can be accomplished using a mathematical algorithm, such as the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci.
USA 87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA
90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST ’ programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to PTS nucleic acid molecules of the invention. BLAST protein searches can be performed with the
XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to PTS protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped
BLAST programs, one of ordinary skill in the art will know how to optimize the parameters of the program (e.g., XBLAST and NBLAST) for the specific sequence being analyzed. : Another example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Meyers and Miller ((1988) Comput. Appl. Biosci. 4: 11- 17).- Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM 120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Additional algorithms for sequence analysis are known in the art, and include ADVANCE and ADAM. described : 20 in Torelli and Robotti (1994) Comput. Appl. Biosci. 10:3-5; and FASTA, described in
Pearson and Lipman (1988) P.N.A.S. 85:2444-8.
The percent homology between two amino acid sequences can also be accomplished using the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blosum 62 matrix or a PAM250 matrix, and a gap weightof 12,10, 8, 6, or 4 and a length weight of 2, 3, or 4. The percent homology between two nucleic acid sequences can be accomplished using the GAP program in the
GCG software package, using standard parameters, such as a gap weight of 50 and a length weight of 3.
A comparative analysis of the gene sequences of the invention with those present in Genbank has been performed using techniques known in the art (see, ¢.g., Bexevanis and Ouellette, eds. (1998) Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins. John Wiley and Sons: New York). The gene sequences of the invention were compared to genes present in Genbank in a three-step process. In a first step, a
BLASTN analysis (e.g, a local alignment analysis) was performed for each of the sequences of the invention against the nucleotide sequences present in Genbank. and the top 500 hits were retained for further analysis. A subsequent FASTA search (e.g, a combined local and global alignment analysis, in which limited regions of the sequences are aligned) was performed on these 500 hits. Each gene sequence of the invention was subsequently globally aligned to each of the top three FASTA hits, using the GAP program in the GCG software package (using standard parameters). In order to obtain correct results, the length of the sequences extracted from Genbank were adjusted to the length of the query sequences by methods well-known in the art. Thc results of this analysis are set forth in Table 4. The resulting data is identical to that which would have been obtained had a GAP (global) analysis alone been performed on each of the genes of the invention in comparison with each of the references in Genbank, but required significantly reduced computational time as compared to such a database-wide GAP (global) analysis. Sequences of the invention for which no alignments above the cutoff values were obtained are indicated on Table 4 by the absence of alignment information.
It will further be understood by one of ordinary skill in the art that the GAP alignment homology percentages set forth in Table 4 under the heading “% homology (GAP) are listed in the European numerical format, wherein a ¢,’ represents a decimal point. For example, a value of “40,345” in this column represents “40.345%”.
Example 12: Construction and Operation of DNA Microarrays
The sequences of the invention may additionally be used in the construction and application of DNA microarrays (the design, methodology, and uses of DNA arrays are well known in the art, and are described, for example, in Schena, M. ef al. (1995)
Science 270: 467-470; Wodicka, L. et al. (1997) Nature Biotechnology 15: 1359-1367;
DeSaizieu, A. ef al. (1998) Nature Biotechnology 16: 45-48; and DeRisi, J.L. et al. (1997) Science 278: 680-686).
DNA microarrays are solid or flexible supports consisting of nitrocellulose, nylon, glass, silicone, or other materials. Nucleic acid molecules may be attached to the surface in an ordered manner. After appropriate labeling, other nucleic acids or nucleic acid mixtures can be hybridized to the immobilized nucleic acid molecules, and the label may be used to monitor and measure the individual signal intensities of the hybridized : molecules at defined regions. This methodology allows the simultaneous ‘quantification of the relative or absolute amount of all or selected nucleic acids in the applied nucleic acid sample or mixture. DNA microarrays, therefore, permit an analysis of the expression of multiple (as many as 6800 or more) nucleic acids in parallel (see, e.g.,
Schena, M. (1996) BioEssays 18(5): 427-431).
The sequences of the invention may be used to design oligonucleotide primers which are able to amplify defined regions of one or more C. glutamicum genes by a : nucleic acid amplification reaction such as the polymerase chain reaction. The choice and design of the 5° or 3’ oligonucleotide primers or of appropriate linkers allows the covalent attachment of the resulting PCR products to the surface of a support medium described above (and also described, for example, Schena, M. et al. (1995) Science 270: 467-470).
Nucleic acid microarrays may also be constructed by in situ oligonucleotide synthesis as described by Wodicka, L. et al. (1997) Nature Biotechnology 15: 1359- 1367. By photolithographic methods, precisely defined regions of the matrix are exposed to light. Protective groups which are photolabile are thereby activated and "undergo nucleotide addition, whereas regions that are masked from light do not undergo any modification. Subsequent cycles of protection and light activation permit the synthesis of different oligonucleotides at defined positions. Small, defined regions of the genes of the invention may be synthesized on microarrays by solid phase oligonucleotide synthesis.
The nucleic acid molecules of the invention present in a sample or mixture of nucleotides may be hybridized to the microarrays. These nucleic acid molecules can be labeled according to standard methods. In brief, nucleic acid molecules (e.g., mRNA molecules or DNA molecules) are labeled by the incorporation of isotopically or fluorescently labeled nucleotides, e.g., during reverse transcription or DNA synthesis.
Hybridization of labeled nucleic acids to microarrays is described (e.g., in Schena, M. et al. (1995) supra; Wodicka, L. et al. (1997), supra; and DeSaizieu A. et al. (1998), supra). The detection and quantification of the hybridized molecule are tailored to the specific incorporated label. Radioactive labels can be detected, for example, as described in Schena, M. et al. (1995) supra) and fluorescent labels may be detected, for example, by the method of Shalon et al. (1996) Genome Research 6: 639-645).
The application of the sequences of the invention to DNA microarray technology, as described above, permits comparative analyses of different strains of C. glutamicum or other Corynebacteria. For example, studies of inter-strain variations based on individual transcript profiles and the identification of genes that are important for specific and/or desired strain properties such as pathogenicity, productivity and stress tolerance are facilitated by nucleic acid array methodologies. Also, comparisons of the profile of expression of genes of the invention during the course of a fermentation reaction are possible using nucleic acid array technology.
Example 13: Analysis of the Dynamics of Cellular Protein Populations (Proteomics)
The genes, compositions, and methods of the invention may be applied to study the interactions and dynamics of populations of proteins, termed ‘proteomics’. Protein populations of interest include, but are not limited to, the total protein population of C. glutamicum (e.g., in comparison with the protein populations of other organisms), those proteins which are active under specific environmental or metabolic conditions (e.g, during fermentation, at high or low temperature, or at high or low pH), or those proteins which are active during specific phases of growth and development.
Protein populations can be analyzed by various well-known techniques, such as gel electrophoresis. Cellular proteins may be obtained, for example, by lysis or extraction, and may be separated from one another using a variety of electrophoretic techniques. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) separates proteins largely on the basis of their molecular weight. Isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) separates proteins by their isoelectric point (which reflects not only the amino acid sequence but also posttranslational modifications of the protein). Another, more preferred method of protein analysis is the consecutive combination of both IEF-PAGE and SDS-PAGE, known as 2-D-gel electrophoresis (described, for example, in Hermann et al. (1998) Electrophoresis 19: 3217-3221; Fountoulakis et al. (1998) Electrophoresis 19: 1193-1202; Langen et al. (1997) Electrophoresis 18: 1184-1192; Antelmana er al. (1997) Electrophoresis 18:
1451-1463). Other separation techniques may also be utilized for protein separation, such as capillary gel electrophoresis; such techniques are well known in the art.
Proteins separated by these methodologies can be visualized by standard techniques, such as by staining or labeling. Suitable stains are known in the art, and include Coomassie Brilliant Blue, silver stain, or fluorescent dyes such as Sypro Ruby (Molecular Probes). The inclusion of radioactively labeled amino acids or other protein precursors (e.g., 35S.methionine, **S-cysteine, “C-labelled amino acids, *N-amino acids, NO; or NH," or C-labelled amino acids) in the medium of C. glutamicum permits the labeling of proteins from these cells prior to their separation. Similarly, fluorescent labels may be employed. These labeled proteins can be extracted, isolated and separated according to the previously described techniques.
Proteins visualized by these techniques can be further analyzed by measuring the : amount of dye or label used. The amount of a given protein can be determined quantitatively using, for example, optical methods and can be compared to the amount of other proteins in the same gel or in other gels. Comparisons of proteins on gels can be made, for example, by optical comparison, by spectroscopy, by image scanning and analysis of gels, or through the use of photographic films and. screens. Such techniques are well-known in the art.
To determine the identity of any given protein, direct sequencing or other standard techniques may be employed. For example, N- and/or C-terminal amino acid sequencing (such as Edman degradation) may be used, as may mass spectrometry (in particular MAL DI or ESI techniques (see, e.g., Langen ef al. (1997) Electrophoresis 18: 1184-1192)). The protein sequences provided herein can be used for the identification of C. glutamicum proteins by these techniques.
The information obtained by these methods can be used to compare patterns of protein presence, activity, or modification between different samples from various biological conditions (e.g., different organisms, time points of fermentation, media conditions, or different biotopes, among others). Data obtained from such experiments alone, or in combination with other techniques, can be used for various applications, such as to compare the behavior of various organisms in a given (e.g., metabolic) situation, to increase the productivity of strains which produce fine chemicals or to increase the efficiency of the production of fine chemicals.
AMENDED SHEET
® BGI-122CPPC
Equivalents
Those of ordinary skill in the art will recognize, or will be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims. "Comprises/comprising" when used in this specification is taken to specify the presence of stated features, integers, steps or components but does not preclude the presence or addition of one or more other features, integers, steps or components or groups thereof.
The sequence listing which follow are to be considered as an integral part of the present disclosure.
SEQ ID NO:35 and SEQ ID NO:36 are the nucleotide sequence for primers, and are not included in the definition of the "odd-numbered SEQ ID NO(s)" or "even-numbered SEQ
ID NO(s)" in the specification and claims. .
Claims (52)
1. An isolated nucleic acid molecule from Corynebacterium glutamicum encoding a phosphoenolpyruvate: sugar phosphotransferase system protein, or a portion thereof, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.
2. The isolated nucleic acid molecule of claim 1, wherein said phosphoenolpyruvate: sugar phosphotransferase system protein is selected from the group consisting of proteins involved in the transport of glucose, sucrose, mannose, fructose, mannitol, raffinose, ribulose, ribose, lactose, maltose, sorbose, sorbitol, xylose, and galactose. : 15
3. An isolated Corynebacterium glutamicum nucleic acid molecule selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing , or a portion thereof, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.
4. An isolated nucleic acid molecule which encodes a polypeptide sequence selected from the group consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing , provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.
5. An isolated nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide selected from the group of amino acid sequences consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing , : provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.
6. An isolated nucleic acid molecule comprising a nucleotide sequence which is at least 50% homologous to a nucleotide sequence selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing , or a portion thereof, provided that the nucleic acid molecule does not consist of any of the F- designated genes set forth in Table 1.
7. An isolated nucleic acid molecule comprising a fragment of at least 15 nucleotides of a nucleic acid comprising a nucleotide sequence selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing , provided that the nucleic acid molccule does not consist of any of the F- designated genes set forth in Table 1.
8. An isolated nucleic acid molecule which hybridizes to the nucleic acid molecule of any one of claims 1-7 under stringent conditions.
9. An isolated nucleic acid molecule comprising the nucleic acid molecule of any one of claims 1-8 or a portion thereof and a nucleotide sequence encoding a heterologous polypeptide. .
10. A vector comprising the nucleic acid molecule of any one of claims 1-9.
11. The vector of claim 10, which is an expression vector.
12. A host cell transfected with the expression vector of claim 11.
13. The host cell of claim 12, wherein said cell is a microorganism.
14. The host cell of claim 13, wherein said cell belongs to the genus Corynebacterium or Brevibacterium.
15. The host cell of claim 12, wherein the expression of said nucleic acid molecule results in the modulation in production of a fine chemical from said cell.
16. The host cell of claim 15, wherein said fine chemical is selected from the group consisting of: organic acids, proteinogenic amino acids, nonproteinogenic amino acids, purine and pyrimidine bases, nucleosides, nucleotides, lipids, saturated and unsaturated fatty acids, diols, carbohydrates, aromatic compounds, vitamins, cofactors, polyketides, and enzymes.
17. A method of producing a polypeptide comprising culturing the host cell of claim 12 in an appropriate culture medium to, thereby, produce the polypeptide.
18. An isolated phosphoenolpyruvate: sugar phosphotransferase system polypeptide from Corynebacterium glutamicum, or a portion thereof.
19. The protein of claim 18, wherein said phosphoenolpyruvate: sugar phosphotransferase system protein is selected from the group consisting of proteins involved in the transport of glucose, sucrose, mannose, fructose, mannitol, raffinose, ribulose, ribose, lactose, maltose, sorbose, and galactose. }
20. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing , provided that the amino acid sequence is not encoded by any of the F-designated genes set forth in Table 1.
21. An isolated polypeptide comprising a naturally occurring allelic variant of a polypeptide comprising an amino acid sequence selected from the group consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing , or a portion thereof, provided that the amino acid sequence is not encoded by any of the F- designated genes set forth in Table 1.
22. The isolated polypeptide of any of claims 18-21, further comprising heterologous amino acid sequences.
23. An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 50% homologous to a nucleic acid selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing , provided that the nucleic acid molecule does not consist of any of the F-designated nucleic acid molecules set forth in Table 1.
24. An isolated polypeptide comprising an amino acid sequence which is at least 50% homologous to an amino acid sequence selected from the group consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing , provided that the amino acid sequence is not encoded by any of the F-designated genes set forth in Table 1.
25. A method for producing a fine chemical, comprising culturing a cell containing a vector of claim 12 such that the fine chemical is produced.
26. The method of claim 25, wherein said method further comprises the step of recovering the fine chemical from said culture.
27. The method of claim 25, wherein said method further comprises the step of transfecting said cell with the vector of claim 11 to result in a cell containing said vector.
28. The method of claim 25, wherein said cell belongs to the genus Corynebacterium or Brevibacterium.
29. The method of claim 25, wherein said cell is selected from the group consisting of: Corynebacterium glutamicum, Corynebacterium herculis, Corynebacterium, lilium, Corynebacterium acetoacidophilum, Corynebacterium acetoglutamicum, Corynebacterium acetophilum, Corynebacterium ammoniagenes, Corynebacterium Jfujiokense, Corynebacterium nitrilophilus, Brevibacterium ammoniagenes, Brevibacterium butanicum, Brevibacterium divaricatum, Brevibacterium flavum, Brevibacterium healii, Brevibacterium ketoglutamicum, Brevibacterium hs
AMENDED SHEET ® BGI-122CPPC ketosoreductum, Brevibacterium lactofermentum, Brevibacterium linens, Brevibacterium paraffinolyticum, and those strains set forth in Table 3.
30. The method of claim 25, wherein expression of the nucleic acid molecule from said vector results in modulation of production of said fine chemical.
31. The method of claim 25, wherein said fine chemical is selected from the group consisting of: organic acids, proteinogenic amino acids, nonproteinogenic amino acids. purine and pyrimidine bases, nucleosides, nucleotides, lipids, saturated and unsaturated fatty acids, diols, carbohydrates, aromatic compounds, vitamins, cofactors, polyketides. and enzymes.
32. The method of claim 25, wherein said fine chemical is an amino acid.
33. The method of claim 32, wherein said amino acid is drawn from the group consisting of: lysine, glutamate, glutamine, alanine, aspartate, glycine, serine, threonine, methionine, cysteine, valine, leucine, isoleucine, arginine, proline, histidine, tyrosine, phenylalanine, and tryptophan. :
34. A method for producing a fine chemical, comprising culturing a cell whose genomic DNA has been altered by the inclusion of a nucleic acid molecule of any one of claims 1-9. :
35. A method for in vitro diagnosing the presence or activity of Corynebacterium diphtheriae in a subject, comprising detecting the presence of one or more of SEQ ID NOs 1 through 34 of the Sequence Listing in the subject. provided that the sequences are not or are not encoded by any of the F-designated sequences set forth in Table 1. thereby diagnosing the presence or activity of Corynebacterium diphtheriae in the subject.
36. A host cell comprising a nucleic acid molecule selected from the group consisting of the nucleic acid molecules set forth as odd-numbered SEQ ID NOs of the Sequence Listing . wherein the nucleic acid molecule is disrupted.
BGIL-122CPPC AMENDED SHEET ® 97.
37. A host cell comprising a nucleic acid molecule selected from the group consisting of the nucleic acid molecules set forth as odd-numbered SEQ ID NOs of the Sequence Listing, wherein the nucleic acid molecule comprises one or more nucleic acid modifications from the sequence set forth in as odd-numbered SEQ ID NOs of the Sequence Listing.
38. A host cell comprising a nucleic acid molecule selected from the group consisting of the nucleic acid molecules set forth as odd-numbered SEQ ID NOs of the Sequence Listing, wherein the regulatory region of the nucleic acid molecule is modified relative to the wild-type regulatory region of the molecule.
39. The isolated nucleic acid molecule as claimed in any one of claims 1 to 9, substantially as hereinbefore described or exemplified.
40. The isolated nucleic acid molecule including any new and inventive integer or combination of integers, substantially as herein described.
41. The vector as claimed in either of claims 10 to 11, substantially as hereinbefore described or exemplified.
42. The vector including any new and inventive integer or combination of integers, substantially as herein described.
43. The host cell as claimed in any one of claims 12 to 16 and 36 to 38, substantially as hereinbefore described or exemplified.
44. The host cell including any new and inventive integer or combination of integers, substantially as herein described.
45. The method according to the invention for producing a polypeptide, substantially as hereinbefore described or exemplified.
46. The method for producing a polypeptide including any new and inventive integer or combination of integers, substantially as herein described.
BGI-122CPPC AMENDED SHEET ® 98.
47. The isolated polypeptide as claimed in any one of claims 18 to 24, substantially as hereinbefore described or exemplified.
48. The isolated polypeptide including any new and inventive integer or combination of integers, substantially as herein described.
49. The method according to the invention for producing a fine chemical, substantially as hereinbefore described or exemplified.
50. The method for producing a fine chemical including any new and inventive integer or combination of integers, substantially as herein described.
51. The method according to the invention for in vitro diagnosing the presence or activity of Corynebacterium diphtheriae, substantially as hereinbefore described or exemplified.
52. The method for in vitro diagnosing the presence or activity of Corynebacterium diphtheriae including any new and inventive integer or combination of integers, substantially as herein described.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14269199P | 1999-07-01 | 1999-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200200816B true ZA200200816B (en) | 2004-10-27 |
Family
ID=34078497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200200816A ZA200200816B (en) | 1999-07-01 | 2002-01-30 | Corynebacterium glutamicum genes encoding phosphoenolpyruvate: Sugar phosphotransferase system proteins. |
Country Status (2)
Country | Link |
---|---|
CN (3) | CN101130778A (en) |
ZA (1) | ZA200200816B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3456833A1 (en) * | 2017-09-18 | 2019-03-20 | Evonik Degussa GmbH | Method for the fermentative production of l-amino acids |
WO2020046215A1 (en) * | 2018-08-31 | 2020-03-05 | Agency For Science, Technology And Research | Methods for terpenoid production |
CN109652490B (en) * | 2019-02-25 | 2019-09-03 | 内蒙古拜克生物有限公司 | A kind of fermentation of L-Leu and isolation and purification method |
CN113249286B (en) * | 2021-05-25 | 2023-12-08 | 洛阳华荣生物技术有限公司 | Method for constructing L-sarcosine producing strain |
CN115746110A (en) * | 2021-09-02 | 2023-03-07 | 中国科学院天津工业生物技术研究所 | Mutant of transcriptional regulatory factor LysG and application thereof |
-
2000
- 2000-06-27 CN CNA2007100920738A patent/CN101130778A/en active Pending
- 2000-06-27 CN CNA2007100920742A patent/CN101054593A/en active Pending
- 2000-06-27 CN CNA2007100920723A patent/CN101054592A/en active Pending
-
2002
- 2002-01-30 ZA ZA200200816A patent/ZA200200816B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101054592A (en) | 2007-10-17 |
CN101130778A (en) | 2008-02-27 |
CN101054593A (en) | 2007-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100878334B1 (en) | Corynebacterium Glutamicum Genes Encoding Metabolic Pathway Proteins | |
KR100856512B1 (en) | Corynebacterium glutamicum genes encoding proteins involved in carbon metabolism and energy production | |
US7273721B2 (en) | Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport | |
KR100834986B1 (en) | Corynebacterium glutamicum genes encoding stress, resistance and tolerance proteins | |
KR100834989B1 (en) | Corynebacterium Glutamicum Genes Encoding Proteins Involved in Membrane Synthesis and Membrane Transport | |
KR100834985B1 (en) | Corynebacterium Glutamicum Genes Encoding Proteins Involved in Homeostasis and Adaptation | |
US7393675B2 (en) | Corynebacterium glutamicum genes encoding proteins involved in carbon metabolism and energy production | |
EP1246922A2 (en) | Orynebacterium glutamicum genes encoding phosphoenolpyruvate: sugar phosphotransferase system proteins | |
EP1345714A1 (en) | Genes of corynebacterium | |
ZA200200816B (en) | Corynebacterium glutamicum genes encoding phosphoenolpyruvate: Sugar phosphotransferase system proteins. | |
RU2312145C2 (en) | Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport | |
EP1661987A1 (en) | Corynebacterium glutamicum gene encoding phosphoenolpyruvate carboxykinase | |
EP1634952A2 (en) | Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport |